<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002471</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>109</s160></s100><s200><s210>1</s210><s211>645</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>Full length NKG2D</s223></s220></s200><s400> 1gggtggattc gtggtcggag gtctcgacac agctgggaga tgagtgaatt tcataattat     60aacttggatc tgaagaagag tgatttttca acacgatggc aaaagcaaag atgtccagta    120gtcaaaagca aatgtagaga aaatgcatct ccattttttt tctgctgctt catcgctgta    180gccatgggaa tccgtttcat tattatggta acaatatgga gtgctgtatt cctaaactca    240ttattcaacc aagaagttca aattcccttg accgaaagtt actgtggccc atgtcctaaa    300aactggatat gttacaaaaa taactgctac caattttttg atgagagtaa aaactggtat    360gagagccagg cttcttgtat gtctcaaaat gccagccttc tgaaagtata cagcaaagag    420gaccaggatt tacttaaact ggtgaagtca tatcattgga tgggactagt acacattcca    480acaaatggat cttggcagtg ggaagatggc tccattctct cacccaacct actaacaata    540attgaaatgc agaagggaga ctgtgcactc tatgcctcga gctttaaagg ctatatagaa    600aactgttcaa ctccaaatac gtacatctgc atgcaaagga ctgtg                    645</s400><s200><s210>2</s210><s211>405</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>Truncated NKG2D</s223></s220></s200><s400> 2ttattcaacc aagaagttca aattcccttg accgaaagtt actgtggccc atgtcctaaa     60aactggatat gttacaaaaa taactgctac caattttttg atgagagtaa aaactggtat    120gagagccagg cttcttgtat gtctcaaaat gccagccttc tgaaagtata cagcaaagag    180gaccaggatt tacttaaact ggtgaagtca tatcattgga tgggactagt acacattcca    240acaaatggat cttggcagtg ggaagatggc tccattctct cacccaacct actaacaata    300attgaaatgc agaagggaga ctgtgcactc tatgcctcga gctttaaagg ctatatagaa    360aactgttcaa ctccaaatac gtacatctgc atgcaaagga ctgtg                    405</s400><s200><s210>3</s210><s211>405</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>Codon Optimized Truncated NKG2D</s223></s220></s200><s400> 3ctgttcaatc aggaagtcca gatccccctg acagagtctt actgcggccc atgtcccaag     60aactggatct gctacaagaa caattgttat cagttctttg acgagagcaa gaactggtat    120gagtcccagg cctcttgcat gagccagaat gcctctctgc tgaaggtgta cagcaaggag    180gaccaggatc tgctgaagct ggtgaagtcc tatcactgga tgggcctggt gcacatccct    240acaaacggct cttggcagtg ggaggacggc tccatcctgt ctccaaatct gctgaccatc    300atcgagatgc agaagggcga ttgcgccctg tacgccagct ccttcaaggg ctatatcgag    360aactgctcca cacccaatac ctacatctgt atgcagagga ccgtg                    405</s400><s200><s210>4</s210><s211>63</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>CD8 Signaling Sequence</s223></s220></s200><s400> 4atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga     60cca                                                                   63</s400><s200><s210>5</s210><s211>135</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>CD8 alpha hinge</s223></s220></s200><s400> 5accacaaccc ctgcaccacg cccccctaca ccagcaccta ccatcgcaag ccagcctctg     60tccctgcggc cagaggcatg tagaccagca gcaggaggag cagtgcacac aagaggcctg    120gacttcgcct gcgat                                                     135</s400><s200><s210>6</s210><s211>1722</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>CD8 beta</s223></s220><s220><s221>misc_feature</s221><s222>(674)..(773)</s222><s223>n is a, c, g, or t</s223></s220><s220><s221>misc_feature</s221><s222>(859)..(958)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 6atctaggtct tgctgcaccc gcacaaccta caaacagcgt cggggccttc tctgcacctc     60cagttcccag ctcacctccc tcagtgtcac agccggttac ctttccttcc tccctggggg    120agggcaagac ttggggcttg ctgactccag gcccagccca gcccggggca cccaggagcc    180cctcaattgc tactcaaaca gacaagaagc ggcccgagtt agtggccagc tccaccatgc    240actacacatc ctgacctctc tgagcctcta ctgtcactcg gggtcacaac cctttcctga    300gcacctcccg gggcaggggg cgatgacaca catgcagctg cctgggggag gccggcggtg    360tcccctcctt tctggaacgc ggagggtcct ggtgggctct ggaaacgcag cccagacctt    420tgcaatgcta ggaggatgag ggcggagacc tcgcggtccc caacaccaga ctcccgcagc    480caccgcgccc ggtcccgccc tccccactgc ccccccagct ccccgaccca ggcgccccgc    540ccggccagct cctcacccac cccagccgcg actgtctccg ccgagccccc ggggccaggt    600gtcccgggcg cgccacgatg cggccgcggc tgtggctcct cctggccgcg cagctgacag    660gtaaggcggc ggcnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn    720nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnttgcttt    780cctcttccag gccggcggag gagagcccgg cttcgtttca tgaaacagta agtgtataac    840ctgggtgtgg ccttgggann nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn    900nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnct    960tgctgttgtt ttcagatttt acaaatgagc agagaatacg gttttggtgt cctgctacaa   1020aaagacatcg gtcagtaacg agcacgatgt ggaaaaatga gagaagggac acattcaacc   1080ctggagagtt caatggctgc tgaagctgcc tgcttttcac tgctgcaagg cctttctgtg   1140tgtgacgtgc atgggagcaa cttgttcgtg ggtcatcggg aatactaggg agaaggtttc   1200attgccccca gggcacttca cagagtgtgc tggaggactg agtaagaaat gctgcccatg   1260ccaccgcttc cggctcctgt gctttccctg aactgggacc tttagtggtg gccatttagc   1320caccatcttt gcaggttgct ttgccctggt agggcagtaa cattgggtcc tgggtctttc   1380atggggtgat gctgggctgg ctccctgttg gtcttcccag gctggggctg accttcctcg   1440cagagaggcc aggtgcaggt tgggaatgag gcttgctgag aggggctgtc cagttcccag   1500aaggcatatc agtctctgag ggcttccttt ggggccggga acttgcgggt ttgaggatag   1560gagttcactt catcttctca gctcccattt ctactcttaa gtttctcagc tcccatttct   1620actctcccat ggcttaatgc ttctttcatt ttctgtttgt tttatacaaa tgtcttagtt   1680gtaaaaataa agtcccaggt taaagataac aaacgggtcc tg                      1722</s400><s200><s210>7</s210><s211>2415</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>CD16 alpha</s223></s220></s200><s400> 7attcttggtg ctgggtggat ccaaatccag gagatggggc aagcatcctg ggatggctga     60gggcacactc tggcagattc tgtgtgtgtc ctcagatgct cagccacaga cctttgaggg    120agtaaagggg gcagacccac ccaccttgcc tccaggctct ttccttcctg gtcctgttct    180atggtggggc tcccttgcca gacttcagac tgagaagtca gatgaagttt caagaaaagg    240aaattggtgg gtgacagaga tgggtggagg ggctggggaa aggctgttta cttcctcctg    300tctagtcggt ttggtccctt tagggctccg gatatctttg gtgacttgtc cactccagtg    360tggcatcatg tggcagctgc tcctcccaac tgctctgcta cttctagttt cagctggcat    420gcggactgaa gatctcccaa aggctgtggt gttcctggag cctcaatggt acagggtgct    480cgagaaggac agtgtgactc tgaagtgcca gggagcctac tcccctgagg acaattccac    540acagtggttt cacaatgaga gcctcatctc aagccaggcc tcgagctact tcattgacgc    600tgccacagtc gacgacagtg gagagtacag gtgccagaca aacctctcca ccctcagtga    660cccggtgcag ctagaagtcc atatcggctg gctgttgctc caggcccctc ggtgggtgtt    720caaggaggaa gaccctattc acctgaggtg tcacagctgg aagaacactg ctctgcataa    780ggtcacatat ttacagaatg gcaaaggcag gaagtatttt catcataatt ctgacttcta    840cattccaaaa gccacactca aagacagcgg ctcctacttc tgcagggggc tttttgggag    900taaaaatgtg tcttcagaga ctgtgaacat caccatcact caaggtttgg cagtgtcaac    960catctcatca ttctttccac ctgggtacca agtctctttc tgcttggtga tggtactcct   1020ttttgcagtg gacacaggac tatatttctc tgtgaagaca aacattcgaa gctcaacaag   1080agactggaag gaccataaat ttaaatggag aaaggaccct caagacaaat gacccccatc   1140ccatgggggt aataagagca gtagcagcag catctctgaa catttctctg gatttgcaac   1200cccatcatcc tcaggcctct ctacaagcag caggaaacat agaactcaga gccagatccc   1260ttatccaact ctcgactttt ccttggtctc cagtggaagg gaaaagccca tgatcttcaa   1320gcagggaagc cccagtgagt agctgcattc ctagaaattg aagtttcaga gctacacaaa   1380cactttttct gtcccaaccg ttccctcaca gcaaagcaac aatacaggct agggatggta   1440atcctttaaa catacaaaaa ttgctcgtgt tataaattac ccagtttaga ggggaaaaaa   1500aaacaattat tcctaaataa atggataagt agaattaatg gttgaggcag gaccatacag   1560agtgtgggaa ctgctgggga tctagggaat tcagtgggac caatgaaagc atggctgaga   1620aatagcaggt agtccaggat agtctaaggg aggtgttccc atctgagccc agagataagg   1680gtgtcttcct agaacattag ccgtagtgga attaacagga aatcatgagg gtgacgtaga   1740attgagtctt ccaggggact ctatcagaac tggaccatct ccaagtatat aacgatgagt   1800cctcttaatg ctaggagtag aaaatggtcc taggaagggg actgaggatt gcggtggggg   1860gtggggtgga aaagaaagta cagaacaaac cctgtgtcac tgtcccaagt tgctaagtga   1920acagaactat ctcagcatca gaatgagaaa gcctgagaag aaagaaccaa ccacaagcac   1980acaggaagga aagcgcagga ggtgaaaatg ctttcttggc cagggtagta agaattagag   2040gttaatgcag ggactgtaaa accacctttt ctgcttcaat atctaattcc tgtgtagctt   2100tgttcattgc atttattaaa caaatgttgt ataaccaata ctaaatgtac tactgagctt   2160cgctgagtta agttatgaaa ctttcaaatc cttcatcatg tcagttccaa tgaggtgggg   2220atggagaaga caattgttgc ttatgaaaga aagctttagc tgtctctgtt ttgtaagctt   2280taagcgcaac atttcttggt tccaataaag cattttacaa gatcttgcat gctactctta   2340gatagaagat gggaaaacca tggtaataaa atatgaatga taaaaaaaaa aaaaaaaaaa   2400aaaaaaaaaa aaaaa                                                    2415</s400><s200><s210>8</s210><s211>2473</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>CD16 beta</s223></s220><s220><s221>misc_feature</s221><s222>(211)..(310)</s222><s223>n is a, c, g, or t</s223></s220><s220><s221>misc_feature</s221><s222>(537)..(636)</s222><s223>n is a, c, g, or t</s223></s220><s220><s221>misc_feature</s221><s222>(968)..(1067)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 8aaagatgggt ggagggactg gggaaaggct gtttactccc tcctgtctag tcggcttggt     60ccctttaggg gtccggatat ctttggtgac ttgtccactc cagtgtggca tcatgtggca    120gctgctcctc ccaactgctc tgctacttct aggtaagtag gatctccctg gttgagggag    180aagtttgaga tgccttgggt tcagcagaga nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn    240nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn    300nnnnnnnnnn aagaggcatg aacagtggaa gaccagagag caggtagcaa ggtttccacc    360agaaacatcc tgattcttgg gaaaattggg ctcctggggc agaggagggc aggggagttt    420taaactcact ctatgttcta atcactctga tctctgcccc tactcaatat ttgatttact    480cttttttctt gcagtttcag ctggcatgcg gactggtgag tcagcttcat ggtcttnnnn    540nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn    600nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnncact gagagctgag ctcccgggcc    660tggggtgtct ctgtgtcttt caggctggct gttgctccag gcccctcggt gggtgttcaa    720ggaggaagac cctattcacc tgaggtgtca cagctggaag aacactgctc tgcataaggt    780cacatattta cagaatggca aagacaggaa gtattttcat cataattctg acttccacat    840tccaaaagcc acactcaaag atagcggctc ctacttctgc agggggcttg ttgggagtaa    900aaatgtgtct tcagagactg tgaacatcac catcactcaa ggtgagacat gtgccaccct    960ggaatgcnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn   1020nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnttt ttcatctctc   1080cacttctcct aataggtttg gcagtgtcaa ccatctcatc attctctcca cctgggtacc   1140aagtctcttt ctgcttggtg atggtactcc tttttgcagt ggacacagga ctatatttct   1200ctgtgaagac aaacatttga agctcaacaa gagactggaa ggaccataaa cttaaatgga   1260gaaaggaccc tcaagacaaa tgacccccat cccatgggag taataagagc agtggcagca   1320gcatctctga acatttctct ggatttgcaa ccccatcatc ctcaggcctc tctacaagca   1380gcaggaaaca tagaactcag agccagatcc tttatccaac tctcgatttt tccttggtct   1440ccagtggaag ggaaaagccc atgatcttca agcagggaag ccccagtgag tagctgcatt   1500cctagaaatt gaagtttcag agctacacaa acactttttc tgtcccaacc attccctcac   1560agtaaaacaa caatacaggc tagggatggt aatcctttaa acatacaaaa attgctcgta   1620ttataaatta cccagtttag accggaaaaa agaaaataat tattcctaaa caaatggata   1680agtagaatta atgattgagg caggacccta cagagtgtgg gaactgctgg ggatctagag   1740aattcagtgg gaccaatgaa agcatggctg agaaatagca gggtagtcca ggagagtcta   1800agggaggtgt tcccatctga gcccagagat aagggtgtct tcctagaaca ttagccgtag   1860tggaattaac aggaaatcat gagggtgacg tagaattgag tcttccaggg gactctatca   1920gaactggacc atttccaagt atataacgat gagccctcta atgctaggag tagcaaatgg   1980tcctaggaag gggactgagg attggggtgg gggtggggtg gaaaagaaag tacagaacaa   2040accctgtgtc actgtcccaa gttaagctaa gtgaacagaa ctatctcagc atcagaatga   2100gaaagcctga gaagaaagaa ccaaccacaa gcacacagga aggaaagcgc aggaggtgaa   2160aatgctttct tggccagggt agtaagaatt agaggttaat gcagggactg taaaaccacc   2220ttttctgctt caatgtctag ttcctgtata gctttgttca ttgcatttat taaacaaatg   2280ttgtataacc aatactaaat gtactactga gcttcactga gttacgctgt gaaactttca   2340aatccttctt catgtcagtt ccaatgaggt ggggatggag aagacaattg ttgcttatga   2400aaaaaagctt tagctgtctc tgttttgtaa gctttcagtg caacatttct tggttccaat   2460aaagcatttt aca                                                      2473</s400><s200><s210>9</s210><s211>370</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>2B4</s223></s220></s200><s400> 9Met Leu Gly Gln Val Val Thr Leu Ile Leu Leu Leu Leu Leu Lys Val1               5                   10                  15Tyr Gln Gly Lys Gly Cys Gln Gly Ser Ala Asp His Val Val Ser Ile            20                  25                  30Ser Gly Val Pro Leu Gln Leu Gln Pro Asn Ser Ile Gln Thr Lys Val        35                  40                  45Asp Ser Ile Ala Trp Lys Lys Leu Leu Pro Ser Gln Asn Gly Phe His    50                  55                  60His Ile Leu Lys Trp Glu Asn Gly Ser Leu Pro Ser Asn Thr Ser Asn65                  70                  75                  80Asp Arg Phe Ser Phe Ile Val Lys Asn Leu Ser Leu Leu Ile Lys Ala                85                  90                  95Ala Gln Gln Gln Asp Ser Gly Leu Tyr Cys Leu Glu Val Thr Ser Ile            100                 105                 110Ser Gly Lys Val Gln Thr Ala Thr Phe Gln Val Phe Val Phe Glu Ser        115                 120                 125Leu Leu Pro Asp Lys Val Glu Lys Pro Arg Leu Gln Gly Gln Gly Lys    130                 135                 140Ile Leu Asp Arg Gly Arg Cys Gln Val Ala Leu Ser Cys Leu Val Ser145                 150                 155                 160Arg Asp Gly Asn Val Ser Tyr Ala Trp Tyr Arg Gly Ser Lys Leu Ile                165                 170                 175Gln Thr Ala Gly Asn Leu Thr Tyr Leu Asp Glu Glu Val Asp Ile Asn            180                 185                 190Gly Thr His Thr Tyr Thr Cys Asn Val Ser Asn Pro Val Ser Trp Glu        195                 200                 205Ser His Thr Leu Asn Leu Thr Gln Asp Cys Gln Asn Ala His Gln Glu    210                 215                 220Phe Arg Phe Trp Pro Phe Leu Val Ile Ile Val Ile Leu Ser Ala Leu225                 230                 235                 240Phe Leu Gly Thr Leu Ala Cys Phe Cys Val Trp Arg Arg Lys Arg Lys                245                 250                 255Glu Lys Gln Ser Glu Thr Ser Pro Lys Glu Phe Leu Thr Ile Tyr Glu            260                 265                 270Asp Val Lys Asp Leu Lys Thr Arg Arg Asn His Glu Gln Glu Gln Thr        275                 280                 285Phe Pro Gly Gly Gly Ser Thr Ile Tyr Ser Met Ile Gln Ser Gln Ser    290                 295                 300Ser Ala Pro Thr Ser Gln Glu Pro Ala Tyr Thr Leu Tyr Ser Leu Ile305                 310                 315                 320Gln Pro Ser Arg Lys Ser Gly Ser Arg Lys Arg Asn His Ser Pro Ser                325                 330                 335Phe Asn Ser Thr Ile Tyr Glu Val Ile Gly Lys Ser Gln Pro Lys Ala            340                 345                 350Gln Asn Pro Ala Arg Leu Ser Arg Lys Glu Leu Glu Asn Phe Asp Val        355                 360                 365Tyr Ser    370</s400><s200><s210>10</s210><s211>279</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DAP10</s223></s220></s200><s400> 10atgatccatc tgggtcacat cctcttcctg cttttgctcc cagtggctgc agctcagacg     60actccaggag agagatcatc actccctgcc ttttaccctg gcacttcagg ctcttgttcc    120ggatgtgggt ccctctctct gccgctcctg gcaggcctcg tggctgctga tgcggtggca    180tcgctgctca tcgtgggggc ggtgttcctg tgcgcacgcc cacgccgcag ccccgcccaa    240gatggcaaag tctacatcaa catgccaggc aggggctga                           279</s400><s200><s210>11</s210><s211>575</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DAP12</s223></s220></s200><s400> 11agacttcctc cttcacttgc ctggacgctg cgccacatcc caccggccct tacactgtgg     60tgtccagcag catccggctt catgggggga cttgaaccct gcagcaggct cctgctcctg    120cctctcctgc tggctgtaag tgattgcagt tgctctacgg tgagcccggg cgtgctggca    180gggatcgtga tgggagacct ggtgctgaca gtgctcattg ccctggccgt gtacttcctg    240ggccggctgg tccctcgggg gcgaggggct gcggaggcag cgacccggaa acagcgtatc    300actgagaccg agtcgcctta tcaggagctc cagggtcaga ggtcggatgt ctacagcgac    360ctcaacacac agaggccgta ttacaaatga gcccgaatca tgacagtcag caacatgata    420cctggatcca gccattcctg aagcccaccc tgcacctcat tccaactcct accgcgatac    480agacccacag agtgccatcc ctgagagacc agaccgctcc ccaatactct cctaaaataa    540acatgaagca caaaaacaaa aaaaaaaaaa aaaaa                               575</s400><s200><s210>12</s210><s211>126</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>4-1BB</s223></s220></s200><s400> 12aaacggggca gaaagaaact cctgtatata ttcaaacaac catttatgag accagtacaa     60actactcaag aggaagatgg ctgtagctgc cgatttccag aagaagaaga aggaggatgt    120gaactg                                                               126</s400><s200><s210>13</s210><s211>339</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>CD3-zeta</s223></s220></s200><s400> 13agagtgaagt tcagcaggag cgcagacgcc cccgcgtacc agcagggcca gaaccagctc     60tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc    120cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat    180gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc    240cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc    300tacgacgccc ttcacatgca ggccctgccc cctcgctaa                           339</s400><s200><s210>14</s210><s211>6</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Canonical hemi-tam</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(5)</s222><s223>X = any amino acid</s223></s220></s200><s400> 14Asp Gly Tyr Xaa Xaa Leu1               5</s400><s200><s210>15</s210><s211>6</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>ITSM Motif</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>N = S or T</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>x = any amino acid</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(5)</s222><s223>x = any amino acid</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>N = L or I</s223></s220></s200><s400> 15Asn Xaa Tyr Xaa Xaa Asn1               5</s400><s200><s210>16</s210><s211>614</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>Membrane-bound IL15</s223></s220></s200><s400> 16atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgaactggg tgaatgtaat aagtgatttg aaaaaaattg aagatcttat tcaatctatg    120catattgatg ctactttata tacggaaagt gatgttcacc ccagttgcaa agtaacagca    180atgaagtgct ttctcttgga gttacaagtt atttcacttg agtccggaga tgcaagtatt    240catgatacag tagaaaatct gatcatccta gcaaacaaca gtttgtcttc taatgggaat    300gtaacagaat ctggatgcaa agaatgtgag gaactggagg aaaaaaatat taaagaattt    360ttgcagagtt ttgtacatat tgtccaaatg ttcatcaaca cttctaccac gacgccagcg    420ccgcgaccac caacaccggc gcccaccatc gcgtcgcagc ccctgtccct gcgcccagag    480gcgtgccggc cagcggcggg gggcgcagtg cacacgaggg ggctggactt cgcctgtgat    540atctacatct gggcgccctt ggccgggact tgtggggtcc ttctcctgtc actggtatca    600ccctttactg ctaa                                                      614</s400><s200><s210>17</s210><s211>204</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Membrane-bound IL15</s223></s220></s200><s400> 17Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys            20                  25                  30Ile Glu Asp Leu Ile Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr        35                  40                  45Glu Ser Asp Val His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe    50                  55                  60Leu Leu Glu Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile65                  70                  75                  80His Asp Thr Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser                85                  90                  95Ser Asn Gly Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu            100                 105                 110Glu Glu Lys Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile Val        115                 120                 125Gln Met Phe Ile Asn Thr Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro    130                 135                 140Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu145                 150                 155                 160Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp                165                 170                 175Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly            180                 185                 190Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys        195                 200</s400><s200><s210>18</s210><s211>1140</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NKG2D/CD8a/4-1BB/CD3z</s223></s220><s220><s221>misc_feature</s221><s223>NKG2D/CD8a/4-1BB/CD3z (aka NK16)</s223></s220></s200><s400> 18atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacatacatc tgcatgcaaa ggactgtgac cacgacgcca    480gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca    540gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcctgt    600gatatctaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactggtt    660atcacccttt actgcaaacg gggcagaaag aaactcctgt atatattcaa acaaccattt    720atgagaccag tacaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa    780gaagaaggag gatgtgaact gagagtgaag ttcagcagga gcgcagacgc ccccgcgtac    840cagcagggcc agaaccagct ctataacgag ctcaatctag gacgaagaga ggagtacgat    900gttttggaca agagacgtgg ccgggaccct gagatggggg gaaagccgag aaggaagaac    960cctcaggaag gcctgtacaa tgaactgcag aaagataaga tggcggaggc ctacagtgag   1020attgggatga aaggcgagcg ccggaggggc aaggggcacg atggccttta ccagggtctc   1080agtacagcca ccaaggacac ctacgacgcc cttcacatgc aggccctgcc ccctcgctaa   1140</s400><s200><s210>19</s210><s211>379</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino acid sequence of NKG2D/CD8a/4-1BB/CD3z</s223></s220><s220><s221>MISC_FEATURE</s221><s223>Amino acid sequence of NKG2D/CD8a/4-1BB/CD3z      (aka NK16)</s223></s220></s200><s400> 19Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu        195                 200                 205Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr    210                 215                 220Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe225                 230                 235                 240Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg                245                 250                 255Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser            260                 265                 270Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr        275                 280                 285Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys    290                 295                 300Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn305                 310                 315                 320Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu                325                 330                 335Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly            340                 345                 350His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr        355                 360                 365Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg    370                 375</s400><s200><s210>20</s210><s211>46</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino acid for NCR1 TM/IC</s223></s220></s200><s400> 20Met Gly Leu Ala Phe Leu Val Leu Val Ala Leu Val Trp Phe Leu Val1               5                   10                  15Glu Asp Trp Leu Ser Arg Lys Arg Thr Arg Glu Arg Ala Ser Arg Ala            20                  25                  30Ser Thr Trp Glu Gly Arg Arg Arg Leu Asn Thr Gln Thr Leu        35                  40                  45</s400><s200><s210>21</s210><s211>276</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Full length NCR2</s223></s220></s200><s400> 21Met Ala Trp Arg Ala Leu His Pro Leu Leu Leu Leu Leu Leu Leu Phe1               5                   10                  15Pro Gly Ser Gln Ala Gln Ser Lys Ala Gln Val Leu Gln Ser Val Ala            20                  25                  30Gly Gln Thr Leu Thr Val Arg Cys Gln Tyr Pro Pro Thr Gly Ser Leu        35                  40                  45Tyr Glu Lys Lys Gly Trp Cys Lys Glu Ala Ser Ala Leu Val Cys Ile    50                  55                  60Arg Leu Val Thr Ser Ser Lys Pro Arg Thr Met Ala Trp Thr Ser Arg65                  70                  75                  80Phe Thr Ile Trp Asp Asp Pro Asp Ala Gly Phe Phe Thr Val Thr Met                85                  90                  95Thr Asp Leu Arg Glu Glu Asp Ser Gly His Tyr Trp Cys Arg Ile Tyr            100                 105                 110Arg Pro Ser Asp Asn Ser Val Ser Lys Ser Val Arg Phe Tyr Leu Val        115                 120                 125Val Ser Pro Ala Ser Ala Ser Thr Gln Thr Ser Trp Thr Pro Arg Asp    130                 135                 140Leu Val Ser Ser Gln Thr Gln Thr Gln Ser Cys Val Pro Pro Thr Ala145                 150                 155                 160Gly Ala Arg Gln Ala Pro Glu Ser Pro Ser Thr Ile Pro Val Pro Ser                165                 170                 175Gln Pro Gln Asn Ser Thr Leu Arg Pro Gly Pro Ala Ala Pro Ile Ala            180                 185                 190Leu Val Pro Val Phe Cys Gly Leu Leu Val Ala Lys Ser Leu Val Leu        195                 200                 205Ser Ala Leu Leu Val Trp Trp Gly Asp Ile Trp Trp Lys Thr Met Met    210                 215                 220Glu Leu Arg Ser Leu Asp Thr Gln Lys Ala Thr Cys His Leu Gln Gln225                 230                 235                 240Val Thr Asp Leu Pro Trp Thr Ser Val Ser Ser Pro Val Glu Arg Glu                245                 250                 255Ile Leu Tyr His Thr Val Ala Arg Thr Lys Ile Ser Asp Asp Asp Asp            260                 265                 270Glu His Thr Leu        275</s400><s200><s210>22</s210><s211>66</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>NCR3 TM/IC domains</s223></s220></s200><s400> 22Ala Gly Thr Val Leu Leu Leu Arg Ala Gly Phe Tyr Ala Val Ser Phe1               5                   10                  15Leu Ser Val Ala Val Gly Ser Thr Val Tyr Tyr Gln Gly Lys Cys Leu            20                  25                  30Thr Trp Lys Gly Pro Arg Arg Gln Leu Pro Ala Val Val Pro Ala Pro        35                  40                  45Leu Pro Pro Pro Cys Gly Ser Ser Ala His Leu Leu Pro Pro Val Pro    50                  55                  60Gly Gly65</s400><s200><s210>23</s210><s211>741</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NKG2D/CD16</s223></s220></s200><s400> 23atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgcccgc     60cccctgttca accaggaagt gcagatcccc ctgaccgagt cctattgtgg cccttgccct    120aagaattgga tttgctataa aaacaactgc taccagttct ttgacgagtc taagaattgg    180tatgagtccc aggcctcttg tatgagccag aacgcctctc tgctgaaggt gtacagcaag    240gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc    300cccacaaacg gctcttggca gtgggaggac ggctccatcc tgtctcctaa tctgctgacc    360atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc    420gagaactgca gcacacccaa tacctacatc tgtatgcagc ggacagtgac cacaacccca    480gcacccaggc cccctacacc tgcaccaacc atcgcaagcc agccactgtc cctgaggcct    540gaggcatgta ggccagcagc aggaggagca gtgcacacac ggggcctgga cttcgcctgc    600gatgtgagct tttgtctggt catggtgctg ctgttcgccg tggataccgg cctgtatttt    660tccgtgaaga caaatatccg gtctagcacc agagactgga aggatcacaa gttcaaatgg    720aggaaggacc cacaggacaa g                                              741</s400><s200><s210>24</s210><s211>247</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>NKG2D/CD16</s223></s220></s200><s400> 24Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Val Ser Phe Cys Leu Val Met        195                 200                 205Val Leu Leu Phe Ala Val Asp Thr Gly Leu Tyr Phe Ser Val Lys Thr    210                 215                 220Asn Ile Arg Ser Ser Thr Arg Asp Trp Lys Asp His Lys Phe Lys Trp225                 230                 235                 240Arg Lys Asp Pro Gln Asp Lys                245</s400><s200><s210>25</s210><s211>870</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>CD8/NKG2DOpt/CD8a/CD16 TM/IC/4-1BB</s223></s220></s200><s400> 25atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga     60ccactgttca atcaggaagt ccagatcccc ctgacagagt cttactgcgg cccatgtccc    120aagaactgga tctgctacaa gaacaattgt tatcagttct ttgacgagag caagaactgg    180tatgagtccc aggcctcttg catgagccag aatgcctctc tgctgaaggt gtacagcaag    240gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc    300cctacaaacg gctcttggca gtgggaggac ggctccatcc tgtctccaaa tctgctgacc    360atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc    420gagaactgct ccacacccaa tacctacatc tgtatgcaga ggaccgtgac cacaacccct    480gcaccacgcc cccctacacc agcacctacc atcgcaagcc agcctctgtc cctgcggcca    540gaggcatgta gaccagcagc aggaggagca gtgcacacaa gaggcctgga cttcgcctgc    600gatgtgagct tttgtctggt catggtgctg ctgttcgccg tggataccgg cctgtacttt    660tccgtgaaga caaatatcag gtctagcacc cgcgactgga aggatcacaa gtttaagtgg    720cggaaggacc ctcaggataa gaagcggggc agaaagaagc tgctgtatat cttcaagcag    780cccttcatgc ggcccgtgca gacaacccag gaggaagacg gctgctcatg tagatttcct    840gaagaagaag aagggggctg tgaactgtaa                                     870</s400><s200><s210>26</s210><s211>289</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>CD8/NKG2DOpt/CD8a/CD16 TM/IC/4-1BB</s223></s220></s200><s400> 26Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Val Ser Phe Cys Leu Val Met        195                 200                 205Val Leu Leu Phe Ala Val Asp Thr Gly Leu Tyr Phe Ser Val Lys Thr    210                 215                 220Asn Ile Arg Ser Ser Thr Arg Asp Trp Lys Asp His Lys Phe Lys Trp225                 230                 235                 240Arg Lys Asp Pro Gln Asp Lys Lys Arg Gly Arg Lys Lys Leu Leu Tyr                245                 250                 255Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu            260                 265                 270Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu        275                 280                 285Leu</s400><s200><s210>27</s210><s211>741</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NKG2D/NCR1</s223></s220></s200><s400> 27atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgcccgc     60cctctgttca accaggaagt gcagatccct ctgaccgaaa gctattgcgg accttgccct    120aagaattgga tttgctataa aaacaactgc taccagttct ttgacgagtc taagaattgg    180tatgagtctc aggccagctg tatgtcccag aacgcctctc tgctgaaggt gtacagcaag    240gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc    300cccacaaacg gctcttggca gtgggaggac ggctctatcc tgagccctaa tctgctgacc    360atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc    420gagaactgca gcacacccaa tacctacatc tgtatgcaga ggacagtgac cacaacccca    480gcaccccgcc cccctacacc tgcaccaacc atcgcaagcc agccactgtc cctgcggcct    540gaggcctgca gaccagcagc aggaggagca gtgcacaccc ggggcctgga cttcgcctgt    600gatatgggcc tggcctttct ggtgctggtg gccctggtgt ggtttctggt ggaggattgg    660ctgtcccgga agagaacaag ggagagggcc tcccgggcct ctacctggga aggaagaagg    720agactgaaca cccagacact g                                              741</s400><s200><s210>28</s210><s211>247</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>NKG2D/NCR1</s223></s220></s200><s400> 28Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Met Gly Leu Ala Phe Leu Val        195                 200                 205Leu Val Ala Leu Val Trp Phe Leu Val Glu Asp Trp Leu Ser Arg Lys    210                 215                 220Arg Thr Arg Glu Arg Ala Ser Arg Ala Ser Thr Trp Glu Gly Arg Arg225                 230                 235                 240Arg Leu Asn Thr Gln Thr Leu                245</s400><s200><s210>29</s210><s211>801</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NKG2D/NCR3</s223></s220></s200><s400> 29atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccaga     60cccctgttca accaggaggt gcagattccc ctgacagaaa gctattgtgg cccttgccct    120aaaaattgga tttgctataa aaacaactgc taccagttct ttgacgagtc taagaattgg    180tatgagtctc aggccagctg tatgtcccag aacgcctctc tgctgaaggt gtacagcaag    240gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc    300cctacaaacg gctcttggca gtgggaggac ggctctatcc tgagcccaaa tctgctgacc    360atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc    420gagaactgca gcacacccaa tacctacatc tgtatgcagc ggacagtgac cacaacccca    480gcacccagac cccctacacc tgcaccaacc atcgccagcc agccactgtc cctgaggccc    540gaggcatgca ggcctgcagc aggaggcgcc gtgcacacaa ggggcctgga ctttgcctgt    600gatgcaggaa ccgtgctgct gctgagagca ggcttctatg ccgtgtcctt tctgtctgtg    660gccgtgggct ccacagtgta ctatcagggc aagtgcctga cctggaaggg cccacggaga    720cagctgcccg ccgtggtgcc cgcccctctg ccaccccctt gtggcagtag cgcccacctg    780ctgccacccg tgcccggagg a                                              801</s400><s200><s210>30</s210><s211>267</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>NKG2D/NCR3</s223></s220></s200><s400> 30Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Ala Gly Thr Val Leu Leu Leu        195                 200                 205Arg Ala Gly Phe Tyr Ala Val Ser Phe Leu Ser Val Ala Val Gly Ser    210                 215                 220Thr Val Tyr Tyr Gln Gly Lys Cys Leu Thr Trp Lys Gly Pro Arg Arg225                 230                 235                 240Gln Leu Pro Ala Val Val Pro Ala Pro Leu Pro Pro Pro Cys Gly Ser                245                 250                 255Ser Ala His Leu Leu Pro Pro Val Pro Gly Gly            260                 265</s400><s200><s210>31</s210><s211>6</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>N is an integer indicating the number of GGGGS      repeated</s223></s220></s200><s400> 31Gly Gly Gly Gly Ser Asn1               5</s400><s200><s210>32</s210><s211>60</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>GS3/CD8a</s223></s220></s200><s400> 32Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Thr1               5                   10                  15Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser            20                  25                  30Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly        35                  40                  45Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp    50                  55                  60</s400><s200><s210>33</s210><s211>45</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>GS9</s223></s220></s200><s400> 33Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser        35                  40                  45</s400><s200><s210>34</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>GS3</s223></s220></s200><s400> 34Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1               5                   10                  15</s400><s200><s210>35</s210><s211>120</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>2B4 ICR</s223></s220></s200><s400> 35Trp Arg Arg Lys Arg Lys Glu Lys Gln Ser Glu Thr Ser Pro Lys Glu1               5                   10                  15Phe Leu Thr Ile Tyr Glu Asp Val Lys Asp Leu Lys Thr Arg Arg Asn            20                  25                  30His Glu Gln Glu Gln Thr Phe Pro Gly Gly Gly Ser Thr Ile Tyr Ser        35                  40                  45Met Ile Gln Ser Gln Ser Ser Ala Pro Thr Ser Gln Glu Pro Ala Tyr    50                  55                  60Thr Leu Tyr Ser Leu Ile Gln Pro Ser Arg Lys Ser Gly Ser Arg Lys65                  70                  75                  80Arg Asn His Ser Pro Ser Phe Asn Ser Thr Ile Tyr Glu Val Ile Gly                85                  90                  95Lys Ser Gln Pro Lys Ala Gln Asn Pro Ala Arg Leu Ser Arg Lys Glu            100                 105                 110Leu Glu Asn Phe Asp Val Tyr Ser        115                 120</s400><s200><s210>36</s210><s211>360</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>2B4 ICR</s223></s220></s200><s400> 36tggaggagga aaaggaagga gaaacagagc gagacctccc ctaaggagtt cctgaccatc     60tacgaggacg tgaaggacct gaagaccagg aggaaccacg agcaggaaca gacctttcct    120ggcggaggca gcaccatcta cagcatgatc cagagccaga gcagcgcccc taccagccaa    180gagcctgcct acaccctgta cagcctgatc cagcccagca ggaaaagcgg ctccaggaag    240aggaaccaca gccccagctt caacagcacc atctatgagg tgatcggcaa gagccagccc    300aaggcccaga accctgccag gctgtccagg aaggagctgg agaacttcga cgtgtacagc    360</s400><s200><s210>37</s210><s211>38</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>NKp80 ICR</s223></s220></s200><s400> 37Met Gln Asp Glu Asp Gly Tyr Met Thr Leu Asn Val Gln Ser Lys Lys1               5                   10                  15Arg Ser Ser Ala Gln Thr Ser Gln Leu Thr Phe Lys Asp Tyr Ser Val            20                  25                  30Thr Leu His Trp Tyr Lys        35</s400><s200><s210>38</s210><s211>114</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NKp80 ICR</s223></s220></s200><s400> 38atgcaggatg aggacggcta tatgaccctg aacgtccagt ccaagaagag gtccagcgct     60cagaccagcc agctgacctt caaggactac tccgtgaccc tgcactggta caag          114</s400><s200><s210>39</s210><s211>30</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>B2Ad N-term ECD</s223></s220></s200><s400> 39Met Gly Gln Pro Gly Asn Gly Ser Ala Phe Leu Leu Ala Pro Asn Arg1               5                   10                  15Ser His Ala Pro Asp His Asp Val Thr Gln Gln Arg Asp Glu            20                  25                  30</s400><s200><s210>40</s210><s211>90</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>B2 AdR N-term ECD</s223></s220></s200><s400> 40atggggcaac ccgggaacgg cagcgccttc ttgctggcac ccaatagaag ccatgcgccg     60gaccacgacg tcacgcagca aagggacgag                                      90</s400><s200><s210>41</s210><s211>33</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>B2 AdR TM helix</s223></s220></s200><s400> 41Val Trp Val Val Gly Met Gly Ile Val Met Ser Leu Ile Val Leu Ala1               5                   10                  15Ile Val Phe Gly Asn Val Leu Val Ile Thr Ala Ile Ala Lys Phe Glu            20                  25                  30Arg</s400><s200><s210>42</s210><s211>99</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>B2AdR TM helix</s223></s220></s200><s400> 42gtgtgggtgg tgggcatggg catcgtcatg tctctcatcg tcctggccat cgtgtttggc     60aatgtgctgg tcatcacagc cattgccaag ttcgagcgt                            99</s400><s200><s210>43</s210><s211>924</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NK15_1</s223></s220></s200><s400> 43gccgccacca tggctctgcc cgtcaccgca ctgctgctgc ctctggctct gctgctgcac     60gccgcacgac cactgttcaa tcaggaagtc cagatccccc tgacagagtc ttactgcggc    120ccatgtccca agaactggat ctgctacaag aacaattgtt atcagttctt tgacgagagc    180aagaactggt atgagtccca ggcctcttgc atgagccaga atgcctctct gctgaaggtg    240tacagcaagg aggaccagga tctgctgaag ctggtgaagt cctatcactg gatgggcctg    300gtgcacatcc ctacaaacgg ctcttggcag tgggaggacg gctccatcct gtctccaaat    360ctgctgacca tcatcgagat gcagaagggc gattgcgccc tgtacgccag ctccttcaag    420ggctatatcg agaactgctc cacacccaat acctacatct gtatgcagag gaccgtgggt    480ggcggtggct cgggcggtgg tgggtcgggt ggcggcggat ctaccacaac ccctgcacca    540cgccccccta caccagcacc taccatcgca agccagcctc tgtccctgcg gccagaggca    600tgtagaccag cagcaggagg agcagtgcac acaagaggcc tggacttcgc ctgcgatgtg    660agcttttgtc tggtcatggt gctgctgttc gccgtggata ccggcctgta cttttccgtg    720aagacaaata tcaggtctag cacccgcgac tggaaggatc acaagtttaa gtggcggaag    780gaccctcagg ataagaagcg gggcagaaag aagctgctgt atatcttcaa gcagcccttc    840atgcggcccg tgcagacaac ccaggaggaa gacggctgct catgtagatt tcctgaagaa    900gaagaagggg gctgtgaact gtaa                                           924</s400><s200><s210>44</s210><s211>789</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NK15_2</s223></s220></s200><s400> 44gccgccacca tggctctgcc cgtcaccgca ctgctgctgc ctctggctct gctgctgcac     60gccgcacgac cactgttcaa tcaggaagtc cagatccccc tgacagagtc ttactgcggc    120ccatgtccca agaactggat ctgctacaag aacaattgtt atcagttctt tgacgagagc    180aagaactggt atgagtccca ggcctcttgc atgagccaga atgcctctct gctgaaggtg    240tacagcaagg aggaccagga tctgctgaag ctggtgaagt cctatcactg gatgggcctg    300gtgcacatcc ctacaaacgg ctcttggcag tgggaggacg gctccatcct gtctccaaat    360ctgctgacca tcatcgagat gcagaagggc gattgcgccc tgtacgccag ctccttcaag    420ggctatatcg agaactgctc cacacccaat acctacatct gtatgcagag gaccgtgggt    480ggcggtggct cgggcggtgg tgggtcgggt ggcggcggat ctgtgagctt ttgtctggtc    540atggtgctgc tgttcgccgt ggataccggc ctgtactttt ccgtgaagac aaatatcagg    600tctagcaccc gcgactggaa ggatcacaag tttaagtggc ggaaggaccc tcaggataag    660aagcggggca gaaagaagct gctgtatatc ttcaagcagc ccttcatgcg gcccgtgcag    720acaacccagg aggaagacgg ctgctcatgt agatttcctg aagaagaaga agggggctgt    780gaactgtaa                                                            789</s400><s200><s210>45</s210><s211>744</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NK15_3</s223></s220></s200><s400> 45gccgccacca tggctctgcc cgtcaccgca ctgctgctgc ctctggctct gctgctgcac     60gccgcacgac cactgttcaa tcaggaagtc cagatccccc tgacagagtc ttactgcggc    120ccatgtccca agaactggat ctgctacaag aacaattgtt atcagttctt tgacgagagc    180aagaactggt atgagtccca ggcctcttgc atgagccaga atgcctctct gctgaaggtg    240tacagcaagg aggaccagga tctgctgaag ctggtgaagt cctatcactg gatgggcctg    300gtgcacatcc ctacaaacgg ctcttggcag tgggaggacg gctccatcct gtctccaaat    360ctgctgacca tcatcgagat gcagaagggc gattgcgccc tgtacgccag ctccttcaag    420ggctatatcg agaactgctc cacacccaat acctacatct gtatgcagag gaccgtggtg    480agcttttgtc tggtcatggt gctgctgttc gccgtggata ccggcctgta cttttccgtg    540aagacaaata tcaggtctag cacccgcgac tggaaggatc acaagtttaa gtggcggaag    600gaccctcagg ataagaagcg gggcagaaag aagctgctgt atatcttcaa gcagcccttc    660atgcggcccg tgcagacaac ccaggaggaa gacggctgct catgtagatt tcctgaagaa    720gaagaagggg gctgtgaact gtaa                                           744</s400><s200><s210>46</s210><s211>1164</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NK15_4</s223></s220></s200><s400> 46gccgccacca tggccctgcc tgtgacagcc ctgctgctgc ctctggctct gctgctgcac     60gctgccagac ccttattcaa ccaagaagtt caaattccct tgaccgaaag ttactgtggc    120ccatgtccta aaaactggat atgttacaaa aataactgct accaattttt tgatgagagt    180aaaaactggt atgagagcca ggcttcttgt atgtctcaaa atgccagcct tctgaaagta    240tacagcaaag aggaccagga tttacttaaa ctggtgaagt catatcattg gatgggacta    300gtacacattc caacaaatgg atcttggcag tgggaagatg gctccattct ctcacccaac    360ctactaacaa taattgaaat gcagaaggga gactgtgcac tctatgcctc gagctttaaa    420ggctatatag aaaactgttc aactccaaat acgtacatct gcatgcaaag gactgtgacc    480acaacccccg ctcccagacc tcctacccct gcccctacaa tcgccagcca gcccctgagc    540ctgagacccg aagcctgtag acctgctgcc ggaggcgctg tgcacacaag aggcctggac    600ttcgcctgcg atatctatat ctgggcccct ctggctggaa cctgtggcgt gctgctgctg    660agcctggtga ttaccaagag gggcaggaag aagctgctgt acatcttcaa gcagcctttc    720atgaggcccg tgcaaaccac ccaggaggag gacggctgca gctgcagatt ccctgaggag    780gaggagggcg gatgcgagct gtggaggagg aaaaggaagg agaaacagag cgagacctcc    840cctaaggagt tcctgaccat ctacgaggac gtgaaggacc tgaagaccag gaggaaccac    900gagcaggaac agacctttcc tggcggaggc agcaccatct acagcatgat ccagagccag    960agcagcgccc ctaccagcca agagcctgcc tacaccctgt acagcctgat ccagcccagc   1020aggaaaagcg gctccaggaa gaggaaccac agccccagct tcaacagcac catctatgag   1080gtgatcggca agagccagcc caaggcccag aaccctgcca ggctgtccag gaaggagctg   1140gagaacttcg acgtgtacag ctga                                          1164</s400><s200><s210>47</s210><s211>1155</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NK15_5</s223></s220></s200><s400> 47gccgccacca tggccctgcc tgtgacagcc ctgctgctgc ctctggctct gctgctgcac     60gctgccagac ccttattcaa ccaagaagtt caaattccct tgaccgaaag ttactgtggc    120ccatgtccta aaaactggat atgttacaaa aataactgct accaattttt tgatgagagt    180aaaaactggt atgagagcca ggcttcttgt atgtctcaaa atgccagcct tctgaaagta    240tacagcaaag aggaccagga tttacttaaa ctggtgaagt catatcattg gatgggacta    300gtacacattc caacaaatgg atcttggcag tgggaagatg gctccattct ctcacccaac    360ctactaacaa taattgaaat gcagaaggga gactgtgcac tctatgcctc gagctttaaa    420ggctatatag aaaactgttc aactccaaat acgtacatct gcatgcaaag gactgtgatg    480ggacagcctg gaaacggcag cgccttcctg ctggccccta acagaagcca cgcccccgat    540cacgatgtga cccagcagag ggacgaggtg tgggtggtgg gcatgggcat cgtgatgagc    600ctgatcgtgc tggctatcgt gttcggcaac gtgctggtga tcaccgccat cgccaagttc    660gagaggaaga ggggcaggaa aaagctgctc tacatcttca agcagccctt catgaggccc    720gtgcagacca cccaggaaga ggatggctgc tcctgtaggt ttcccgagga ggaggagggc    780ggctgtgagc tgtggaggag aaaaaggaag gagaagcaga gcgagaccag ccccaaggag    840ttcctgacca tctacgagga cgtgaaggac ctgaagacca ggaggaacca cgagcaggaa    900cagaccttcc ccggcggagg cagcaccatc tacagcatga tccagagcca gtccagcgcc    960cccacaagcc aggaacccgc ctacacactg tatagcctga tccagccctc caggaagagc   1020ggcagcagga agaggaacca cagccccagc ttcaacagca ccatttacga ggtgatcgga   1080aagagccagc ccaaggctca gaaccccgcc aggctgagca ggaaggagct cgaaaacttc   1140gacgtgtaca gctga                                                    1155</s400><s200><s210>48</s210><s211>1349</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NK15_6</s223></s220></s200><s400> 48ggatccgaat tcgccgccac catggccctg cctgtgacag ccctgctgct gcctctggct     60ctgctgctgc acgctgccag acccttattc aaccaagaag ttcaaattcc cttgaccgaa    120agttactgtg gcccatgtcc taaaaactgg atatgttaca aaaataactg ctaccaattt    180tttgatgaga gtaaaaactg gtatgagagc caggcttctt gtatgtctca aaatgccagc    240cttctgaaag tatacagcaa agaggaccag gatttactta aactggtgaa gtcatatcat    300tggatgggac tagtacacat tccaacaaat ggatcttggc agtgggaaga tggctccatt    360ctctcaccca acctactaac aataattgaa atgcagaagg gagactgtgc actctatgcc    420tcgagcttta aaggctatat agaaaactgt tcaactccaa atacgtacat ctgcatgcaa    480aggactgtga ccacaacccc tgctcccaga cctcccacac ccgcccctac aatcgcctcc    540cagcctctga gcctgagacc cgaagcctgt agacctgccg ccggcggagc tgtgcataca    600agaggcctgg acttcgcctg cgacatctac atctgggccc ctctggctgg cacatgcgga    660gtcctgctgc tgagcctggt gatcaccaag aggggcagga agaagctgct gtacatcttc    720aagcagccct tcatgaggcc tgtgcagacc acacaggagg aggacggctg ctcctgcagg    780ttccctgagg aggaggaggg aggctgcgag ctgtggagga ggaagagaaa ggagaagcag    840tccgagacct cccccaagga gttcctcacc atttacgagg acgtgaagga cctgaagacc    900aggagaaacc acgagcagga acaaaccttc cccggcggcg gcagcaccat ctacagcatg    960atccagagcc agtcctccgc ccctacaagc caggagcctg cctacaccct gtacagcctg   1020atccagccta gcaggaagag cggctccagg aagaggaacc actcccccag cttcaacagc   1080accatttatg aggtgatcgg caagtcccag cccaaggccc agaaccctgc cagactgtcc   1140aggaaggagc tggagaactt cgacgtctac tccggcggcg gcggcagcgg cggaggaggc   1200tccggaggag gcggcagcat gcaggatgag gacggctata tgaccctgaa cgtccagtcc   1260aagaagaggt ccagcgctca gaccagccag ctgaccttca aggactactc cgtgaccctg   1320cactggtaca agtgagcggc cgcgtcgac                                     1349</s400><s200><s210>49</s210><s211>989</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NK15_7</s223></s220></s200><s400> 49ggatccgaat tcgccgccac catggccctg cctgtgacag ccctgctgct gcctctggct     60ctgctgctgc atgccgccag acccttattc aaccaagaag ttcaaattcc cttgaccgaa    120agttactgtg gcccatgtcc taaaaactgg atatgttaca aaaataactg ctaccaattt    180tttgatgaga gtaaaaactg gtatgagagc caggcttctt gtatgtctca aaatgccagc    240cttctgaaag tatacagcaa agaggaccag gatttactta aactggtgaa gtcatatcat    300tggatgggac tagtacacat tccaacaaat ggatcttggc agtgggaaga tggctccatt    360ctctcaccca acctactaac aataattgaa atgcagaagg gagactgtgc actctatgcc    420tcgagcttta aaggctatat agaaaactgt tcaactccaa atacgtacat ctgcatgcaa    480aggactgtga ccaccacccc tgctcccaga ccccctacac ctgcccctac aatcgccagc    540cagcccctga gcctgagacc tgaggcctgc agacctgctg ctggaggcgc tgtgcacaca    600aggggcctcg acttcgcctg cgacatctac atctgggccc ctctggccgg cacatgtgga    660gtgctgctgc tgtccctggt gatcaccaag aggggcagga agaagctgct gtacatcttc    720aagcagccct tcatgaggcc cgtgcagacc acccaggagg aggacggctg ctcctgcaga    780ttccccgagg aggaggaggg cggatgtgaa ctgggcggag gaggcagcgg cggcggcggc    840agcggcggcg gcggcagcat gcaggatgag gacggctaca tgaccctgaa cgtgcagagc    900aagaagagga gcagcgccca gaccagccag ctgaccttca aggactacag cgtgaccctg    960cactggtaca agtgagcggc cgcgtcgac                                      989</s400><s200><s210>50</s210><s211>1430</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NK15_8</s223></s220></s200><s400> 50ggatccgaat tcgccgccac catggccctg cccgtgacag ctctgctgct gcctctggcc     60ctgctgctgc atgccgctag acccctgttc aaccaggagg tgcagatccc cctgaccgaa    120agctactgcg gcccctgccc caagaactgg atctgttaca agaacaactg ctatcagttc    180ttcgacgaga gcaagaactg gtacgagagc caggccagct gtatgagcca gaacgccagc    240ctgctgaaag tgtatagcaa ggaggaccag gacctgctga agctggtgaa gagctaccac    300tggatgggcc tggtgcacat ccccaccaac ggaagctggc agtgggagga cggcagcatc    360ctgagcccca acctgctgac catcatcgag atgcagaagg gcgactgcgc cctgtatgcc    420agcagcttca agggctacat cgagaactgt agcaccccca acacctacat ctgcatgcag    480aggaccgtgg gcggcggcgg cagcggcgga ggcggctccg gcggcggcgg cagcttattc    540aaccaagaag ttcaaattcc cttgaccgaa agttactgtg gcccatgtcc taaaaactgg    600atatgttaca aaaataactg ctaccaattt tttgatgaga gtaaaaactg gtatgagagc    660caggcttctt gtatgtctca aaatgccagc cttctgaaag tatacagcaa agaggaccag    720gatttactta aactggtgaa gtcatatcat tggatgggac tagtacacat tccaacaaat    780ggatcttggc agtgggaaga tggctccatt ctctcaccca acctactaac aataattgaa    840atgcagaagg gagactgtgc actctatgcc tcgagcttta aaggctatat agaaaactgt    900tcaactccaa atacgtacat ctgcatgcaa aggactgtga tgggccagcc tggcaacggc    960agcgcctttc tgctggcccc caacaggagc catgcccctg accacgacgt gacccagcag   1020agggacgagg tgtgggtggt gggcatgggc atcgtgatga gcctgatcgt gctggccatc   1080gtgttcggca acgtgctggt gatcaccgcc atcgccaagt tcgagaggaa gaggggcagg   1140aagaagctgc tgtacatctt caagcagccc ttcatgagac ccgtgcaaac cacccaggag   1200gaggacggct gcagctgcag gtttcccgag gaggaggagg gcggatgcga actgggaggc   1260ggaggaagcg gaggaggagg atccggagga ggcggaagca tgcaggacga ggacggctac   1320atgaccctga acgtccagag caagaagagg agcagcgccc agacctccca gctgaccttc   1380aaggactact ccgtgaccct gcactggtac aagtgagcgg ccgcgtcgac              1430</s400><s200><s210>51</s210><s211>1439</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NK15_9</s223></s220></s200><s400> 51ggatccgaat tcgccgccac catggccctg cccgtgacag ctctgctgct gcctctggcc     60ctgctgctgc atgccgctag acccctgttc aaccaggagg tgcagatccc cctgaccgaa    120agctactgcg gcccctgccc caagaactgg atctgttaca agaacaactg ctatcagttc    180ttcgacgaga gcaagaactg gtacgagagc caggccagct gtatgagcca gaacgccagc    240ctgctgaaag tgtatagcaa ggaggaccag gacctgctga agctggtgaa gagctaccac    300tggatgggcc tggtgcacat ccccaccaac ggaagctggc agtgggagga cggcagcatc    360ctgagcccca acctgctgac catcatcgag atgcagaagg gcgactgcgc cctgtatgcc    420agcagcttca agggctacat cgagaactgt agcaccccca acacctacat ctgcatgcag    480aggaccgtgg gcggcggcgg cagcggcgga ggcggctccg gcggcggcgg cagcttattc    540aaccaagaag ttcaaattcc cttgaccgaa agttactgtg gcccatgtcc taaaaactgg    600atatgttaca aaaataactg ctaccaattt tttgatgaga gtaaaaactg gtatgagagc    660caggcttctt gtatgtctca aaatgccagc cttctgaaag tatacagcaa agaggaccag    720gatttactta aactggtgaa gtcatatcat tggatgggac tagtacacat tccaacaaat    780ggatcttggc agtgggaaga tggctccatt ctctcaccca acctactaac aataattgaa    840atgcagaagg gagactgtgc actctatgcc tcgagcttta aaggctatat agaaaactgt    900tcaactccaa atacgtacat ctgcatgcaa aggactgtga ccaccacccc tgctcccaga    960ccccctacac ctgcccctac aatcgccagc cagcccctga gcctgagacc tgaggcctgc   1020agacctgctg ctggaggcgc tgtgcacaca aggggcctcg acttcgcctg cgacatctac   1080atctgggccc ctctggccgg cacatgtgga gtgctgctgc tgtccctggt gatcaccaag   1140aggggcagga agaagctgct gtacatcttc aagcagccct tcatgaggcc cgtgcagacc   1200acccaggagg aggacggctg ctcctgcaga ttccccgagg aggaggaggg cggatgtgaa   1260ctgggcggag gaggcagcgg cggcggcggc agcggcggcg gcggcagcat gcaggatgag   1320gacggctaca tgaccctgaa cgtgcagagc aagaagagga gcagcgccca gaccagccag   1380ctgaccttca aggactacag cgtgaccctg cactggtaca agtgagcggc cgcgtcgac    1439</s400><s200><s210>52</s210><s211>1329</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NK15_10</s223></s220></s200><s400> 52gccgccacaa tggccctgcc tgtgacagcc ctgctgctgc ctctggccct gctgctgcat     60gctgccaggc ctctgttcaa ccaggaggtg cagatccctc tgaccgagag ctactgcggc    120ccctgcccca agaactggat ctgctacaag aacaactgct accagttctt cgacgagagc    180aagaactggt acgagagcca ggccagctgc atgtcccaga acgctagcct gctgaaggtg    240tatagcaagg aggaccagga cctgctgaag ctggtgaaga gctaccactg gatgggcctg    300gtgcacatcc ccaccaacgg ctcctggcag tgggaggacg gcagcatcct gagccctaac    360ctgctgacca tcatcgagat gcagaaggga gactgcgccc tgtacgccag ctcctttaag    420ggctacatcg agaactgcag cacccccaac acctacatct gtatgcagag gaccgtggga    480ggcggcggca gcggcggcgg cggcagcggc ggcggcggca gcttattcaa ccaagaagtt    540caaattccct tgaccgaaag ttactgtggc ccatgtccta aaaactggat atgttacaaa    600aataactgct accaattttt tgatgagagt aaaaactggt atgagagcca ggcttcttgt    660atgtctcaaa atgccagcct tctgaaagta tacagcaaag aggaccagga tttacttaaa    720ctggtgaagt catatcattg gatgggacta gtacacattc caacaaatgg atcttggcag    780tgggaagatg gctccattct ctcacccaac ctactaacaa taattgaaat gcagaaggga    840gactgtgcac tctatgcctc gagctttaaa ggctatatag aaaactgttc aactccaaat    900acgtacatct gcatgcaaag gactgtgacc accacccctg cccctagacc ccctacacct    960gcccctacca tcgccagcca gcctctgagc ctgagacccg aggcctgtag acctgctgcc   1020ggaggagccg tgcacacaag aggcctggac ttcgcctgcg acgtgagctt ctgcctggtg   1080atggtgctgc tgttcgccgt ggacaccggc ctgtacttca gcgtgaagac caacatcagg   1140agcagcacca gggactggaa ggaccacaaa ttcaagtgga ggaaggaccc ccaggacaag   1200aagaggggca ggaagaagct gctgtacatc ttcaagcagc ccttcatgag gcctgtgcag   1260accacccagg aggaggacgg ctgcagctgc aggttccctg aggaggaaga gggcggctgc   1320gagctgtga                                                           1329</s400><s200><s210>53</s210><s211>1239</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NK15_11</s223></s220></s200><s400> 53gccgccacca tggctctgcc cgtcaccgca ctgctgctgc ctctggctct gctgctgcac     60gccgcacgac cactgttcaa tcaggaagtc cagatccccc tgacagagtc ttactgcggc    120ccatgtccca agaactggat ctgctacaag aacaattgtt atcagttctt tgacgagagc    180aagaactggt atgagtccca ggcctcttgc atgagccaga atgcctctct gctgaaggtg    240tacagcaagg aggaccagga tctgctgaag ctggtgaagt cctatcactg gatgggcctg    300gtgcacatcc ctacaaacgg ctcttggcag tgggaggacg gctccatcct gtctccaaat    360ctgctgacca tcatcgagat gcagaagggc gattgcgccc tgtacgccag ctccttcaag    420ggctatatcg agaactgctc cacacccaat acctacatct gtatgcagag gaccgtgacc    480acaacccctg caccacgccc ccctacacca gcacctacca tcgcaagcca gcctctgtcc    540ctgcggccag aggcatgtag accagcagca ggaggagcag tgcacacaag aggcctggac    600ttcgcctgcg atgtgagctt ttgtctggtc atggtgctgc tgttcgccgt ggataccggc    660ctgtactttt ccgtgaagac aaatatcagg tctagcaccc gcgactggaa ggatcacaag    720tttaagtggc ggaaggaccc tcaggataag aagcggggca gaaagaagct gctgtatatc    780ttcaagcagc ccttcatgcg gcccgtgcag acaacccagg aggaagacgg ctgctcatgt    840agatttcctg aagaagaaga agggggctgt gaactgtgga ggaggaaaag gaaggagaaa    900cagagcgaga cctcccctaa ggagttcctg accatctacg aggacgtgaa ggacctgaag    960accaggagga accacgagca ggaacagacc tttcctggcg gaggcagcac catctacagc   1020atgatccaga gccagagcag cgcccctacc agccaagagc ctgcctacac cctgtacagc   1080ctgatccagc ccagcaggaa aagcggctcc aggaagagga accacagccc cagcttcaac   1140agcaccatct atgaggtgat cggcaagagc cagcccaagg cccagaaccc tgccaggctg   1200tccaggaagg agctggagaa cttcgacgtg tacagctga                          1239</s400><s200><s210>54</s210><s211>1064</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NK15_12</s223></s220></s200><s400> 54ggatccgaat tcgccgccac catggctctg cccgtcaccg cactgctgct gcctctggct     60ctgctgctgc acgccgcacg accactgttc aatcaggaag tccagatccc cctgacagag    120tcttactgcg gcccatgtcc caagaactgg atctgctaca agaacaattg ttatcagttc    180tttgacgaga gcaagaactg gtatgagtcc caggcctctt gcatgagcca gaatgcctct    240ctgctgaagg tgtacagcaa ggaggaccag gatctgctga agctggtgaa gtcctatcac    300tggatgggcc tggtgcacat ccctacaaac ggctcttggc agtgggagga cggctccatc    360ctgtctccaa atctgctgac catcatcgag atgcagaagg gcgattgcgc cctgtacgcc    420agctccttca agggctatat cgagaactgc tccacaccca atacctacat ctgtatgcag    480aggaccgtga ccacaacccc tgcaccacgc ccccctacac cagcacctac catcgcaagc    540cagcctctgt ccctgcggcc agaggcatgt agaccagcag caggaggagc agtgcacaca    600agaggcctgg acttcgcctg cgatgtgagc ttttgtctgg tcatggtgct gctgttcgcc    660gtggataccg gcctgtactt ttccgtgaag acaaatatca ggtctagcac ccgcgactgg    720aaggatcaca agtttaagtg gcggaaggac cctcaggata agaagcgggg cagaaagaag    780ctgctgtata tcttcaagca gcccttcatg cggcccgtgc agacaaccca ggaggaagac    840ggctgctcat gtagatttcc tgaagaagaa gaagggggct gtgaactggg cggaggaggc    900agcggcggcg gcggcagcgg cggcggcggc agcatgcagg atgaggacgg ctacatgacc    960ctgaacgtgc agagcaagaa gaggagcagc gcccagacca gccagctgac cttcaaggac   1020tacagcgtga ccctgcactg gtacaagtga gcggccgcgt cgac                    1064</s400><s200><s210>55</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>FLAG tag</s223></s220></s200><s400> 55Asp Tyr Lys Asp Asp Asp Asp Lys1               5</s400><s200><s210>56</s210><s211>6</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>His tag</s223></s220></s200><s400> 56His His His His His His1               5</s400><s200><s210>57</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Myc tag</s223></s220></s200><s400> 57Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu1               5                   10</s400><s200><s210>58</s210><s211>1499</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence for Variant 13</s223></s220></s200><s400> 58atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca    480gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca    540gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcctgt    600gatatctaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactggtt    660atcacccttt actgcaaacg gggcagaaag aaactcctgt atatattcaa acaaccattt    720atgagaccag tacaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa    780gaagaaggag gatgtgaact gtggaggagg aaaaggaagg agaaacagag cgagacctcc    840cctaaggagt tcctgaccat ctacgaggac gtgaaggacc tgaagaccag gaggaaccac    900gagcaggaac agacctttcc tggcggaggc agcaccatct acagcatgat ccagagccag    960agcagcgccc ctaccagcca agagcctgcc tacaccctgt acagcctgat ccagcccagc   1020aggaaaagcg gctccaggaa gaggaaccac agccccagct tcaacagcac catctatgag   1080gtgatcggca agagccagcc caaggcccag aaccctgcca ggctgtccag gaaggagctg   1140gagaacttcg acgtgtacag cagagtgaag ttcagcagga gcgcagacgc ccccgcgtac   1200cagcagggcc agaaccagct ctataacgag ctcaatctag gacgaagaga ggagtacgat   1260gttttggaca agagacgtgg ccgggaccct gagatggggg gaaagccgag aaggaagaac   1320cctcaggaag gcctgtacaa tgaactgcag aaagataaga tggcggaggc ctacagtgag   1380attgggatga aaggcgagcg ccggaggggc aaggggcacg atggccttta ccagggtctc   1440agtacagcca ccaaggacac ctacgacgcc cttcacatgc aggccctgcc ccctcgcta    1499</s400><s200><s210>59</s210><s211>499</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence for Variant 13</s223></s220></s200><s400> 59Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu        195                 200                 205Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr    210                 215                 220Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe225                 230                 235                 240Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg                245                 250                 255Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Trp Arg Arg Lys Arg            260                 265                 270Lys Glu Lys Gln Ser Glu Thr Ser Pro Lys Glu Phe Leu Thr Ile Tyr        275                 280                 285Glu Asp Val Lys Asp Leu Lys Thr Arg Arg Asn His Glu Gln Glu Gln    290                 295                 300Thr Phe Pro Gly Gly Gly Ser Thr Ile Tyr Ser Met Ile Gln Ser Gln305                 310                 315                 320Ser Ser Ala Pro Thr Ser Gln Glu Pro Ala Tyr Thr Leu Tyr Ser Leu                325                 330                 335Ile Gln Pro Ser Arg Lys Ser Gly Ser Arg Lys Arg Asn His Ser Pro            340                 345                 350Ser Phe Asn Ser Thr Ile Tyr Glu Val Ile Gly Lys Ser Gln Pro Lys        355                 360                 365Ala Gln Asn Pro Ala Arg Leu Ser Arg Lys Glu Leu Glu Asn Phe Asp    370                 375                 380Val Tyr Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr385                 390                 395                 400Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg                405                 410                 415Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met            420                 425                 430Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu        435                 440                 445Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys    450                 455                 460Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu465                 470                 475                 480Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu                485                 490                 495Pro Pro Arg</s400><s200><s210>60</s210><s211>870</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence Variant 14</s223></s220></s200><s400> 60atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca    480gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca    540gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcctgt    600gatatctaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactggtt    660atcacccttt actgcaaacg gggcagaaag aaactcctgt atatattcaa acaaccattt    720atgagaccag tacaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa    780gaagaaggag gatgtgaact gctgtgcgca cgcccacgcc gcagccccgc ccaagatggc    840aaagtctaca tcaacatgcc aggcaggggc                                     870</s400><s200><s210>61</s210><s211>290</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence Variant 14</s223></s220></s200><s400> 61Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu        195                 200                 205Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr    210                 215                 220Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe225                 230                 235                 240Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg                245                 250                 255Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Leu Cys Ala Arg Pro            260                 265                 270Arg Arg Ser Pro Ala Gln Asp Gly Lys Val Tyr Ile Asn Met Pro Gly        275                 280                 285Arg Gly    290</s400><s200><s210>62</s210><s211>1230</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence Variant 15</s223></s220></s200><s400> 62atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca    480gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca    540gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcctgt    600gatatctaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactggtt    660atcacccttt actgcaaacg gggcagaaag aaactcctgt atatattcaa acaaccattt    720atgagaccag tacaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa    780gaagaaggag gatgtgaact gctgtgcgca cgcccacgcc gcagccccgc ccaagatggc    840aaagtctaca tcaacatgcc aggcaggggc tggaggagga aaaggaagga gaaacagagc    900gagacctccc ctaaggagtt cctgaccatc tacgaggacg tgaaggacct gaagaccagg    960aggaaccacg agcaggaaca gacctttcct ggcggaggca gcaccatcta cagcatgatc   1020cagagccaga gcagcgcccc taccagccaa gagcctgcct acaccctgta cagcctgatc   1080cagcccagca ggaaaagcgg ctccaggaag aggaaccaca gccccagctt caacagcacc   1140atctatgagg tgatcggcaa gagccagccc aaggcccaga accctgccag gctgtccagg   1200aaggagctgg agaacttcga cgtgtacagc                                    1230</s400><s200><s210>63</s210><s211>410</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence Variant 15</s223></s220></s200><s400> 63Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu        195                 200                 205Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr    210                 215                 220Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe225                 230                 235                 240Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg                245                 250                 255Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Leu Cys Ala Arg Pro            260                 265                 270Arg Arg Ser Pro Ala Gln Asp Gly Lys Val Tyr Ile Asn Met Pro Gly        275                 280                 285Arg Gly Trp Arg Arg Lys Arg Lys Glu Lys Gln Ser Glu Thr Ser Pro    290                 295                 300Lys Glu Phe Leu Thr Ile Tyr Glu Asp Val Lys Asp Leu Lys Thr Arg305                 310                 315                 320Arg Asn His Glu Gln Glu Gln Thr Phe Pro Gly Gly Gly Ser Thr Ile                325                 330                 335Tyr Ser Met Ile Gln Ser Gln Ser Ser Ala Pro Thr Ser Gln Glu Pro            340                 345                 350Ala Tyr Thr Leu Tyr Ser Leu Ile Gln Pro Ser Arg Lys Ser Gly Ser        355                 360                 365Arg Lys Arg Asn His Ser Pro Ser Phe Asn Ser Thr Ile Tyr Glu Val    370                 375                 380Ile Gly Lys Ser Gln Pro Lys Ala Gln Asn Pro Ala Arg Leu Ser Arg385                 390                 395                 400Lys Glu Leu Glu Asn Phe Asp Val Tyr Ser                405                 410</s400><s200><s210>64</s210><s211>1232</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence Variant 16</s223></s220></s200><s400> 64atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca    480gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca    540gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcctgt    600gatatctaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactggtt    660atcacccttt actgcaaacg gggcagaaag aaactcctgt atatattcaa acaaccattt    720atgagaccag tacaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa    780gaagaaggag gatgtgaact gtggaggagg aaaaggaagg agaaacagag cgagacctcc    840cctaaggagt tcctgaccat ctacgaggac gtgaaggacc tgaagaccag gaggaaccac    900gagcaggaac agacctttcc tggcggaggc agcaccatct acagcatgat ccagagccag    960agcagcgccc ctaccagcca agagcctgcc tacaccctgt acagcctgat ccagcccagc   1020aggaaaagcg gctccaggaa gaggaaccac agccccagct tcaacagcac catctatgag   1080gtgatcggca agagccagcc caaggcccag aaccctgcca ggctgtccag gaaggagctg   1140gagaacttcg acgtgtacag cctgtgcgca cgcccacgcc gcagccccgc ccaagatggc   1200aaagtctaca tcaacatgcc aggcaggggc tg                                 1232</s400><s200><s210>65</s210><s211>410</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence Variant 16</s223></s220></s200><s400> 65Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu        195                 200                 205Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr    210                 215                 220Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe225                 230                 235                 240Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg                245                 250                 255Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Trp Arg Arg Lys Arg            260                 265                 270Lys Glu Lys Gln Ser Glu Thr Ser Pro Lys Glu Phe Leu Thr Ile Tyr        275                 280                 285Glu Asp Val Lys Asp Leu Lys Thr Arg Arg Asn His Glu Gln Glu Gln    290                 295                 300Thr Phe Pro Gly Gly Gly Ser Thr Ile Tyr Ser Met Ile Gln Ser Gln305                 310                 315                 320Ser Ser Ala Pro Thr Ser Gln Glu Pro Ala Tyr Thr Leu Tyr Ser Leu                325                 330                 335Ile Gln Pro Ser Arg Lys Ser Gly Ser Arg Lys Arg Asn His Ser Pro            340                 345                 350Ser Phe Asn Ser Thr Ile Tyr Glu Val Ile Gly Lys Ser Gln Pro Lys        355                 360                 365Ala Gln Asn Pro Ala Arg Leu Ser Arg Lys Glu Leu Glu Asn Phe Asp    370                 375                 380Val Tyr Ser Leu Cys Ala Arg Pro Arg Arg Ser Pro Ala Gln Asp Gly385                 390                 395                 400Lys Val Tyr Ile Asn Met Pro Gly Arg Gly                405                 410</s400><s200><s210>66</s210><s211>1587</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence Variant 17</s223></s220></s200><s400> 66atggccctgc ccgtgacagc tctgctgctg cctctggccc tgctgctgca tgccgctaga     60cccctgttca accaggaggt gcagatcccc ctgaccgaaa gctactgcgg cccctgcccc    120aagaactgga tctgttacaa gaacaactgc tatcagttct tcgacgagag caagaactgg    180tacgagagcc aggccagctg tatgagccag aacgccagcc tgctgaaagt gtatagcaag    240gaggaccagg acctgctgaa gctggtgaag agctaccact ggatgggcct ggtgcacatc    300cccaccaacg gaagctggca gtgggaggac ggcagcatcc tgagccccaa cctgctgacc    360atcatcgaga tgcagaaggg cgactgcgcc ctgtatgcca gcagcttcaa gggctacatc    420gagaactgta gcacccccaa cacctacatc tgcatgcaga ggaccgtggg cggcggcggc    480agcggcggag gcggctccgg cggcggcggc agcttattca accaagaagt tcaaattccc    540ttgaccgaaa gttactgtgg cccatgtcct aaaaactgga tatgttacaa aaataactgc    600taccaatttt ttgatgagag taaaaactgg tatgagagcc aggcttcttg tatgtctcaa    660aatgccagcc ttctgaaagt atacagcaaa gaggaccagg atttacttaa actggtgaag    720tcatatcatt ggatgggact agtacacatt ccaacaaatg gatcttggca gtgggaagat    780ggctccattc tctcacccaa cctactaaca ataattgaaa tgcagaaggg agactgtgca    840ctctatgcct cgagctttaa aggctatata gaaaactgtt caactccaaa tacgtacatc    900tgcatgcaaa ggactgtgac cacgacgcca gcgccgcgac caccaacacc ggcgcccacc    960atcgcgtcgc agcccctgtc cctgcgccca gaggcgtgcc ggccagcggc ggggggcgca   1020gtgcacacga gggggctgga cttcgcctgt gatatctaca tctgggcgcc cttggccggg   1080acttgtgggg tccttctcct gtcactggtt atcacccttt actgcaaacg gggcagaaag   1140aaactcctgt atatattcaa acaaccattt atgagaccag tacaaactac tcaagaggaa   1200gatggctgta gctgccgatt tccagaagaa gaagaaggag gatgtgaact gagagtgaag   1260ttcagcagga gcgcagacgc ccccgcgtac cagcagggcc agaaccagct ctataacgag   1320ctcaatctag gacgaagaga ggagtacgat gttttggaca agagacgtgg ccgggaccct   1380gagatggggg gaaagccgag aaggaagaac cctcaggaag gcctgtacaa tgaactgcag   1440aaagataaga tggcggaggc ctacagtgag attgggatga aaggcgagcg ccggaggggc   1500aaggggcacg atggccttta ccagggtctc agtacagcca ccaaggacac ctacgacgcc   1560cttcacatgc aggccctgcc ccctcgc                                       1587</s400><s200><s210>67</s210><s211>529</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence Variant 17</s223></s220></s200><s400> 67Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Gly Gly Gly Gly145                 150                 155                 160Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Leu Phe Asn Gln Glu                165                 170                 175Val Gln Ile Pro Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn            180                 185                 190Trp Ile Cys Tyr Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys        195                 200                 205Asn Trp Tyr Glu Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu    210                 215                 220Leu Lys Val Tyr Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys225                 230                 235                 240Ser Tyr His Trp Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp                245                 250                 255Gln Trp Glu Asp Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile            260                 265                 270Glu Met Gln Lys Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly        275                 280                 285Tyr Ile Glu Asn Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg    290                 295                 300Thr Val Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr305                 310                 315                 320Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala                325                 330                 335Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile            340                 345                 350Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser        355                 360                 365Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr    370                 375                 380Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu385                 390                 395                 400Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu                405                 410                 415Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln            420                 425                 430Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu        435                 440                 445Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly    450                 455                 460Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln465                 470                 475                 480Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu                485                 490                 495Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr            500                 505                 510Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro        515                 520                 525Arg</s400><s200><s210>68</s210><s211>405</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence for alternative NKG2D codon-      optimized extracellular domain</s223></s220></s200><s400> 68ctgttcaacc aggaggtgca gatccccctg accgaaagct actgcggccc ctgccccaag     60aactggatct gttacaagaa caactgctat cagttcttcg acgagagcaa gaactggtac    120gagagccagg ccagctgtat gagccagaac gccagcctgc tgaaagtgta tagcaaggag    180gaccaggacc tgctgaagct ggtgaagagc taccactgga tgggcctggt gcacatcccc    240accaacggaa gctggcagtg ggaggacggc agcatcctga gccccaacct gctgaccatc    300atcgagatgc agaagggcga ctgcgccctg tatgccagca gcttcaaggg ctacatcgag    360aactgtagca cccccaacac ctacatctgc atgcagagga ccgtg                    405</s400><s200><s210>69</s210><s211>21</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence CD3zeta transmembrane</s223></s220></s200><s400> 69Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu1               5                   10                  15Thr Ala Leu Phe Leu            20</s400><s200><s210>70</s210><s211>876</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence Variant 18 (NK39)</s223></s220></s200><s400> 70atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga     60ccactgttca atcaggaagt ccagatcccc ctgacagagt cttactgcgg cccatgtccc    120aagaactgga tctgctacaa gaacaattgt tatcagttct ttgacgagag caagaactgg    180tatgagtccc aggcctcttg catgagccag aatgcctctc tgctgaaggt gtacagcaag    240gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc    300cctacaaacg gctcttggca gtgggaggac ggctccatcc tgtctccaaa tctgctgacc    360atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc    420gagaactgct ccacacccaa tacctacatc tgtatgcaga ggaccgtgac cacaacccct    480gcaccacgcc cccctacacc agcacctacc atcgcaagcc agcctctgtc cctgcggcca    540gaggcatgta gaccagcagc aggaggagca gtgcacacaa gaggcctgga cttcgcctgc    600gatcccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact    660gccttgttcc tgaagacaaa tatcaggtct agcacccgcg actggaagga tcacaagttt    720aagtggcgga aggaccctca ggataagaag cggggcagaa agaagctgct gtatatcttc    780aagcagccct tcatgcggcc cgtgcagaca acccaggagg aagacggctg ctcatgtaga    840tttcctgaag aagaagaagg gggctgtgaa ctgtaa                              876</s400><s200><s210>71</s210><s211>291</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence Variant 18 (NK39)</s223></s220></s200><s400> 71Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu        195                 200                 205Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu    210                 215                 220Lys Thr Asn Ile Arg Ser Ser Thr Arg Asp Trp Lys Asp His Lys Phe225                 230                 235                 240Lys Trp Arg Lys Asp Pro Gln Asp Lys Lys Arg Gly Arg Lys Lys Leu                245                 250                 255Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln            260                 265                 270Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly        275                 280                 285Cys Glu Leu    290</s400><s200><s210>72</s210><s211>1323</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NK39_1</s223></s220></s200><s400> 72atggccctgc ccgtgacagc tctgctgctg cctctggccc tgctgctgca tgccgctaga     60cccctgttca accaggaggt gcagatcccc ctgaccgaaa gctactgcgg cccctgcccc    120aagaactgga tctgttacaa gaacaactgc tatcagttct tcgacgagag caagaactgg    180tacgagagcc aggccagctg tatgagccag aacgccagcc tgctgaaagt gtatagcaag    240gaggaccagg acctgctgaa gctggtgaag agctaccact ggatgggcct ggtgcacatc    300cccaccaacg gaagctggca gtgggaggac ggcagcatcc tgagccccaa cctgctgacc    360atcatcgaga tgcagaaggg cgactgcgcc ctgtatgcca gcagcttcaa gggctacatc    420gagaactgta gcacccccaa cacctacatc tgcatgcaga ggaccgtggg cggcggcggc    480agcggcggag gcggctccgg cggcggcggc agcttattca accaagaagt tcaaattccc    540ttgaccgaaa gttactgtgg cccatgtcct aaaaactgga tatgttacaa aaataactgc    600taccaatttt ttgatgagag taaaaactgg tatgagagcc aggcttcttg tatgtctcaa    660aatgccagcc ttctgaaagt atacagcaaa gaggaccagg atttacttaa actggtgaag    720tcatatcatt ggatgggact agtacacatt ccaacaaatg gatcttggca gtgggaagat    780ggctccattc tctcacccaa cctactaaca ataattgaaa tgcagaaggg agactgtgca    840ctctatgcct cgagctttaa aggctatata gaaaactgtt caactccaaa tacgtacatc    900tgcatgcaaa ggactgtgac caccacccct gctcccagac cccctacacc tgcccctaca    960atcgccagcc agcccctgag cctgagacct gaggcctgca gacctgctgc tggaggcgct   1020gtgcacacaa ggggcctcga cttcgcctgc gaccccaaac tctgctacct gctggatgga   1080atcctcttca tctatggtgt cattctcact gccttgttcc tgaagacaaa tatcaggtct   1140agcacccgcg actggaagga tcacaagttt aagtggcgga aggaccctca ggataagaag   1200cggggcagaa agaagctgct gtatatcttc aagcagccct tcatgcggcc cgtgcagaca   1260acccaggagg aagacggctg ctcatgtaga tttcctgaag aagaagaagg gggctgtgaa   1320ctg                                                                 1323</s400><s200><s210>73</s210><s211>441</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NK39_1</s223></s220></s200><s400> 73Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Gly Gly Gly Gly145                 150                 155                 160Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Leu Phe Asn Gln Glu                165                 170                 175Val Gln Ile Pro Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn            180                 185                 190Trp Ile Cys Tyr Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys        195                 200                 205Asn Trp Tyr Glu Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu    210                 215                 220Leu Lys Val Tyr Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys225                 230                 235                 240Ser Tyr His Trp Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp                245                 250                 255Gln Trp Glu Asp Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile            260                 265                 270Glu Met Gln Lys Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly        275                 280                 285Tyr Ile Glu Asn Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg    290                 295                 300Thr Val Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr305                 310                 315                 320Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala                325                 330                 335Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro            340                 345                 350Lys Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile        355                 360                 365Leu Thr Ala Leu Phe Leu Lys Thr Asn Ile Arg Ser Ser Thr Arg Asp    370                 375                 380Trp Lys Asp His Lys Phe Lys Trp Arg Lys Asp Pro Gln Asp Lys Lys385                 390                 395                 400Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg                405                 410                 415Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro            420                 425                 430Glu Glu Glu Glu Gly Gly Cys Glu Leu        435                 440</s400><s200><s210>74</s210><s211>1032</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NK39_2</s223></s220></s200><s400> 74atggccctgc ccgtgacagc tctgctgctg cctctggccc tgctgctgca tgccgctaga     60cccttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac caccacccct    480gctcccagac cccctacacc tgcccctaca atcgccagcc agcccctgag cctgagacct    540gaggcctgca gacctgctgc tggaggcgct gtgcacacaa ggggcctcga cttcgcctgc    600gaccccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact    660gccttgttcc tgaagacaaa tatcaggtct agcacccgcg actggaagga tcacaagttt    720aagtggcgga aggaccctca ggataagaag cggggcagaa agaagctgct gtatatcttc    780aagcagccct tcatgcggcc cgtgcagaca acccaggagg aagacggctg ctcatgtaga    840tttcctgaag aagaagaagg gggctgtgaa ctgggcggag gaggcagcgg cggcggcggc    900agcggcggcg gcggcagcat gcaggatgag gacggctaca tgaccctgaa cgtgcagagc    960aagaagagga gcagcgccca gaccagccag ctgaccttca aggactacag cgtgaccctg   1020cactggtaca ag                                                       1032</s400><s200><s210>75</s210><s211>344</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NK39_2</s223></s220></s200><s400> 75Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu        195                 200                 205Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu    210                 215                 220Lys Thr Asn Ile Arg Ser Ser Thr Arg Asp Trp Lys Asp His Lys Phe225                 230                 235                 240Lys Trp Arg Lys Asp Pro Gln Asp Lys Lys Arg Gly Arg Lys Lys Leu                245                 250                 255Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln            260                 265                 270Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly        275                 280                 285Cys Glu Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly    290                 295                 300Gly Ser Met Gln Asp Glu Asp Gly Tyr Met Thr Leu Asn Val Gln Ser305                 310                 315                 320Lys Lys Arg Ser Ser Ala Gln Thr Ser Gln Leu Thr Phe Lys Asp Tyr                325                 330                 335Ser Val Thr Leu His Trp Tyr Lys            340</s400><s200><s210>76</s210><s211>1416</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NK39_3</s223></s220></s200><s400> 76atggccctgc ccgtgacagc tctgctgctg cctctggccc tgctgctgca tgccgctaga     60cccctgttca accaggaggt gcagatcccc ctgaccgaaa gctactgcgg cccctgcccc    120aagaactgga tctgttacaa gaacaactgc tatcagttct tcgacgagag caagaactgg    180tacgagagcc aggccagctg tatgagccag aacgccagcc tgctgaaagt gtatagcaag    240gaggaccagg acctgctgaa gctggtgaag agctaccact ggatgggcct ggtgcacatc    300cccaccaacg gaagctggca gtgggaggac ggcagcatcc tgagccccaa cctgctgacc    360atcatcgaga tgcagaaggg cgactgcgcc ctgtatgcca gcagcttcaa gggctacatc    420gagaactgta gcacccccaa cacctacatc tgcatgcaga ggaccgtggg cggcggcggc    480agcggcggag gcggctccgg cggcggcggc agcttattca accaagaagt tcaaattccc    540ttgaccgaaa gttactgtgg cccatgtcct aaaaactgga tatgttacaa aaataactgc    600taccaatttt ttgatgagag taaaaactgg tatgagagcc aggcttcttg tatgtctcaa    660aatgccagcc ttctgaaagt atacagcaaa gaggaccagg atttacttaa actggtgaag    720tcatatcatt ggatgggact agtacacatt ccaacaaatg gatcttggca gtgggaagat    780ggctccattc tctcacccaa cctactaaca ataattgaaa tgcagaaggg agactgtgca    840ctctatgcct cgagctttaa aggctatata gaaaactgtt caactccaaa tacgtacatc    900tgcatgcaaa ggactgtgac caccacccct gctcccagac cccctacacc tgcccctaca    960atcgccagcc agcccctgag cctgagacct gaggcctgca gacctgctgc tggaggcgct   1020gtgcacacaa ggggcctcga cttcgcctgc gaccccaaac tctgctacct gctggatgga   1080atcctcttca tctatggtgt cattctcact gccttgttcc tgctttactg caagcggggc   1140agaaagaagc tgctgtatat cttcaagcag cccttcatgc ggcccgtgca gacaacccag   1200gaggaagacg gctgctcatg tagatttcct gaagaagaag aagggggctg tgaactgggc   1260ggaggaggca gcggcggcgg cggcagcggc ggcggcggca gcatgcagga tgaggacggc   1320tacatgaccc tgaacgtgca gagcaagaag aggagcagcg cccagaccag ccagctgacc   1380ttcaaggact acagcgtgac cctgcactgg tacaag                             1416</s400><s200><s210>77</s210><s211>472</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NK39_3</s223></s220></s200><s400> 77Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Gly Gly Gly Gly145                 150                 155                 160Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Leu Phe Asn Gln Glu                165                 170                 175Val Gln Ile Pro Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn            180                 185                 190Trp Ile Cys Tyr Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys        195                 200                 205Asn Trp Tyr Glu Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu    210                 215                 220Leu Lys Val Tyr Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys225                 230                 235                 240Ser Tyr His Trp Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp                245                 250                 255Gln Trp Glu Asp Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile            260                 265                 270Glu Met Gln Lys Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly        275                 280                 285Tyr Ile Glu Asn Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg    290                 295                 300Thr Val Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr305                 310                 315                 320Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala                325                 330                 335Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro            340                 345                 350Lys Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile        355                 360                 365Leu Thr Ala Leu Phe Leu Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu    370                 375                 380Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln385                 390                 395                 400Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly                405                 410                 415Cys Glu Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly            420                 425                 430Gly Ser Met Gln Asp Glu Asp Gly Tyr Met Thr Leu Asn Val Gln Ser        435                 440                 445Lys Lys Arg Ser Ser Ala Gln Thr Ser Gln Leu Thr Phe Lys Asp Tyr    450                 455                 460Ser Val Thr Leu His Trp Tyr Lys465                 470</s400><s200><s210>78</s210><s211>807</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NK39_4</s223></s220></s200><s400> 78atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga     60ccactgttca atcaggaagt ccagatcccc ctgacagagt cttactgcgg cccatgtccc    120aagaactgga tctgctacaa gaacaattgt tatcagttct ttgacgagag caagaactgg    180tatgagtccc aggcctcttg catgagccag aatgcctctc tgctgaaggt gtacagcaag    240gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc    300cctacaaacg gctcttggca gtgggaggac ggctccatcc tgtctccaaa tctgctgacc    360atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc    420gagaactgct ccacacccaa tacctacatc tgtatgcaga ggaccgtgac cacaacccct    480gcaccacgcc cccctacacc agcacctacc atcgcaagcc agcctctgtc cctgcggcca    540gaggcatgta gaccagcagc aggaggagca gtgcacacaa gaggcctgga cttcgcctgc    600gatcccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact    660gccttgttcc tgctttactg caagcggggc agaaagaagc tgctgtatat cttcaagcag    720cccttcatgc ggcccgtgca gacaacccag gaggaagacg gctgctcatg tagatttcct    780gaagaagaag aagggggctg tgaactg                                        807</s400><s200><s210>79</s210><s211>269</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NK39_4</s223></s220></s200><s400> 79Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu        195                 200                 205Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu    210                 215                 220Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln225                 230                 235                 240Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser                245                 250                 255Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu            260                 265</s400><s200><s210>80</s210><s211>1143</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NK39_5</s223></s220></s200><s400> 80atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga     60ccactgttca atcaggaagt ccagatcccc ctgacagagt cttactgcgg cccatgtccc    120aagaactgga tctgctacaa gaacaattgt tatcagttct ttgacgagag caagaactgg    180tatgagtccc aggcctcttg catgagccag aatgcctctc tgctgaaggt gtacagcaag    240gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc    300cctacaaacg gctcttggca gtgggaggac ggctccatcc tgtctccaaa tctgctgacc    360atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc    420gagaactgct ccacacccaa tacctacatc tgtatgcaga ggaccgtgac cacaacccct    480gcaccacgcc cccctacacc agcacctacc atcgcaagcc agcctctgtc cctgcggcca    540gaggcatgta gaccagcagc aggaggagca gtgcacacaa gaggcctgga cttcgcctgc    600gatcccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact    660gccttgttcc tgctttactg caagcggggc agaaagaagc tgctgtatat cttcaagcag    720cccttcatgc ggcccgtgca gacaacccag gaggaagacg gctgctcatg tagatttcct    780gaagaagaag aagggggctg tgaactgaga gtgaagttca gcaggagcgc agacgccccc    840gcgtaccagc agggccagaa ccagctctat aacgagctca atctaggacg aagagaggag    900tacgatgttt tggacaagag acgtggccgg gaccctgaga tggggggaaa gccgagaagg    960aagaaccctc aggaaggcct gtacaatgaa ctgcagaaag ataagatggc ggaggcctac   1020agtgagattg ggatgaaagg cgagcgccgg aggggcaagg ggcacgatgg cctttaccag   1080ggtctcagta cagccaccaa ggacacctac gacgcccttc acatgcaggc cctgccccct   1140cgc                                                                 1143</s400><s200><s210>81</s210><s211>381</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NK39_5</s223></s220></s200><s400> 81Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu        195                 200                 205Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu    210                 215                 220Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln225                 230                 235                 240Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser                245                 250                 255Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys            260                 265                 270Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln        275                 280                 285Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu    290                 295                 300Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg305                 310                 315                 320Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met                325                 330                 335Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly            340                 345                 350Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp        355                 360                 365Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg    370                 375                 380</s400><s200><s210>82</s210><s211>965</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NK39_6</s223></s220></s200><s400> 82atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga     60ccactgttca atcaggaagt ccagatcccc ctgacagagt cttactgcgg cccatgtccc    120aagaactgga tctgctacaa gaacaattgt tatcagttct ttgacgagag caagaactgg    180tatgagtccc aggcctcttg catgagccag aatgcctctc tgctgaaggt gtacagcaag    240gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc    300cctacaaacg gctcttggca gtgggaggac ggctccatcc tgtctccaaa tctgctgacc    360atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc    420gagaactgct ccacacccaa tacctacatc tgtatgcaga ggaccgtgac cacaacccct    480gcaccacgcc cccctacacc agcacctacc atcgcaagcc agcctctgtc cctgcggcca    540gaggcatgta gaccagcagc aggaggagca gtgcacacaa gaggcctgga cttcgcctgc    600gatcccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact    660gccttgttcc tgctttactg caagcggggc agaaagaagc tgctgtatat cttcaagcag    720cccttcatgc ggcccgtgca gacaacccag gaggaagacg gctgctcatg tagatttcct    780gaagaagaag aagggggctg tgaactgggc ggaggaggca gcggcggcgg cggcagcggc    840ggcggcggca gcatgcagga tgaggacggc tacatgaccc tgaacgtgca gagcaagaag    900aggagcagcg cccagaccag ccagctgacc ttcaaggact acagcgtgac cctgcactgg    960tacaa                                                                965</s400><s200><s210>83</s210><s211>322</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NK39_6</s223></s220></s200><s400> 83Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu        195                 200                 205Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu    210                 215                 220Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln225                 230                 235                 240Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser                245                 250                 255Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly            260                 265                 270Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Met Gln Asp Glu        275                 280                 285Asp Gly Tyr Met Thr Leu Asn Val Gln Ser Lys Lys Arg Ser Ser Ala    290                 295                 300Gln Thr Ser Gln Leu Thr Phe Lys Asp Tyr Ser Val Thr Leu His Trp305                 310                 315                 320Tyr Lys</s400><s200><s210>84</s210><s211>927</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NK39_7</s223></s220></s200><s400> 84atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga     60ccactgttca atcaggaagt ccagatcccc ctgacagagt cttactgcgg cccatgtccc    120aagaactgga tctgctacaa gaacaattgt tatcagttct ttgacgagag caagaactgg    180tatgagtccc aggcctcttg catgagccag aatgcctctc tgctgaaggt gtacagcaag    240gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc    300cctacaaacg gctcttggca gtgggaggac ggctccatcc tgtctccaaa tctgctgacc    360atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc    420gagaactgct ccacacccaa tacctacatc tgtatgcaga ggaccgtgac cacaacccct    480gcaccacgcc cccctacacc agcacctacc atcgcaagcc agcctctgtc cctgcggcca    540gaggcatgta gaccagcagc aggaggagca gtgcacacaa gaggcctgga cttcgcctgc    600gatcccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact    660gccttgttcc tgctttactg caagcggggc agaaagaagc tgctgtatat cttcaagcag    720cccttcatgc ggcccgtgca gacaacccag gaggaagacg gctgctcatg tagatttcct    780gaagaagaag aagggggctg tgaactgggc ggaggaggca gcggcggcgg cggcagcggc    840ggcggcggca gcaagacaaa tatcaggtct agcacccgcg actggaagga tcacaagttt    900aagtggcgga aggaccctca ggataag                                        927</s400><s200><s210>85</s210><s211>309</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NK39_7</s223></s220></s200><s400> 85Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu        195                 200                 205Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu    210                 215                 220Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln225                 230                 235                 240Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser                245                 250                 255Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly            260                 265                 270Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Lys Thr Asn Ile        275                 280                 285Arg Ser Ser Thr Arg Asp Trp Lys Asp His Lys Phe Lys Trp Arg Lys    290                 295                 300Asp Pro Gln Asp Lys305</s400><s200><s210>86</s210><s211>933</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NK39_8</s223></s220></s200><s400> 86atggccctgc ccgtgacagc tctgctgctg cctctggccc tgctgctgca tgccgctaga     60cccttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac caccacccct    480gctcccagac cccctacacc tgcccctaca atcgccagcc agcccctgag cctgagacct    540gaggcctgca gacctgctgc tggaggcgct gtgcacacaa ggggcctcga cttcgcctgc    600gaccccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact    660gccttgttcc tgctttactg caagcggggc agaaagaagc tgctgtatat cttcaagcag    720cccttcatgc ggcccgtgca gacaacccag gaggaagacg gctgctcatg tagatttcct    780gaagaagaag aagggggctg tgaactgcga ctgaagatcc aagtgcgaaa ggcagctata    840accagctatg agaaatcaga tggtgtttac acgggcctga gcaccaggaa ccaggagact    900tacgagactc tgaagcatga gaaaccacca cag                                 933</s400><s200><s210>87</s210><s211>311</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NK39_8</s223></s220></s200><s400> 87Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu        195                 200                 205Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu    210                 215                 220Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln225                 230                 235                 240Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser                245                 250                 255Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Leu Lys            260                 265                 270Ile Gln Val Arg Lys Ala Ala Ile Thr Ser Tyr Glu Lys Ser Asp Gly        275                 280                 285Val Tyr Thr Gly Leu Ser Thr Arg Asn Gln Glu Thr Tyr Glu Thr Leu    290                 295                 300Lys His Glu Lys Pro Pro Gln305                 310</s400><s200><s210>88</s210><s211>1605</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NK39_9</s223></s220></s200><s400> 88atgagaattt cgaaaccaca tttgagaagt atttccatcc agtgctactt gtgtttactt     60ctaaacagtc attttctaac tgaagctggc attcatgtct tcattttggg ctgtttcagt    120gcagggcttc ctaaaacaga agccaactgg gtcaacgtga ttagcgattt gaagaaaatc    180gaggacctta tacagtctat gcatattgac gctacactgt atactgagag tgatgtacac    240ccgtcctgta aggtaacggc catgaaatgc tttcttctgg agctccaggt catcagcttg    300gagtctgggg acgcaagcat ccacgatacg gttgaaaacc tcatcatcct tgcgaacaac    360tctctctcat ctaatggaaa cgttacagag agtgggtgta aggagtgcga agagttggaa    420gaaaaaaaca tcaaagaatt tcttcaatcc ttcgttcaca tagtgcaaat gttcattaac    480acgtccggcg gaggaggcag cggcggcggc ggcagcggcg gcggcggcag cttattcaac    540caagaagttc aaattccctt gaccgaaagt tactgtggcc catgtcctaa aaactggata    600tgttacaaaa ataactgcta ccaatttttt gatgagagta aaaactggta tgagagccag    660gcttcttgta tgtctcaaaa tgccagcctt ctgaaagtat acagcaaaga ggaccaggat    720ttacttaaac tggtgaagtc atatcattgg atgggactag tacacattcc aacaaatgga    780tcttggcagt gggaagatgg ctccattctc tcacccaacc tactaacaat aattgaaatg    840cagaagggag actgtgcact ctatgcctcg agctttaaag gctatataga aaactgttca    900actccaaata cgtacatctg catgcaaagg actgtgacca cgacgccagc gccgcgacca    960ccaacaccgg cgcccaccat cgcgtcgcag cccctgtccc tgcgcccaga ggcgtgccgg   1020ccagcggcgg ggggcgcagt gcacacgagg gggctggact tcgcctgtga tatctacatc   1080tgggcgccct tggccgggac ttgtggggtc cttctcctgt cactggttat caccctttac   1140tgcaaacggg gcagaaagaa actcctgtat atattcaaac aaccatttat gagaccagta   1200caaactactc aagaggaaga tggctgtagc tgccgatttc cagaagaaga agaaggagga   1260tgtgaactga gagtgaagtt cagcaggagc gcagacgccc ccgcgtacca gcagggccag   1320aaccagctct ataacgagct caatctagga cgaagagagg agtacgatgt tttggacaag   1380agacgtggcc gggaccctga gatgggggga aagccgagaa ggaagaaccc tcaggaaggc   1440ctgtacaatg aactgcagaa agataagatg gcggaggcct acagtgagat tgggatgaaa   1500ggcgagcgcc ggaggggcaa ggggcacgat ggcctttacc agggtctcag tacagccacc   1560aaggacacct acgacgccct tcacatgcag gccctgcccc ctcgc                   1605</s400><s200><s210>89</s210><s211>535</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NK39_9</s223></s220></s200><s400> 89Met Arg Ile Ser Lys Pro His Leu Arg Ser Ile Ser Ile Gln Cys Tyr1               5                   10                  15Leu Cys Leu Leu Leu Asn Ser His Phe Leu Thr Glu Ala Gly Ile His            20                  25                  30Val Phe Ile Leu Gly Cys Phe Ser Ala Gly Leu Pro Lys Thr Glu Ala        35                  40                  45Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile    50                  55                  60Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His65                  70                  75                  80Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln                85                  90                  95Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu            100                 105                 110Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val        115                 120                 125Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile    130                 135                 140Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn145                 150                 155                 160Thr Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly                165                 170                 175Ser Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr Glu Ser Tyr Cys            180                 185                 190Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn Asn Cys Tyr Gln        195                 200                 205Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln Ala Ser Cys Met    210                 215                 220Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys Glu Asp Gln Asp225                 230                 235                 240Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly Leu Val His Ile                245                 250                 255Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser Ile Leu Ser Pro            260                 265                 270Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp Cys Ala Leu Tyr        275                 280                 285Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser Thr Pro Asn Thr    290                 295                 300Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro Ala Pro Arg Pro305                 310                 315                 320Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro                325                 330                 335Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu            340                 345                 350Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys        355                 360                 365Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly    370                 375                 380Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val385                 390                 395                 400Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu                405                 410                 415Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp            420                 425                 430Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn        435                 440                 445Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg    450                 455                 460Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly465                 470                 475                 480Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu                485                 490                 495Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu            500                 505                 510Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His        515                 520                 525Met Gln Ala Leu Pro Pro Arg    530                 535</s400><s200><s210>90</s210><s211>1122</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence  NKG2D-Ox40-CD3z</s223></s220></s200><s400> 90atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca    480gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca    540gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcctgt    600gatatctaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactggtt    660atcacccttt actgccggag ggaccagagg ctgccccccg atgcccacaa gccccctggg    720ggaggcagtt tccggacccc catccaagag gagcaggccg acgcccactc caccctggcc    780aagatcagag tgaagttcag caggagcgca gacgcccccg cgtaccagca gggccagaac    840cagctctata acgagctcaa tctaggacga agagaggagt acgatgtttt ggacaagaga    900cgtggccggg accctgagat ggggggaaag ccgagaagga agaaccctca ggaaggcctg    960tacaatgaac tgcagaaaga taagatggcg gaggcctaca gtgagattgg gatgaaaggc   1020gagcgccgga ggggcaaggg gcacgatggc ctttaccagg gtctcagtac agccaccaag   1080gacacctacg acgcccttca catgcaggcc ctgccccctc gc                      1122</s400><s200><s210>91</s210><s211>341</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NKG2D-OX40-CD3z</s223></s220></s200><s400> 91Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Glu Ser Lys Tyr145                 150                 155                 160Gly Pro Pro Cys Pro Ser Cys Pro Ile Tyr Ile Trp Ala Pro Leu Ala                165                 170                 175Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys            180                 185                 190Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly Gly        195                 200                 205Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His Ser    210                 215                 220Thr Leu Ala Lys Ile Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro225                 230                 235                 240Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly                245                 250                 255Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro            260                 265                 270Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr        275                 280                 285Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly    290                 295                 300Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln305                 310                 315                 320Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln                325                 330                 335Ala Leu Pro Pro Arg            340</s400><s200><s210>92</s210><s211>1143</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NKG2D-CD28 - CD3z</s223></s220></s200><s400> 92atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca    480gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca    540gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcctgt    600gatttttggg tgctggtggt ggttggtgga gtcctggctt gctatagctt gctagtaaca    660gtggccttta ttattttctg ggtgaggagt aagaggagca ggctcctgca cagtgactac    720atgaacatga ctccccgccg ccccgggccc acccgcaagc attaccagcc ctatgcccca    780ccacgcgact tcgcagccta tcgctccaga gtgaagttca gcaggagcgc agacgccccc    840gcgtaccagc agggccagaa ccagctctat aacgagctca atctaggacg aagagaggag    900tacgatgttt tggacaagag acgtggccgg gaccctgaga tggggggaaa gccgagaagg    960aagaaccctc aggaaggcct gtacaatgaa ctgcagaaag ataagatggc ggaggcctac   1020agtgagattg ggatgaaagg cgagcgccgg aggggcaagg ggcacgatgg cctttaccag   1080ggtctcagta cagccaccaa ggacacctac gacgcccttc acatgcaggc cctgccccct   1140cgc                                                                 1143</s400><s200><s210>93</s210><s211>381</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NKG2D-CD28 - CD3z</s223></s220></s200><s400> 93Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Phe Trp Val Leu Val Val Val        195                 200                 205Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile    210                 215                 220Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr225                 230                 235                 240Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln                245                 250                 255Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys            260                 265                 270Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln        275                 280                 285Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu    290                 295                 300Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg305                 310                 315                 320Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met                325                 330                 335Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly            340                 345                 350Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp        355                 360                 365Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg    370                 375                 380</s400><s200><s210>94</s210><s211>1269</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NKG2D - CD28 - 41BB - CD3z</s223></s220></s200><s400> 94atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca    480gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca    540gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcctgt    600gatttttggg tgctggtggt ggttggtgga gtcctggctt gctatagctt gctagtaaca    660gtggccttta ttattttctg ggtgaggagt aagaggagca ggctcctgca cagtgactac    720atgaacatga ctccccgccg ccccgggccc acccgcaagc attaccagcc ctatgcccca    780ccacgcgact tcgcagccta tcgctccaaa cggggcagaa agaaactcct gtatatattc    840aaacaaccat ttatgagacc agtacaaact actcaagagg aagatggctg tagctgccga    900tttccagaag aagaagaagg aggatgtgaa ctgagagtga agttcagcag gagcgcagac    960gcccccgcgt accagcaggg ccagaaccag ctctataacg agctcaatct aggacgaaga   1020gaggagtacg atgttttgga caagagacgt ggccgggacc ctgagatggg gggaaagccg   1080agaaggaaga accctcagga aggcctgtac aatgaactgc agaaagataa gatggcggag   1140gcctacagtg agattgggat gaaaggcgag cgccggaggg gcaaggggca cgatggcctt   1200taccagggtc tcagtacagc caccaaggac acctacgacg cccttcacat gcaggccctg   1260ccccctcgc                                                           1269</s400><s200><s210>95</s210><s211>423</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NKG2D - CD28 - 41BB - CD3z</s223></s220></s200><s400> 95Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Phe Trp Val Leu Val Val Val        195                 200                 205Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile    210                 215                 220Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr225                 230                 235                 240Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln                245                 250                 255Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Lys Arg Gly            260                 265                 270Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val        275                 280                 285Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu    290                 295                 300Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp305                 310                 315                 320Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn                325                 330                 335Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg            340                 345                 350Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly        355                 360                 365Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu    370                 375                 380Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu385                 390                 395                 400Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His                405                 410                 415Met Gln Ala Leu Pro Pro Arg            420</s400><s200><s210>96</s210><s211>1038</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NKG2D(short hinge) - 41BB - CD3z</s223></s220></s200><s400> 96atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgga gtccaaatat    480ggtcccccat gcccatcatg cccaatctac atctgggcgc ccttggccgg gacttgtggg    540gtccttctcc tgtcactggt tatcaccctt tactgcaaac ggggcagaaa gaaactcctg    600tatatattca aacaaccatt tatgagacca gtacaaacta ctcaagagga agatggctgt    660agctgccgat ttccagaaga agaagaagga ggatgtgaac tgagagtgaa gttcagcagg    720agcgcagacg cccccgcgta ccagcagggc cagaaccagc tctataacga gctcaatcta    780ggacgaagag aggagtacga tgttttggac aagagacgtg gccgggaccc tgagatgggg    840ggaaagccga gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag    900atggcggagg cctacagtga gattgggatg aaaggcgagc gccggagggg caaggggcac    960gatggccttt accagggtct cagtacagcc accaaggaca cctacgacgc ccttcacatg   1020caggccctgc cccctcgc                                                 1038</s400><s200><s210>97</s210><s211>346</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NKG2D(short hinge) - 41BB -      CD3z</s223></s220></s200><s400> 97Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Glu Ser Lys Tyr145                 150                 155                 160Gly Pro Pro Cys Pro Ser Cys Pro Ile Tyr Ile Trp Ala Pro Leu Ala                165                 170                 175Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys            180                 185                 190Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met        195                 200                 205Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe    210                 215                 220Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg225                 230                 235                 240Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn                245                 250                 255Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg            260                 265                 270Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro        275                 280                 285Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala    290                 295                 300Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His305                 310                 315                 320Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp                325                 330                 335Ala Leu His Met Gln Ala Leu Pro Pro Arg            340                 345</s400><s200><s210>98</s210><s211>1044</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NKG2D (SH)-CD28 - CD3z</s223></s220></s200><s400> 98atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgga gtccaaatat    480ggtcccccat gcccatcatg cccattttgg gtgctggtgg tggttggtgg agtcctggct    540tgctatagct tgctagtaac agtggccttt attattttct gggtgaggag taagaggagc    600aggctcctgc acagtgacta catgaacatg actccccgcc gccccgggcc cacccgcaag    660cattaccagc cctatgcccc accacgcgac ttcgcagcct atcgctccag agtgaagttc    720agcaggagcg cagacgcccc cgcgtaccag cagggccaga accagctcta taacgagctc    780aatctaggac gaagagagga gtacgatgtt ttggacaaga gacgtggccg ggaccctgag    840atggggggaa agccgagaag gaagaaccct caggaaggcc tgtacaatga actgcagaaa    900gataagatgg cggaggccta cagtgagatt gggatgaaag gcgagcgccg gaggggcaag    960gggcacgatg gcctttacca gggtctcagt acagccacca aggacaccta cgacgccctt   1020cacatgcagg ccctgccccc tcgc                                          1044</s400><s200><s210>99</s210><s211>348</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NKG2D (SH)-CD28 - CD3z</s223></s220></s200><s400> 99Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Glu Ser Lys Tyr145                 150                 155                 160Gly Pro Pro Cys Pro Ser Cys Pro Phe Trp Val Leu Val Val Val Gly                165                 170                 175Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile            180                 185                 190Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met        195                 200                 205Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro    210                 215                 220Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe225                 230                 235                 240Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu                245                 250                 255Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp            260                 265                 270Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys        275                 280                 285Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala    290                 295                 300Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys305                 310                 315                 320Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr                325                 330                 335Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg            340                 345</s400><s200><s210>100</s210><s211>1023</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NKG2D (SH) - OX40 - CD3z</s223></s220></s200><s400> 100atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgga gtccaaatat    480ggtcccccat gcccatcatg cccaatctac atctgggcgc ccttggccgg gacttgtggg    540gtccttctcc tgtcactggt tatcaccctt tactgccgga gggaccagag gctgcccccc    600gatgcccaca agccccctgg gggaggcagt ttccggaccc ccatccaaga ggagcaggcc    660gacgcccact ccaccctggc caagatcaga gtgaagttca gcaggagcgc agacgccccc    720gcgtaccagc agggccagaa ccagctctat aacgagctca atctaggacg aagagaggag    780tacgatgttt tggacaagag acgtggccgg gaccctgaga tggggggaaa gccgagaagg    840aagaaccctc aggaaggcct gtacaatgaa ctgcagaaag ataagatggc ggaggcctac    900agtgagattg ggatgaaagg cgagcgccgg aggggcaagg ggcacgatgg cctttaccag    960ggtctcagta cagccaccaa ggacacctac gacgcccttc acatgcaggc cctgccccct   1020cgc                                                                 1023</s400><s200><s210>101</s210><s211>346</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Seqeunce NKG2D (SH) - OX40 - CD3z</s223></s220></s200><s400> 101Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Glu Ser Lys Tyr145                 150                 155                 160Gly Pro Pro Cys Pro Ser Cys Pro Phe Trp Val Leu Val Val Val Gly                165                 170                 175Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile            180                 185                 190Phe Trp Val Arg Ser Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His        195                 200                 205Lys Pro Pro Gly Gly Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln    210                 215                 220Ala Asp Ala His Ser Thr Leu Ala Lys Ile Arg Val Lys Phe Ser Arg225                 230                 235                 240Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn                245                 250                 255Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg            260                 265                 270Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro        275                 280                 285Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala    290                 295                 300Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His305                 310                 315                 320Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp                325                 330                 335Ala Leu His Met Gln Ala Leu Pro Pro Arg            340                 345</s400><s200><s210>102</s210><s211>1125</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence NKG2D-CD3TM -CD28 - CD3z</s223></s220></s200><s400> 102atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca    480gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca    540gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcctgt    600gatcccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact    660gccttgttcc tgaagaggag caggctcctg cacagtgact acatgaacat gactccccgc    720cgccccgggc ccacccgcaa gcattaccag ccctatgccc caccacgcga cttcgcagcc    780tatcgctcca gagtgaagtt cagcaggagc gcagacgccc ccgcgtacca gcagggccag    840aaccagctct ataacgagct caatctagga cgaagagagg agtacgatgt tttggacaag    900agacgtggcc gggaccctga gatgggggga aagccgagaa ggaagaaccc tcaggaaggc    960ctgtacaatg aactgcagaa agataagatg gcggaggcct acagtgagat tgggatgaaa   1020ggcgagcgcc ggaggggcaa ggggcacgat ggcctttacc agggtctcag tacagccacc   1080aaggacacct acgacgccct tcacatgcag gccctgcccc ctcgc                   1125</s400><s200><s210>103</s210><s211>375</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence NKG2D-CD3TM -CD28 - CD3z</s223></s220></s200><s400> 103Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu        195                 200                 205Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu    210                 215                 220Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg225                 230                 235                 240Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg                245                 250                 255Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp            260                 265                 270Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn        275                 280                 285Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg    290                 295                 300Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly305                 310                 315                 320Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu                325                 330                 335Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu            340                 345                 350Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His        355                 360                 365Met Gln Ala Leu Pro Pro Arg    370                 375</s400><s200><s210>104</s210><s211>36</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>DNA Sequence IgG 4 hinge</s223></s220></s200><s400> 104gagtccaaat atggtccccc atgcccatca tgccca                               36</s400><s200><s210>105</s210><s211>29</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence CD28 Transmembrane domain</s223></s220></s200><s400> 105Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu1               5                   10                  15Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser            20                  25</s400><s200><s210>106</s210><s211>39</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence CD28 IC domain</s223></s220></s200><s400> 106Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg1               5                   10                  15Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg            20                  25                  30Asp Phe Ala Ala Tyr Arg Ser        35</s400><s200><s210>107</s210><s211>37</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>Amino Acid Sequence OX40 IC Domain</s223></s220></s200><s400> 107Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly Gly1               5                   10                  15Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His Ser            20                  25                  30Thr Leu Ala Lys Ile        35</s400><s200><s210>108</s210><s211>1140</s211><s212>DNA</s212><s213>Homo sapiens</s213><s220><s221>misc_feature</s221><s223>NKG2D-P-frag/CD8a/4-1BB/CD3z</s223></s220></s200><s400> 108atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg     60ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct    120aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg    180tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa    240gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt    300ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca    360ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata    420gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca    480gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca    540gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcctgt    600gatatctaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactggtt    660atcacccttt actgcaaacg gggcagaaag aaactcctgt atatattcaa acaaccattt    720atgagaccag tacaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa    780gaagaaggag gatgtgaact gagagtgaag ttcagcagga gcgcagacgc ccccgcgtac    840cagcagggcc agaaccagct ctataacgag ctcaatctag gacgaagaga ggagtacgat    900gttttggaca agagacgtgg ccgggaccct gagatggggg gaaagccgag aaggaagaac    960cctcaggaag gcctgtacaa tgaactgcag aaagataaga tggcggaggc ctacagtgag   1020attgggatga aaggcgagcg ccggaggggc aaggggcacg atggccttta ccagggtctc   1080agtacagcca ccaaggacac ctacgacgcc cttcacatgc aggccctgcc ccctcgctaa   1140</s400><s200><s210>109</s210><s211>374</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>MISC_FEATURE</s221><s223>NKG2D-V2-OX40-CD3z</s223></s220></s200><s400> 109Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr            20                  25                  30Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn        35                  40                  45Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln    50                  55                  60Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys65                  70                  75                  80Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly                85                  90                  95Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser            100                 105                 110Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp        115                 120                 125Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser    130                 135                 140Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro145                 150                 155                 160Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu                165                 170                 175Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His            180                 185                 190Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu        195                 200                 205Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr    210                 215                 220Cys Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly225                 230                 235                 240Gly Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His                245                 250                 255Ser Thr Leu Ala Lys Ile Arg Val Lys Phe Ser Arg Ser Ala Asp Ala            260                 265                 270Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu        275                 280                 285Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp    290                 295                 300Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu305                 310                 315                 320Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile                325                 330                 335Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr            340                 345                 350Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met        355                 360                 365Gln Ala Leu Pro Pro Arg    370</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002472A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002472</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>16966656</doc-number><date>20190130</date></document-id></application-reference><us-application-series-code>16</us-application-series-code><priority-claims><priority-claim sequence="01" kind="national"><country>KR</country><doc-number>10-2018-0013381</doc-number><date>20180202</date></priority-claim><priority-claim sequence="02" kind="national"><country>KR</country><doc-number>10-2019-0011181</doc-number><date>20190129</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>705</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>85</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>70532</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>85</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e79">PD-1 VARIANT HAVING IMPROVED BINDING ABILITY TO PD-L1</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>NEURACLE GENETICS INC.</orgname><address><city>Seoul</city><country>KR</country></address></addressbook><residence><country>KR</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>JUNG</last-name><first-name>Sang Taek</first-name><address><city>Gyeonggi-do</city><country>KR</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>CHUN</last-name><first-name>Kwang-Jin</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>HA</last-name><first-name>Ji Yeon</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>NEURACLE GENETICS INC.</orgname><role>03</role><address><city>Seoul</city><country>KR</country></address></addressbook></assignee></assignees><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/KR2019/001290</doc-number><date>20190130</date></document-id><us-371c12-date><date>20200731</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present disclosure relates to a PD-1 variant having improved binding affinity to PD-L1. In addition, the present disclosure relates to a method for preparing the PD-1 variant and a method for screening the PD-1 variant. The PD-1 variant of the present disclosure effectively inhibits the binding between wild-type PD-1 and PD-L1, and thus is expected to have significantly higher penetration ability and anticancer effect by immune cells or therapeutic effect for infectious diseases as compared to existing immune checkpoint inhibitors. At the same time, the possibility of immunogenicity can be minimized. In addition, the convenience of developing biomedicine may be promoted through aglycosylation.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="88.39mm" wi="150.96mm" file="US20230002472A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="185.93mm" wi="155.96mm" file="US20230002472A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="217.34mm" wi="127.93mm" orientation="landscape" file="US20230002472A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="223.44mm" wi="156.80mm" orientation="landscape" file="US20230002472A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="222.84mm" wi="156.46mm" orientation="landscape" file="US20230002472A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="223.44mm" wi="95.93mm" orientation="landscape" file="US20230002472A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="200.83mm" wi="156.38mm" orientation="landscape" file="US20230002472A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="192.02mm" wi="120.65mm" orientation="landscape" file="US20230002472A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="192.53mm" wi="129.29mm" orientation="landscape" file="US20230002472A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="105.07mm" wi="154.35mm" file="US20230002472A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="115.06mm" wi="154.43mm" file="US20230002472A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="193.38mm" wi="148.08mm" orientation="landscape" file="US20230002472A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="213.44mm" wi="112.69mm" orientation="landscape" file="US20230002472A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="201.08mm" wi="129.79mm" orientation="landscape" file="US20230002472A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="198.04mm" wi="121.16mm" orientation="landscape" file="US20230002472A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="207.60mm" wi="110.57mm" orientation="landscape" file="US20230002472A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="106.34mm" wi="152.06mm" file="US20230002472A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="113.96mm" wi="156.72mm" file="US20230002472A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">TECHNICAL FIELD</heading><p id="p-0002" num="0001">The present disclosure relates to a PD-1 variant having improved binding affinity to PD-L1 and, thus, effectively inhibiting the binding between wild-type PD-1 and PD-L1, and a method for preparing the same.</p><heading id="h-0002" level="1">BACKGROUND ART</heading><p id="p-0003" num="0002">Drugs for treating cancer are largely classified into low-molecular-weight drugs and high-molecular-weight drugs. The high-molecular-weight drugs having specificity are more popular than the low-molecular-weight drugs which lack specificity and, thus, have relatively more side effects.</p><p id="p-0004" num="0003">Recently, it was reported that the inhibition of the binding of immune checkpoint inhibitor proteins, particularly PD-1/PD-L1, is significantly effective in treating cancer and that they have fewer side effects as compared to other immune checkpoint inhibitor proteins (J. Naidoo et al. (2015) Annals of Oncology, Lucia Gelao et al. (2014) Toxins, Gorge K. Philips et al. (2015) International Immunology).</p><p id="p-0005" num="0004">Big pharmaceutical companies such as Bristol-Myers Squibb, etc. are making efforts to develop therapeutic drugs such as through inhibition of PD-1/PD-L1 immune checkpoint inhibitors, and anticancer drugs such as Yervoy (ipilimumab) and Opdivo (nivolumab) are being developed using antibody formats.</p><p id="p-0006" num="0005">In order to remove the binding of tumor-infiltrating lymphocytes (TILs) to PD-1/PD-L1, a therapeutic agent with excellent cell infiltration ability is necessary. However, antibodies have disadvantages in infiltrating into cells because they are macromolecular proteins with a very large size of about 150 kDa.</p><p id="p-0007" num="0006">For treatment of cancer through effective immune checkpoint inhibition, PD-1 having superior cell infiltration ability due to smaller size seems more suitable than PD-L1. However, the existing PD-1 engineering has been based on screening through yeast display and there is a risk of immunogenicity due to glycan heterogeneity and various mutations.</p><p id="p-0008" num="0007">Meanwhile, aglycosylated protein drugs can be easily produced in large scale in bacteria and have great advantages in biomedicine preparation with no glycan heterogeneity problem associated with cell lines, culturing process or purification process.</p><p id="p-0009" num="0008">Accordingly, screening of an aglycosylated PD-1 variant having little mutation and high binding affinity to PD-L1 is necessary.</p><p id="p-0010" num="0009">The foregoing description of the background art is given only for enhancing the understanding of the background of the present disclosure and it should not be accepted to acknowledge as a prior art well known to those of ordinary skill in the art.</p><heading id="h-0003" level="1">DISCLOSURE</heading><heading id="h-0004" level="1">Technical Problem</heading><p id="p-0011" num="0010">The inventors of the present disclosure have made consistent efforts to screen a PD-1 variant having high binding affinity to PD-L1 and thus capable of effectively inhibiting the binding between wild-type PD-1 and PD-L1 and minimizing the possibility of immunogenicity at the same time. As a result, they have identified that, the binding affinity to PD-L1 can be improved greatly by substituting a part of the amino sequence of wild-type PD-1 with another amino sequence and the possibility of immunogenicity can be reduced through minimization of mutation sites and/or aglycosylated PD-1, and have completed the present disclosure.</p><p id="p-0012" num="0011">The present disclosure is directed to providing a PD-1 variant having improved binding affinity to PD-L1.</p><p id="p-0013" num="0012">The present disclosure is also directed to providing a nucleic acid molecule encoding the PD-1 variant.</p><p id="p-0014" num="0013">The present disclosure is also directed to providing a vector including the nucleic acid molecule.</p><p id="p-0015" num="0014">The present disclosure is also directed to providing a host cell including the vector.</p><p id="p-0016" num="0015">The present disclosure is also directed to providing a composition including the PD-1 variant, the nucleic acid molecule or the vector.</p><p id="p-0017" num="0016">The present disclosure is also directed to providing a method for preparing the PD-1 variant.</p><p id="p-0018" num="0017">The present disclosure is also directed to providing an inhibitor of the binding between wild-type PD-1 and PD-L1, which includes the PD-1 variant, the nucleic acid molecule or the vector as an active ingredient.</p><p id="p-0019" num="0018">The present disclosure is also directed to providing a method for inhibiting the binding between wild-type PD-1 and PD-L1, which includes a step of administering an effective amount of the PD-1 variant, the nucleic acid molecule or the vector to a subject.</p><p id="p-0020" num="0019">The present disclosure is also directed to providing a method for treating a cancer disease or an infectious disease, which includes a step of administering a therapeutically effective amount of the PD-1 variant, the nucleic acid molecule or the vector to a subject.</p><p id="p-0021" num="0020">The present disclosure is also directed to providing a method for screening the PD-1 variant.</p><p id="p-0022" num="0021">Other purposes and advantages of the present disclosure will become more apparent by the following detailed description, claims and drawings.</p><heading id="h-0005" level="1">Technical Solution</heading><p id="p-0023" num="0022">In an aspect of the present disclosure, the present disclosure provides a PD-1 variant having improved binding affinity to PD-L1.</p><p id="p-0024" num="0023">The inventors of the present disclosure have made consistent efforts to screen a PD-1 variant having high binding affinity to PD-L1 and thus capable of effectively inhibiting the binding between wild-type PD-1 and PD-L1 and minimizing the possibility of immunogenicity at the same time. As a result, they have identified that, the binding affinity to PD-L1 can be improved greatly by substituting a part of the amino sequence of wild-type PD-1 with another amino sequence and the possibility of immunogenicity can be reduced through minimization of mutation sites and/or aglycosylated PD-1, and have completed the present disclosure.</p><p id="p-0025" num="0024">As used herein, the term &#x201c;PD-1 variant&#x201d; or &#x201c;programmed cell death protein 1 variant&#x201d; refers to a variant of wild-type PD-1, wherein one or two or more amino acids in the amino sequence includes a substitution, deletion or addition mutation.</p><p id="p-0026" num="0025">In a specific exemplary embodiment of the present disclosure, the amino sequence of wild-type PD-1 includes an amino sequence of SEQ ID NO 61.</p><p id="p-0027" num="0026">In a specific exemplary embodiment of the present disclosure, the PD-1 (programmed cell death protein 1) variant having improved binding affinity to PD-L1 (programmed death-ligand 1) includes a part of the amino sequence of wild-type PD-1, and includes substitution of the 69th amino acid of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with a sequence different from the wild-type amino acid.</p><p id="p-0028" num="0027">In a specific exemplary embodiment of the present disclosure, the 69th amino acid is substituted with C69S, C69T, C69Y, C69G or C69A.</p><p id="p-0029" num="0028">In a specific exemplary embodiment of the present disclosure, the PD-1 variant further includes substitution of the 36th amino acid of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with S36P.</p><p id="p-0030" num="0029">In a specific exemplary embodiment of the present disclosure, the PD-1 variant further includes substitution of the 114th amino acid of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with L114P.</p><p id="p-0031" num="0030">In a specific exemplary embodiment of the present disclosure, the PD-1 variant further includes substitution of one or more amino acid selected from a group consisting of the 12th, 34th, 92nd, 107th, 131st, 132nd and 142nd amino acids of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with a sequence different from the wild-type amino acid.</p><p id="p-0032" num="0031">In a specific exemplary embodiment of the present disclosure, the PD-1 variant includes one or more amino acid substitutions selected from a group consisting of T12S, N34T, N92K or N92S, K107N, H131R, P132L and F142L.</p><p id="p-0033" num="0032">In a specific exemplary embodiment of the present disclosure, the PD-1 variant further includes substitution of the 13th amino acid of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with F13I or F13L, and the 46th amino acid with M46I.</p><p id="p-0034" num="0033">In a specific exemplary embodiment of the present disclosure, the PD-1 variant further includes substitution of one or more amino acids selected from a group consisting of the 1st, 17th, 36th, 50th, 79th, 100th, 114th, 127th and 139th amino acids of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with a sequence different from the wild-type amino acid.</p><p id="p-0035" num="0034">In a specific exemplary embodiment of the present disclosure, the PD-1 variant includes one or more amino acid substitutions selected from a group consisting of N1S, L17M, S36P, N505, G79R, G100V, L114P, V127A and A139L.</p><p id="p-0036" num="0035">In a specific exemplary embodiment of the present disclosure, the PD-1 variant further includes substitution of the 25th amino acid of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with N25D, and the 92nd amino acid with N92S or N92K.</p><p id="p-0037" num="0036">In a specific exemplary embodiment of the present disclosure, the PD-1 variant further includes substitution of the 13th amino acid of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with F13I or F13L.</p><p id="p-0038" num="0037">In a specific exemplary embodiment of the present disclosure, the PD-1 variant further includes substitution of one or more amino acids selected from a group consisting of the 9th, 88th, 101st, 125th and 137th amino acids of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with a sequence different from the wild-type amino acid.</p><p id="p-0039" num="0038">In a specific exemplary embodiment of the present disclosure, the PD-1 variant includes one or more amino acid substitutions selected from a group consisting of N9D, R88K, A101V, A125S and R137K.</p><p id="p-0040" num="0039">In a specific exemplary embodiment of the present disclosure, the PD-1 variant is an aglycosylated PD-1 variant.</p><p id="p-0041" num="0040">At present, most of commercially available therapeutic proteins are produced through animal cell culturing. When the proteins are produced, they are modified by various sugar (carbohydrate) variants. In this regard, glycan heterogeneity causes variation in the efficacy and stability of the therapeutic proteins, and a significant cost is required for purification, analysis and quality control (QC) during the preparation process of the proteins.</p><p id="p-0042" num="0041">When compared with glycosylated proteins requiring the expensive animal cell culturing system, the aglycosylated proteins can be produced on a large scale in bacteria and exhibit superior excellence in terms of production speed and costs.</p><p id="p-0043" num="0042">In another aspect of the present disclosure, the present disclosure provides a nucleic acid molecule encoding the PD-1 variant, a vector including the same or a host cell including the vector.</p><p id="p-0044" num="0043">In a specific exemplary embodiment of the present disclosure, the host cell is a bacterial cell.</p><p id="p-0045" num="0044">The nucleic acid molecule of the present disclosure may be an isolated or recombinant nucleic acid molecule, and includes not only single-stranded and double-stranded DNA and RNA but also complementary sequences corresponding thereto. When the &#x201c;isolated nucleic acid&#x201d; is a nucleic acid isolated from a natural origin, the nucleic acid is a nucleic acid separated from nearby gene sequences existing in the isolated genome of an individual. For nucleic acids, e.g., PCR products, cDNA molecules or oligonucleotides, enzymatically or chemically synthesized from a template, the nucleic acids produced from these procedures may be understood as isolated nucleic acid molecules. An isolated nucleic acid molecule may be a component of a fragment or a lager nucleic acid construct. A nucleic acid is &#x201c;operably linked&#x201d; when it is placed into a functional relationship with another nucleic acid sequence. For example, a DNA for a pre-sequence or a secretory leader is operably linked to a DNA for a polypeptide if it is expressed as a pre-protein that participates in the secretion of the polypeptide. A promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the polypeptide sequence. And, a ribosome-binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. In general, &#x201c;operably linked&#x201d; means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and present in the same reading frame. However, enhancers do not have to be contiguous. The linking is accomplished by ligation at convenient restriction enzyme sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with common methods.</p><p id="p-0046" num="0045">As used herein, the term &#x201c;vector&#x201d; refers to a carrier capable of inserting a nucleic acid sequence for introduction into a cell capable of replicating the nucleic acid sequence. The nucleic acid sequence may be exogenous or heterologous. The vector may be a plasmid, a cosmid or a virus (e.g., a bacteriophage), although not being limited thereto. Those skilled in the art can construct the vector according to the standard recombination technology (Maniatis, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1988; Ausubel et al., In: Current Protocols in Molecular Biology, John, Wiley &#x26; Sons, Inc., NY, 1994, etc.).</p><p id="p-0047" num="0046">As used herein, the term &#x201c;expression vector&#x201d; refers to a vector including a nucleic acid sequence encoding at least a part of a transcribed gene product. In some cases, an RNA molecule is post-translated into a protein, a polypeptide or a peptide. The expression vector may contain various regulatory sequences. A vector or an expression vector may further contain a nucleic acid sequence that provides another function, in addition to a regulatory sequence regulating transcription and translation.</p><p id="p-0048" num="0047">As used herein, the term &#x201c;host cell&#x201d; refers to a cell of any transformable organism, including a eukaryote and a prokaryote, which is capable of replicating the vector or expressing a gene encoded by the vector. The host cell may be transfected or transformed by the vector, which means a process by which an exogenous nucleic acid molecule is delivered or introduced into the host cell.</p><p id="p-0049" num="0048">In a specific exemplary embodiment of the present disclosure, the host cell of the present disclosure is a bacterial cell, more specifically a Gram-negative bacterial cell. The cell is adequate for the present disclosure in that it has a periplasmic region between the inner and outer membranes. Specific examples of the host cell according to the present disclosure include the cell of <i>E. coli, Pseudomonas aeruginosa, Vibrio cholera, Salmonella typhimurium, Shigella flexneri, Haemophilus </i>influenza, <i>Bordotella pertussi, Erwinia amylovora, Rhizobium </i>sp., etc., although not being limited thereto.</p><p id="p-0050" num="0049">In another aspect of the present disclosure, the present disclosure provides an inhibitor of the binding between wild-type PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1), which includes the PD-1 variant, the nucleic acid molecule or the vector as an active ingredient.</p><p id="p-0051" num="0050">In another aspect of the present disclosure, the present disclosure provides a composition including the PD-1 variant, the nucleic acid molecule or the vector as an active ingredient.</p><p id="p-0052" num="0051">The composition is specifically a pharmaceutical composition, more specifically a pharmaceutical composition for preventing or treating a cancer disease or an infectious disease.</p><p id="p-0053" num="0052">In another aspect of the present disclosure, the present disclosure provides a method for inhibiting binding between wild-type PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1), which includes a step of administering an effective amount of the PD-1 variant, the nucleic acid molecule or the vector to a subject.</p><p id="p-0054" num="0053">In another aspect of the present disclosure, the present disclosure provides a method for enhancing immune response, which includes a step of administering an effective amount of the PD-1 variant, the nucleic acid molecule or the vector to a subject.</p><p id="p-0055" num="0054">In another aspect of the present disclosure, the present disclosure provides a method for treating a cancer disease or an infectious disease, which includes a step of administering a therapeutically effective amount of the PD-1 variant, the nucleic acid molecule or the vector to a subject.</p><p id="p-0056" num="0055">The pharmaceutical composition of the present disclosure may include: (a) the PD-1 variant, the nucleic acid molecule or the vector; and (b) a pharmaceutically acceptable carrier.</p><p id="p-0057" num="0056">The type of the cancer to be prevented or treated in the present disclosure is not limited. The pharmaceutical composition may be administered to treat various cancers including leukemia such as acute lymphocytic leukemia, acute nonlymphocytic leukemia, chronic lymphocytic leukemia and chronic myelogenous leukemia, lymphomas such as Hodgkin's disease, non-Hodgkin lymphoma, multiple myeloma, etc., childhood solid tumors such as brain tumor, neuroblastoma, retinoblastoma, Wilms' tumors, bone tumors, soft-tissue sarcomas, etc., and common solid tumors in adults such as lung cancer, breast cancer, prostate cancer, urinary cancer, uterine cancer, oral cancer, pancreatic cancer, melanoma and other skin cancers, stomach cancer, ovarian cancer, brain tumor, liver cancer, laryngeal cancer, thyroid cancer, esophageal cancer, testicular cancer, etc.</p><p id="p-0058" num="0057">The infectious diseases to be prevented or treated in the present disclosure are not limited in type and includes viral infection, influenza infection, bacterial infection and fungal infection.</p><p id="p-0059" num="0058">The pharmaceutically acceptable carrier contained in the pharmaceutical composition of the present disclosure is one commonly used for preparation and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc., although not being limited thereto. The pharmaceutical composition of the present disclosure may further include a lubricant, a humectant, a sweetener, a flavorant, an emulsifier, a suspending agent, a preservative, etc. in addition to the above-described ingredients. Adequate pharmaceutically acceptable carriers and preparations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).</p><p id="p-0060" num="0059">The pharmaceutical composition of the present disclosure may be administered orally or parenterally, specifically parenterally. For example, it may be administered via intravenous injection, topical injection, intraperitoneal injection, etc.</p><p id="p-0061" num="0060">As used herein, the term &#x201c;subject&#x201d; refers to a subject in which the above-described disease is to be prevented or treated by inhibiting the binding between PD-1 and PD-L1, and includes specifically human and animals.</p><p id="p-0062" num="0061">An adequate administration dosage of the pharmaceutical composition of the present disclosure varies depending on factors such as formulation method, administration method, the age, body weight, sex and pathological condition of a patient, diet, administration time, administration route, excretion rate and response sensitivity. A normally skilled practitioner can easily determine and prescribe an administration dosage effective for desired treatment or prevention. In a specific exemplary embodiment of the present disclosure, a daily administration dosage of the pharmaceutical composition of the present disclosure is 0.0001-100 mg/kg.</p><p id="p-0063" num="0062">The pharmaceutical composition of the present disclosure may be prepared as a single-dose or multiple-dose formulation using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by those of ordinary skill in the art to which the present disclosure belongs. The formulation may be in the form of a solution in an oily or aqueous medium, a suspension, an emulsion, an extract, a powder, a granule, a tablet or a capsule, and may further contain a dispersant or a stabilizer.</p><p id="p-0064" num="0063">The pharmaceutical composition of the present disclosure may be used either alone or in combination with common biological, chemical or radiation therapies. The combined therapies may be more effective in treating a cancer or an infectious disease. A chemotherapeutic agent that may be used together with the composition of the present disclosure includes cisplatin, carboplatin, procarbazine, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, bisulfan, nitrosourea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin, etoposide, tamoxifen, taxol, transplatinum, 5-fluorouracil, vincristine, vinblastine, methotrexate, etc. The radiation therapy that may be used together with the composition of the present disclosure includes X-ray radiation, &#x3b3;-ray radiation, etc.</p><p id="p-0065" num="0064">In another aspect of the present disclosure, the present disclosure provides a method for preparing the PD-1 variant, which includes the following steps:</p><p id="p-0066" num="0065">a) a step of culturing a host cell including a vector including a nucleic acid molecule encoding the PD-1 variant; and</p><p id="p-0067" num="0066">b) a step of recovering the PD-1 variant expressed by the host cell.</p><p id="p-0068" num="0067">In another aspect, the present disclosure is a method for screening the PD-1 variant, which includes the following steps:</p><p id="p-0069" num="0068">a) a step of establishing a library of the PD-1 variant to which random point mutations have been introduced or a nucleic acid molecule encoding the same; and</p><p id="p-0070" num="0069">b) a step of screening the PD-1 variant which inhibits the binding between wild-type PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1) from the library.</p><p id="p-0071" num="0070">The screening method according to the present disclosure may employ fluorescence-activated cell sorting (FACS) screening or other automated flow cytometry techniques. The instruments for carrying out flow cytometry are known to those skilled in the art. Examples of the instruments include FACSAria, FACS Star Plus, FACScan and FACSort (Becton Dickinson, Foster City, Calif.), Epics C (Coulter Epics Division, Hialeah, Fla.), MOFLO (Cytomation, Colo. Springs, Colo.), and MOFLO-XDP (Beckman Coulter, Indianapolis, Ind.). Generally, the flow cytometry technique involves separation of cells or other particles from a liquid sample. Typically, the purpose of flow cytometry is to analyze the separated particles for one or more characteristics (for example, the presence of a labeled ligand or other molecules). The particles are sorted based on their size, refraction, light scattering, opacity, roughness, shape, fluorescence, etc. by a sensor as they flow one by one.</p><heading id="h-0006" level="1">Advantageous Effects</heading><p id="p-0072" num="0071">The features and advantages of the present disclosure may be summarized as follows:</p><p id="p-0073" num="0072">(i) The present disclosure provides a PD-1 variant having improved binding affinity to PD-L1.</p><p id="p-0074" num="0073">(ii) The present disclosure also provides a method for preparing and a method for screening the PD-1 variant.</p><p id="p-0075" num="0074">(iii) The PD-1 variant of the present disclosure effectively inhibits the binding between wild-type PD-1 and PD-L1, and thus is expected to have significantly higher penetration affinity and anticancer effect by immune cells or therapeutic effect for infectious diseases as compared to existing immune checkpoint inhibitors. At the same time, the possibility of immunogenicity can be minimized. In addition, the convenience of developing biomedicine may be promoted through aglycosylation.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0007" level="1">BRIEF DESCRIPTION OF DRAWINGS</heading><p id="p-0076" num="0075"><figref idref="DRAWINGS">FIG. <b>1</b></figref> shows SDS-PAGE images of wild-type PD-1 and four PD-1 glycovariants, which have been produced in animal cells and then purified.</p><p id="p-0077" num="0076"><figref idref="DRAWINGS">FIG. <b>2</b></figref> shows a result of investigating the binding affinity of wild-type PD-1 and four PD-1 variants to PD-L1.</p><p id="p-0078" num="0077"><figref idref="DRAWINGS">FIG. <b>3</b></figref> shows a result of preparing fluorescence-labeling tetrameric PD-L1 and investigating its activity.</p><p id="p-0079" num="0078"><figref idref="DRAWINGS">FIG. <b>4</b></figref> shows a result of analyzing the expression of aglycosylated PD-1 in <i>E. coli </i>using anti-FLAG-FITC.</p><p id="p-0080" num="0079"><figref idref="DRAWINGS">FIG. <b>5</b></figref> shows a result of measuring the activation of aglycosylated PD-1s.</p><p id="p-0081" num="0080"><figref idref="DRAWINGS">FIG. <b>6</b></figref> shows the amino sequences of an established primary library.</p><p id="p-0082" num="0081"><figref idref="DRAWINGS">FIG. <b>7</b></figref> shows the result of library enrichment by flow cytometry.</p><p id="p-0083" num="0082"><figref idref="DRAWINGS">FIG. <b>8</b></figref> shows a result of analyzing the binding affinity of <i>E. coli </i>cells displaying aglycosylated PD-1 variants to PD-L1.</p><p id="p-0084" num="0083"><figref idref="DRAWINGS">FIG. <b>9</b></figref> shows a result of analyzing the protein expression level in <i>E. coli </i>cells displaying aglycosylated PD-1 variants using anti-FLAG-FITC.</p><p id="p-0085" num="0084"><figref idref="DRAWINGS">FIG. <b>10</b></figref> shows a result of analyzing the binding affinity of <i>E. coli </i>cells displaying aglycosylated PD-1 variants to PD-L1.</p><p id="p-0086" num="0085"><figref idref="DRAWINGS">FIG. <b>11</b></figref> shows a result of analyzing the protein expression level in <i>E. coli </i>cells displaying aglycosylated PD-1 variants using anti-FLAG-FITC.</p><p id="p-0087" num="0086"><figref idref="DRAWINGS">FIG. <b>12</b></figref> shows a result of screening variants having novel mutations on CKJ 41.</p><p id="p-0088" num="0087"><figref idref="DRAWINGS">FIG. <b>13</b></figref> shows the analysis of amino acid sequences of a secondary library established using CKJ 41T as a template.</p><p id="p-0089" num="0088"><figref idref="DRAWINGS">FIG. <b>14</b></figref> shows a result of library enrichment by flow cytometry.</p><p id="p-0090" num="0089"><figref idref="DRAWINGS">FIG. <b>15</b></figref> shows a result of analyzing the binding affinity of <i>E. coli </i>cells displaying aglycosylated PD-1 variants screened through secondary screening to PD-L1.</p><p id="p-0091" num="0090"><figref idref="DRAWINGS">FIG. <b>16</b></figref> shows a result of comparing the binding affinity of PD-1 variants and a consensus sequence variant to PD-L1.</p><p id="p-0092" num="0091"><figref idref="DRAWINGS">FIG. <b>17</b></figref> shows the SDS-PAGE images of purified HAC-V and two PD-1 variant proteins.</p><p id="p-0093" num="0092"><figref idref="DRAWINGS">FIG. <b>18</b></figref> shows a result of investigating the binding affinity of wild-type PD-1, HAC-V and two PD-1 variants to PD-L1.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0008" level="1">BEST MODE</heading><p id="p-0094" num="0093">Hereinafter, the present disclosure will be described in detail through examples. The examples are provided only for the purpose of describing the present disclosure specifically and it will be obvious to those of ordinary skill in the art that the scope of the present disclosure is not limited by the examples.</p><heading id="h-0009" level="1">EXAMPLES</heading><heading id="h-0010" level="1">Example 1: Verification of N-Linked Glycosylation Site Affecting Binding to Human PD-L1</heading><p id="p-0095" num="0094">In order to verify that the glycosylation of human PD-1 actually plays an important role in binding affinity to PD-L1, the effect of each glycosylation on the binding affinity was tested by deglycosylating the four glycosylation sites existing in PD-1. Because PD-1 has four N-glycosylation sites, four genes (N25A, N34A, N50A, N92A) were prepared by replacing each asparagine at the four sites with alanine. The DNA fragment encoding the outer membrane site (amino sequences L25-Q167) of PD-1 was amplified by PCR using a template gene (catalog number: HG10377-M) and primers (CKJ#1, CKJ#2) of PD-1 and Vent polymerase. The amplified DNA fragment was treated with BssHll and XbaI enzymes and was ligated into the pMaz vector, which is a vector for expression in animal cells, which was treated with the same enzymes. The sequences of the ligated plasmids were analyzed to identify a desired plasmid by individual colony analysis after transforming into Judet ((F-mcrA &#x394;(mrr-hsdRMS-mcrBC) &#x3c6;80lacZ&#x394;M15 &#x394;lacX74 recA1 endA1 araD139 &#x394;(ara, leu)7697 galU galK A-rpsL nupG) <i>E. coli</i>. Primers (CKJ#3, CKJ#4, CKJ#5, CKJ#6, CKJ#7, CKJ#8, CKJ#9, CKJ#10) were designed to obtain variants with asparagine substituted with alanine through site-directed mutagenesis by QuikChange PCR using the plasmid. The DNA fragments containing the gene were amplified using the designed primers and Pfu Turbo polymerase (Agilent). The amplified genes were sequenced and confirmed after transforming into Jude1. After transfecting animal cells (HEK293F) with the prepared vectors for expressing wild-type PD-1 (pMaz-wild-type PD-1-His tag) and PD-1 glycovariants (pMaz-N25A PD-1-His tag, pMaz-N34A PD-1-His tag, pMaz-N50A PD-1-His tag, pMaz-N92A PD-1-His tag) and culturing for 6 days, the cell culture was centrifuged at 6,000 rpm for 20 minutes and then the supernatant was filtered through a 0.22-&#x3bc;m filter. The filtered supernatant was incubated with 1 mL of Ni-NTA resin (Qiagen) at 4&#xb0; C. for 16 hours. The protein-bound resin was washed with 10 CV (column volume) of a PBS solution containing 10 mM imidazole (Sigma), and then washed again with 10 CV of a PBS solution containing 20 mM imidazole. Finally, an eluate was recovered with a PBS solution containing 250 mM imidazole (<figref idref="DRAWINGS">FIG. <b>1</b></figref>). The binding affinity of the wild-type PD-1 and four PD-1 glycovariants to PD-L1 was investigated by ELISA. Each protein was diluted with 0.05 M Na<sub>2</sub>CO<sub>3 </sub>(pH 9.6, Junsei) to 200 ng/well and then bound to a high-binding 96-well plate (Costar) at 4&#xb0; C. for 16 hours. After removing the protein, each 96-well plate was incubated in a PBST (PBS containing 0.5% Tween 20) solution containing 5% skim milk solution at 5% (w/v) for 1 hour at room temperature. After discarding the upper solution and washing 4 times with 200 &#x3bc;L of a PBS solution containing 0.5% Tween 20, the PD-L1 tetramer was diluted with a PBS solution and then added to each 96-well plate and incubated for 1 hour at room temperature. After washing 4 times with 200 &#x3bc;L of a 0.5% PBST solution, anti-streptavidin-HRP (Genetex) diluted with PBS to 1:2,000 was added to each 96-well plate and incubated for 1 hour at room temperature. After discarding the upper solution and washing 4 times with 200 &#x3bc;L of a 0.5% PBST solution, reaction was initiated by adding 50 &#x3bc;L of TMB (Thermo Scientific) and was terminated after 20 minutes with 4 N H<sub>2</sub>SO<sub>4 </sub>(<figref idref="DRAWINGS">FIG. <b>2</b></figref>). As a result, whereas the N92A variant showed no significant difference in binding affinity from the wild-type PD-1, the remaining three glycovariants showed remarkable reduction in binding affinity, showing that the glycosylation of N25, N34 and N50 has a significant effect on the binding affinity to PD-L1.</p><p id="p-0096" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="168pt" align="left"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE&#x2003;1</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>SEQ&#x2003;ID&#x2003;NO</entry><entry>Primer</entry><entry>Sequence&#x2003;(5&#x2032;&#x2192;3&#x2032;)</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;1</entry><entry>CKJ#1</entry><entry>GCGGAATTCG<u style="single">GCGCGC</u>ACTCCGAATTAGACTCCCC</entry></row><row><entry/><entry/><entry>AGACAGGCCC</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;2</entry><entry>CKJ#2</entry><entry>GAATTCCGC<u style="single">TCTAGA</u>TTATCAATGATGATGGTGGTG</entry></row><row><entry/><entry/><entry>ATGTTGGAACTGGCCGGCTGG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;3</entry><entry>CKJ#3</entry><entry>CGTGGTGACCGAAGGGGACGCCGCCACCTTCACC</entry></row><row><entry/><entry/><entry>TGCAGCT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;4</entry><entry>CKJ#4</entry><entry>AGCTGCAGGTGAAGGTGGCGGCGTCCCCTTCGGT</entry></row><row><entry/><entry/><entry>CACCACG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;5</entry><entry>CKJ#5</entry><entry>ACCTTCACCTGCAGCTTCTCCGCCACATCGGAGAG</entry></row><row><entry/><entry/><entry>CTTCGTGCTAAAC</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;6</entry><entry>CKJ#6</entry><entry>GTTTAGCACGAAGCTCTCCGATGTGGCGGAGAAGC</entry></row><row><entry/><entry/><entry>TGCAGGTGAAGGT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;7</entry><entry>CKJ#7</entry><entry>GTACCGCATGAGCCCCAGCGCCCAGACGGACAAG</entry></row><row><entry/><entry/><entry>CTGGCCG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;8</entry><entry>CKJ#8</entry><entry>CGGCCAGCTTGTCCGTCTGGGCGCTGGGGCTCAT</entry></row><row><entry/><entry/><entry>GCGGTAC</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;9</entry><entry>CKJ#9</entry><entry>GTCAGGGCCCGGCGCGCCGACAGCGGCACCTACC</entry></row><row><entry/><entry/><entry>TCTG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;10</entry><entry>CKJ#10</entry><entry>CAGAGGTAGGTGCCGCTGTCGGCGCGCCGGGCCC</entry></row><row><entry/><entry/><entry>TGAC</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;11</entry><entry>Hw#1</entry><entry>GCGGAATTCG<u style="single">GCGCGC</u>ACTCCGAATTTACTGTCAC</entry></row><row><entry/><entry/><entry>GGTTCCCAAGGACC</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;12</entry><entry>Hw#2</entry><entry>CTTGTGCCTTGCTATCTTTAGACGGGTCAGAGCCA</entry></row><row><entry/><entry/><entry>CCGCCACCCCTTTCATTTGGAGGATGTGCCAGAG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;13</entry><entry>HW#3</entry><entry>GACCCGTCTAAAGATAGCAAGGCACAAG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;14</entry><entry>HW#4</entry><entry>GAATTCCGC<u style="single">TCTAGA</u>TCATTAGTGGTGATGATGGT</entry></row><row><entry/><entry/><entry>GGTGAG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;15</entry><entry>JY#1</entry><entry>CGCAGCGA<u style="single">GGCCCAGCCGGCC</u>TTAGACTCCCCAG</entry></row><row><entry/><entry/><entry>ACAGGCCC</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;16</entry><entry>JY#2</entry><entry>CGCAGCGA<u style="single">GGCCCCCGAGGCC</u>CCTTGGAACTGGC</entry></row><row><entry/><entry/><entry>CGGCTGG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;17</entry><entry>JY#3</entry><entry>CGCAGCGA<u style="single">GGCCCAGCCGGCC</u></entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;18</entry><entry>JY#4</entry><entry>CGCAGCGA<u style="single">GGCCCCCGAGGCC</u>CC</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0097" num="0095">Primers Used in the Experiment</p><heading id="h-0011" level="1">Example 2: Cloning of Tetrameric Human PD-L1 (PD-L1-Streptavidin) for PD-1 Engineering</heading><p id="p-0098" num="0096">The cDNA of the human PD-L1 gene was purchased from Sino Biotech (Catalog number: HG10084-M) and the gene of the outer membrane of PD-L1 cells (amino sequences F19-R238) was amplified by PCR using primers (HW#1, HW#2) and Vent polymerase. Because the dissociation constant of wild-type PD-1 to wild-type PD-L1 is not good enough (equilibrium dissociation constant, K<sub>D</sub>=&#x2dc;8.7 &#x3bc;M), avidity effect was induced through tetramerization for effective screening of aglycosylated PD-1 variants. The tetramerization was induced by expressing streptavidin at the C-terminal of PD-L1, and a GS linker was inserted between streptavidin and PD-L1 to ensure the flexibility of each protein. After amplifying the gene using primers (HW#3, HW#4) and Vent polymerase (New England Biolab), assembly PCR was conducted using the previously amplified PD-L1 gene and Vent polymerase. The prepared gene was treated with BssHII and XbaI restriction enzymes (New England Biolab). The restriction enzyme-treated PD-L1-streptavidin-His tag gene was ligated into a pMaz vector, which is a vector for mammalian expression, which had been treated with the same restriction enzymes. The ligated plasmid was transformed into Jude1 <i>E. coli</i>. Single clones were obtained and then it was confirmed through sequencing that the PD-L1-streptavidin-His tag was successfully inserted into the pMaz vector.</p><heading id="h-0012" level="1">Example 3: Expression of Tetrameric PD-L1-Streptavidin in Animal Cells Purification, and Fluorescence Labeling</heading><p id="p-0099" num="0097">The prepared vector for tetrameric PD-L1 expression was transfected into animal cells (HEK293F). After culturing the cells for 6 days, the cell culture was centrifuged at 6,000 rpm for 20 minutes and the supernatant was taken and filtered through a 0.22-&#x3bc;m filter. The filtered supernatant was induced to bind to 1 mL of Ni-NTA resin (Qiagen) at 4&#xb0; C. for 16 hours. The bound resin was washed with 10 CV of a PBS solution containing 10 mM imidazole (Sigma) and then washed again with 10 CV of a PBS solution containing 20 mM imidazole. Finally, proteins were eluted and recovered with a PBS solution containing 250 mM imidazole. The purified PD-L1 tetramer was fluorescence-labeled using an Alexa-488 labeling kit. As a result of ELISA assay, the fluorescence-labeled tetrameric PD-L1 showed superior binding affinity to PD-1 (<figref idref="DRAWINGS">FIG. <b>3</b></figref>).</p><heading id="h-0013" level="1">Example 4: Construction of Wild-Type PD-1, HAC-V PD-1 Expressing Plasmids for Displaying Human PD-1 in Inner Membrane of Bacterial Cells</heading><p id="p-0100" num="0098">In order to display the outer membrane site of PD-1, the DNA of PD-1 (amino sequences L25-Q167) was amplified by PCR using primers (JY#1, JY#2) and Vent polymerase and then treated with a SfiI restriction enzyme. In order to immobilize PD-1 protein to the cellular inner membrane during the transport to the periplasmic region of <i>E. coli </i>through NIpA signal peptide, a pMopac12-NIpA-WTPD-1-FLAG vector was prepared by ligating SfiI-treated PD-1 DNA fragment with a SfiI fragment of pMopac12-NIpA-FLAG vector. For a HAC-V variant as a control group, a synthesized HAC-V DNA fragment was also cloned into SfiI site of pMopac12-NIpA-FLAG vector to construct pMopac12-NIpA-HAC-V PD-1-FLAG. Then, after transforming into <i>E. coli </i>Jude1 and obtaining single clones, it was confirmed through sequencing that wild-type PD-1 and HAC-V PD-1 were successfully inserted into the pMopac-12 vector.</p><heading id="h-0014" level="1">Example 5: Verification of Expression of PD-1 and PD-1 Variants (Wild-Type PD-1, HAC-V PD-1) in <i>E. coli </i>and Binding Affinity to PD-L1 by Flow Cytometry</heading><p id="p-0101" num="0099">Each of the plasmids (pMopac12-NIpA-PD-1-FLAG, pMopac12-NIpA-HAC-V PD-1-FLAG, pMopac12-NIpA-Fc-FLAG) prepared through cloning was transformed into Jude1. Each of the prepared samples was cultured in a TB medium containing 2% glucose and 40 &#x3bc;g/mL chloramphenicol at 37&#xb0; C. and 250 rpm for 16 hours. The cultured cells were inoculated into 6 mL of a TB medium containing 40 &#x3bc;g/mL chloramphenicol at a ratio of 1:50. After culturing to OD<sub>600</sub>=0.5, followed by cooling for 20 minutes at 25&#xb0; C. and 250 rpm, the protein overexpression was induced at 25&#xb0; C. and 250 rpm for 5 hours by adding 1 mM IPTG. The same number of the protein-overexpressing <i>E. coli </i>was added to an e-tube through OD<sub>600 </sub>normalization and the cells were recovered through centrifugation at 14,000 rpm for 1 minute. In order to remove the remaining medium, the cells were washed twice through resuspension of the pellet in 1 mL of 10 mM Tris-HCl (pH 8.0) and centrifugation at 13,500 rpm for 1 minute. The cells were resuspended in 1 mL of STE [0.5 M sucrose, 10 mM Tris-HCl, 10 mM EDTA (pH 8.0)] solution and rotated at 37&#xb0; C. for 30 minutes to remove the outer membrane of the cells. After collecting <i>E. coli </i>by centrifuging at 13,500 rpm for 1 minute, the supernatant was removed. The <i>E. coli </i>cell pellet was resuspended in 1 mL of solution A [0.5 M sucrose, 20 mM MgCl<sub>2</sub>, 10 mM MOPS, pH 6.8] and then centrifuged at 13,500 rpm for 1 minute. After resuspending the cell pellet by adding 1 mL of a solution prepared by mixing 1 mL of solution A with 20 &#x3bc;L of a 50 mg/mL lysozyme solution, a peptidoglycan layer was removed by rotating at 37&#xb0; C. for 15 minutes. After the centrifugation, the supernatant was removed. After resuspending the pellt in 1 mL of PBS, 300 &#x3bc;L was taken and added by 700 &#x3bc;L of PBS, 12.5 nM of a tetrameric PD-L1-Alexa488 probe and 33 nM of anti-FLAG-FTIC (Sigma). Then, spheroplasts were labeled with the fluorescent probe by rotating at room temperature. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cells were washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. The cells were resuspended in 1 mL of PBS and then analyzed using the Guava instrument (Merck Millipore). As a result, it was confirmed that the aglycosylated PD-1 was expressed well in <i>E. coli </i>(<figref idref="DRAWINGS">FIG. <b>4</b></figref>) but did not show binding affinity to PD-L1. It was also confirmed that the aglycosylated HAC-V PD-1 show weak binding affinity to PD-L1 (<figref idref="DRAWINGS">FIG. <b>5</b></figref>).</p><heading id="h-0015" level="1">Example 6: Construction of Error-Prone PD-1 Library for Use in High-Throughput Screening</heading><p id="p-0102" num="0100">For high-throughput screening of aglycosylated PD-1 showing high binding affinity to PD-L1, primers having SfiI sites on both sides (JY#3, JY#4) were designed such that errors can be inserted in all the sites of PD-1 during PCR-based amplification using pMopac12-NIpA-PD-1-FLAG as a template. In order to construct a library using the designed primers, Taq polymerase (Takara), dNTPs (Invitrogen), MgCl<sub>2 </sub>and MnCl<sub>2 </sub>(Sigma), the gene was amplified by error-prone PCR. The PCR product was treated with the SfiI enzyme, ligated to a SfiI fragment of pMopac12-NIpA-FLAG vector, and then transformed into Jude1 cells. The transformed <i>E. coli </i>cells were spread onto a square plate and cultured at 37&#xb0; C. for 16 hours. Then, a primary library was obtained by recovering the <i>E. coli </i>cells with TB containing 2% glucose (<figref idref="DRAWINGS">FIG. <b>6</b></figref>).</p><heading id="h-0016" level="1">Example 7: Screening of PD-1 Variant by Flow Cytometry Sorting</heading><p id="p-0103" num="0101">After adding 40 &#x3bc;g/mL chloramphenicol to 25 mL of a TB medium containing 2% glucose, the constructed <i>E. coli </i>library was inoculated to a 250-mL flask and incubated at 37&#xb0; C. and 250 rpm for 4 hours. Then, the <i>E. coli </i>cells were inoculated to 100 mL of a TB medium containing 40 &#x3bc;g/mL chloramphenicol at a ratio of 1:100. After culturing to OD<sub>600</sub>=0.5, followed by cooling for 20 minutes at 25&#xb0; C. and 250 rpm, protein overexpression was induced at 25&#xb0; C. and 250 rpm for 5 hours by adding 1 mM IPTG, and the cells were recovered by centrifuging at 14,000 rpm for 1 minute. In order to remove the remaining medium, the cells were resuspended in 1 mL of 10 mM Tris-HCl (pH 8.0), centrifuged at 13,500 rpm for 1 minute and then washed. This procedure was repeated 2 times. The cells were resuspended in 1 mL of STE [0.5 M sucrose, 10 mM Tris-HCl, 10 mM EDTA (pH 8.0)] solution and rotated at 37&#xb0; C. for 30 minutes to remove the outer membrane of the cells. After collecting <i>E. coli </i>by centrifuging at 13,500 rpm for 1 minute, the supernatant was removed. The cells were resuspended in 1 mL of solution A [0.5 M sucrose, 20 mM MgCl<sub>2</sub>, 10 mM MOPS, pH 6.8] and then centrifuged at 13,500 rpm for 1 minute. After resuspending the cells by adding 1 mL of a solution prepared by mixing 1 mL of solution A with 20 &#x3bc;L of a 50 mg/mL lysozyme solution, a peptidoglycan layer was removed by rotating at 37&#xb0; C. for 15 minutes. After the centrifugation, the supernatant was removed. After resuspending the cells in 1 mL of PBS, 300 &#x3bc;L was taken and 700 &#x3bc;L of PBS and 12.5 nM of a tetrameric PD-L1-Alexa488 probe were added. Then, spheroplasts were labeled with the fluorescent probe by rotating at room temperature. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cells were washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. From the cells resuspended in 1 mL of PBS, <i>E. coli </i>cells with high binding affinity to PD-L1 were chosen and recovered using an S3 sorter (Bio-Rad). Genes were obtained from the recovered <i>E. coli </i>by PCR using primers (JY#1, JY#2). The genes were treated with the SfiI restriction enzyme and then ligated to SfiI fragment of pMopac12-NIpA-FLAG vector. The resulting plasmid was transformed into Jude1 and the cells were spread onto a square plate. After incubation at 37&#xb0; C. for 16 hours, the cells were recovered and stored in a deep freezer. This screening procedure was repeated 5 more times.</p><heading id="h-0017" level="1">Example 8: Culturing of <i>E. coli </i>for Investigation of Enrichment of PD-1 Variants with Increased Affinity for PD-L1</heading><p id="p-0104" num="0102">After adding 40 &#x3bc;g/mL chloramphenicol to 25 mL of TB containing 2% glucose, a primary library, a 1st-round library, a 2vd-round library, a 3rd-round library, a 4th-round library, a 5th-round library and a 6th-round library were added to a 250-mL flask. After incubation at 37&#xb0; C. and 250 rpm for 4 hours, <i>E. coli </i>cultured in 100 mL of TB containing 40 &#x3bc;g/mL chloramphenicol was inoculated at a ratio of 1:100. After culturing to OD<sub>600</sub>=0.5, followed by cooling for 20 minutes at 25&#xb0; C. and 250 rpm, protein overexpression was induced at 25&#xb0; C. and 250 rpm for 5 hours by adding 1 mM IPTG. In addition, wild-type PD-1 and HAC-V-PD-1 expressing cells for use as a control group were inoculated into 4 mL of a TB medium containing 2% glucose and 40 &#x3bc;g/mL chloramphenicol and grown at 37&#xb0; C. and 250 rpm for 16 hours. The cultured cells were inoculated to 6 mL of a TB medium containing 40 &#x3bc;g/mL chloramphenicol at a ratio of 1:50. After culturing to OD<sub>600</sub>=0.5, followed by cooling for 20 minutes at 25&#xb0; C. and 250 rpm, protein overexpression was induced at 25&#xb0; C. and 250 rpm for 5 hours by adding 1 mM IPTG. The same number of the <i>E. coli </i>was added to an e-tube through OD<sub>600 </sub>normalization and the cells were recovered through centrifugation at 14,000 rpm for 1 minute.</p><heading id="h-0018" level="1">Example 9: Investigation of Enrichment of PD-1 Variants with Increased Affinity for PD-L1 by Flow Cytometry</heading><p id="p-0105" num="0103">In order to remove the remaining medium, the cells that had been added to an e-tube were resuspended in 1 mL of 10 mM Tris-HCl (pH 8.0), centrifuged at 13,500 rpm for 1 minute and then washed. This procedure was repeated 2 times. The cells were resuspended in 1 mL of STE [0.5 M sucrose, 10 mM Tris-HCl, 10 mM EDTA (pH 8.0)] solution and rotated at 37&#xb0; C. for 30 minutes to remove the outer membrane of the cells. After collecting <i>E. coli </i>by centrifuging at 13,500 rpm for 1 minute, the supernatant was removed. The cell pellet was resuspended in 1 mL of solution A [0.5 M sucrose, 20 mM MgCl<sub>2</sub>, 10 mM MOPS, pH 6.8] and then centrifuged at 13,500 rpm for 1 minute. After resuspending the cells by adding 1 mL of a solution prepared by mixing 1 mL of solution A with 20 &#x3bc;L of a 50 mg/mL lysozyme solution, a peptidoglycan layer was removed by rotating at 37&#xb0; C. for 15 minutes. After the centrifugation, the supernatant was removed. After resuspending in 1 mL of PBS, 300 &#x3bc;L was taken and 700 &#x3bc;L of PBS and 12.5 nM of a tetrameric PD-L1-Alexa488 probe were added together. Then, spheroplasts were labeled with the fluorescent probe by rotating at room temperature. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cell pellet was washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. After resuspending the cells in 1 mL of PBS, the binding affinity to PD-L1 was analyzed by measuring mean fluorescence intensity (MFI) using a flow cytometer (Guava, Millipore). It was confirmed that variants with higher binding affinity to PD-L1 were amplified from the libraries as the screening proceeded (<figref idref="DRAWINGS">FIG. <b>7</b></figref>).</p><heading id="h-0019" level="1">Example 10: Securing of PD-1 Variants Having Improved Binding Affinity to PD-L1 by Flow Cytometry</heading><p id="p-0106" num="0104">The individual colonies from the final round were inoculated to a TB medium containing 2% glucose and 40 &#x3bc;g/mL chloramphenicol and then cultured at 37&#xb0; C. and 250 rpm for 16 hours. The cultured cells were inoculated to 6 mL of a TB medium containing 40 &#x3bc;g/mL chloramphenicol by diluting to a ratio of 1:50. After culturing to OD<sub>600</sub>=0.5, followed by cooling for 20 minutes at 25&#xb0; C. and 250 rpm, the protein overexpression was induced at 25&#xb0; C. and 250 rpm for 5 hours by adding 1 mM IPTG. The same number of the <i>E. coli </i>was added to an e-tube through OD<sub>600 </sub>normalization and the cells were recovered through centrifugation at 14,000 rpm for 1 minute. In order to remove the remaining medium, the cells that had been added into the e-tube were resuspended in 1 mL of 10 mM Tris-HCl (pH 8.0), centrifuged at 13,500 rpm for 1 minute and then washed. This procedure was repeated 2 times. The cells were resuspended in 1 mL of STE [0.5 M sucrose, 10 mM Tris-HCl, 10 mM EDTA (pH 8.0)] solution and rotated at 37&#xb0; C. for 30 minutes to remove the outer membrane of the cells. After collecting cells by centrifuging at 13,500 rpm for 1 minute, the supernatant was removed. The cell pellet was resuspended in 1 mL of solution A [0.5 M sucrose, 20 mM MgCl<sub>2</sub>, 10 mM MOPS, pH 6.8] and then centrifuged at 13,500 rpm for 1 minute. After resuspending the cells by adding 1 mL of a solution prepared by mixing 1 mL of solution A with 20 &#x3bc;L of a 50 mg/mL lysozyme solution, a peptidoglycan layer was removed by rotating at 37&#xb0; C. for 15 minutes. After the centrifugation, the supernatant was removed. After resuspending in 1 mL of PBS, 300 &#x3bc;L was taken and 700 &#x3bc;L of PBS and 12.5 nM of a tetrameric PD-L1-Alexa488 probe were added together. Then, spheroplasts were labeled with the fluorescent probe by rotating at room temperature. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cells were washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. The cells were resuspended in 1 mL of PBS and the binding affinity to PD-L1 was analyzed by measuring fluorescence signals using the Guava instrument (<figref idref="DRAWINGS">FIG. <b>8</b></figref>). In addition, as the expression level of the PD-1 protein displayed by <i>E. coli </i>can affect fluorescence intensity, it was necessary to determine the expression level of PD-1. For this, 300 &#x3bc;L of the <i>E. coli</i>, remained after resuspending in PBS, was added to 700 &#x3bc;L of PBS and 1 &#x3bc;L of anti-FLAG-FITC and rotated at room temperature to label spheroplasts with the fluorescent probe. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cells were washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. The cells were resuspended in 1 mL of PBS and the binding affinity to anti-FLAG-FITC was analyzed by measuring fluorescence signals by flow cytometry (<figref idref="DRAWINGS">FIG. <b>9</b></figref>).</p><p id="p-0107" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="112pt" align="left"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 2</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry> SEQ ID NO</entry><entry> PD-1 variant</entry><entry>Location of PD-1 variant and  substituted amino acids</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>SEQ ID NO 48</entry><entry>No. 41 (CKJ 41)</entry><entry>S36P/C69S/L114P</entry></row><row><entry>SEQ ID NO 50</entry><entry>No. 45 (CKJ 45)</entry><entry>S36P/C69S/K107N/L114P/F142L</entry></row><row><entry>SEQ ID NO 51</entry><entry>No. 46 (CKJ 46)</entry><entry>S36P/C69S/L114P/P132L</entry></row><row><entry>SEQ ID NO 56</entry><entry>No. 56 (CKJ 56)</entry><entry>S36P/C69S/N92K/L114P/H131R</entry></row><row><entry>SEQ ID NO 58</entry><entry>No. 67 (CKJ 67)</entry><entry>N34T/S36P/C69S/L114P</entry></row><row><entry>SEQ ID NO 59</entry><entry>No. 70 (CKJ 70)</entry><entry>S36P/C69S</entry></row><row><entry>SEQ ID NO 60</entry><entry>No. 78 (CKJ 78)</entry><entry>T12S/S36P/C69S/L114P</entry></row><row><entry>SEQ ID NO 49</entry><entry>No. 44 (CKJ 44)</entry><entry>F13I/M46I/N50S/C69Y/V127A</entry></row><row><entry>SEQ ID NO 54</entry><entry>No. 52 (CKJ 52)</entry><entry>F13I/M46I/C69Y</entry></row><row><entry>SEQ ID NO 52</entry><entry>No. 49 (CKJ 49)</entry><entry>F13L/N25D/C69S/N92S/R137K</entry></row><row><entry>SEQ ID NO 53</entry><entry>No. 50 (CKJ 50)</entry><entry>F13L/N25D/C69S/R88K/N92S/A125S</entry></row><row><entry>SEQ ID NO 55</entry><entry>No. 55 (CKJ 55)</entry><entry>N25D/C69S/N92S/A101V</entry></row><row><entry>SEQ ID NO 57</entry><entry>No. 66 (CKJ 66)</entry><entry>N9D/N25D/C69S/N92S/A101V</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0108" num="0105">PD-1 Variants Having Improved Binding Affinity to PD-L1</p><heading id="h-0020" level="1">Example 11. Cloning for Comparison with PD-1 Variants of Additional Control Groups (PD-1 S.6.8.3 and S.5.1T)</heading><p id="p-0109" num="0106">For use as additional control groups, S.6.8.3 and S.5.1T variants were cloned through primer assembly PCR. First, after conducting primer assembly PCR using primers (S.6.8.3: JY#5,6,7,8,9,10,11,12/S.5.1T: JY#13,14,15,16,17,18,19,20) and Vent polymerase, the assembled gene was amplified through Amplify PCR. The assembled gene was treated with SfiI and then ligated with SfiI fragment of pMopac12-NIpA-FLAG vector to construct pMopac12-NIpA-PD-1 S.6.8.3-FLAG and pMopac12-NIpA-PD-1 S.5.1T-FLAG vectors. Then, after obtaining single clones by transforming into <i>E. coli </i>Jude1, it was confirmed through sequencing that they were inserted successfully.</p><p id="p-0110" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="168pt" align="left"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE&#x2003;3</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>SEQ&#x2003;ID&#x2003;NO</entry><entry>Primer</entry><entry>Sequence&#x2003;(5&#x2032;&#x2192;3&#x2032;)</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;62</entry><entry>JY#5</entry><entry>TTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACC</entry></row><row><entry/><entry/><entry>TTCTCCCCAGCCCTGCTCGTGGTGA</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;63</entry><entry>JY#6</entry><entry>ACGAAGCTCTCCGATGTGTTGGAGAAGCTGCAGGTG</entry></row><row><entry/><entry/><entry>AAGGTGGCGTTGTCCCCTTCGGTCACCACGAGCAGG</entry></row><row><entry/><entry/><entry>GCT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;64</entry><entry>JY#7</entry><entry>AACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCA</entry></row><row><entry/><entry/><entry>TGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCT</entry></row><row><entry/><entry/><entry>TC</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;65</entry><entry>JY#8</entry><entry>TGGGCAGTTGTGTGACACGGAAGCGGCTGGCCTGGC</entry></row><row><entry/><entry/><entry>CCAGCTGGCCGCGGTCCTCGGGGAAGGCGGCCAGC</entry></row><row><entry/><entry/><entry>TTGT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;66</entry><entry>JY#9</entry><entry>CGTGTCACACAACTGCCCAACGGGCGTGACTTCCAC</entry></row><row><entry/><entry/><entry>ATGAGCGTGGTCAGGGCCCGGCGCAGCGACAGCGG</entry></row><row><entry/><entry/><entry>CACC</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;67</entry><entry>JY#10</entry><entry>ACCCGCAGGCTCTCCCGGATCTGGATCCGGGGGGCC</entry></row><row><entry/><entry/><entry>AGCAGGATGGCGCTACAGAGGTAGGTGCCGCTGTCG</entry></row><row><entry/><entry/><entry>CTG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;68</entry><entry>JY#11</entry><entry>GGGAGAGCCTGCGGGTGGAGCTCAGGGTGACAGAG</entry></row><row><entry/><entry/><entry>AGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCC</entry></row><row><entry/><entry/><entry>TCAC</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;69</entry><entry>JY#12</entry><entry>TTGGAACTGGCCGGCTGGCCTGGGTGAGGGGCTGG</entry></row><row><entry/><entry/><entry>GGTG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;70</entry><entry>JY#13</entry><entry>TTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACC</entry></row><row><entry/><entry/><entry>TTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;71</entry><entry>JY#14</entry><entry>CAGTTTAGCACGAAGCTCTCCGATGTGTTGGAGAAGC</entry></row><row><entry/><entry/><entry>TGCAGGTGAAGGTGGCGCTGTCCCCTTCGGTCACCA</entry></row><row><entry/><entry/><entry>CG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;72</entry><entry>JY#15</entry><entry>GGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCC</entry></row><row><entry/><entry/><entry>CAGCAACCAGGCCGACAAGCTGGCCGCCTTCCCCGA</entry></row><row><entry/><entry/><entry>GGA</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;73</entry><entry>JY#16</entry><entry>CACGCCCGTTGGGCAGTTGTGTGACACGGAAGCGGG</entry></row><row><entry/><entry/><entry>AGTCCTGGCCGGGCTGGCTGCGGTCCTCGGGGAAG</entry></row><row><entry/><entry/><entry>GCGG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;74</entry><entry>JY#17</entry><entry>CTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTC</entry></row><row><entry/><entry/><entry>GGGGCCCGGCGCTCCGACAGCGGCACCTACCTCTGT</entry></row><row><entry/><entry/><entry>TCC</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;75</entry><entry>JY#18</entry><entry>CTGAGCTCTGCCCGCAGGCTCTCCCGGATCTGCACC</entry></row><row><entry/><entry/><entry>TTGGGGGCCAGGGAGATGGCGGAACAGAGGTAGGT</entry></row><row><entry/><entry/><entry>GCCG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;76</entry><entry>JY#19</entry><entry>CTGCGGGCAGAGCTCAGGGTGGCAGAGAGAAGGGC</entry></row><row><entry/><entry/><entry>AGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAG</entry></row><row><entry/><entry/><entry>GCCA</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;77</entry><entry>JY#20</entry><entry>TTGGAACTGGCCGGCTGGCCTGGGTGAGGGG</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;78</entry><entry>JY#21</entry><entry>CCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCC</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO&#x2003;79</entry><entry>JY#22</entry><entry>GGAACTGGCCGGCTGGCCTGGGTGAGGGGCTGGGG</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0111" num="0107">Primers Used in Additional Experiments</p><heading id="h-0021" level="1">Example 12. Comparison of Screened PD-1 Variants with Control Groups in Binding Affinity to PD-L1 by Flow Cytometry</heading><p id="p-0112" num="0108">In order to compare the binding affinity to PD-L1 of PD-1 variants having high binding affinity with those of additional control groups, each of wild-type PD-1, PD-1 HAC-V, S.6.8.3 and S.5.1T, as control groups, CKJ 49 and CKJ 50 was inoculated to a TB medium containing 2% glucose and 40 &#x3bc;g/mL chloramphenicol and then cultured at 37&#xb0; C. and 250 rpm for 16 hours. The cultured cells were inoculated to 6 mL of a TB medium containing 40 &#x3bc;g/mL chloramphenicol by diluting to a ratio of 1:100. After culturing to OD<sub>600</sub>=0.5, followed by cooling for 20 minutes at 25&#xb0; C. and 250 rpm, the protein overexpression was induced at 25&#xb0; C. and 250 rpm for 5 hours by adding 1 mM IPTG. The same number of the <i>E. coli </i>was added to an e-tube through OD<sub>600 </sub>normalization and the cells were recovered through centrifugation at 14,000 rpm for 1 minute. After conducting spheroplasting in the same manner as described in Example 5, 12.5 nM of a tetrameric PD-L1-Alexa488 probe was added to the prepared spheroplasts and they were labeled with the fluorescent probe by rotating at room temperature. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cells were washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. The cells were resuspended in 1 mL of PBS and the binding affinity to PD-L1 was analyzed by measuring fluorescence using the Guava instrument (<figref idref="DRAWINGS">FIG. <b>10</b></figref>). In addition, because the expression level of the PD-1 protein displayed by <i>E. coli </i>can affect fluorescence intensity, the expression level of PD-1 was determined. For this, 300 &#x3bc;L of the <i>E. coli </i>remaining after resuspending in PBS was taken and 700 &#x3bc;L of PBS and 1 &#x3bc;L of anti-FLAG-FITC were added together and spheroplasts were labeled with the fluorescent probe by rotating at room temperature. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cells were washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. The cells were resuspended in 1 mL of PBS and the binding affinity to anti-FLAG-FITC was analyzed by measuring fluorescence signals by flow cytometry (<figref idref="DRAWINGS">FIG. <b>11</b></figref>).</p><heading id="h-0022" level="1">Example 13. Cloning for Screening of Variants Having Novel Mutations</heading><p id="p-0113" num="0109">In order to screen variants having novel mutations of CKJ 41, which has the newest mutation and high binding affinity from among the screened variants, the C69S in CKJ 41 was substituted with several amino acids (C, T, Y, A, G). For this, genes were amplified by Quikchange PCR using designed primers and Pfu Turbo polymerase (Agilent). The amplified genes were transformed into Jude1 and then analyzed by sequencing.</p><heading id="h-0023" level="1">Example 14. Screening of Variants Having Novel Mutations by Flow Cytometry</heading><p id="p-0114" num="0110">CKJ 41, the HAC-V variant (control group) and CKJ 41C, CKJ 41T, CKJ 41Y, CKJ 41A, and CKJ 41G, wherein the 69th amino acid of CKJ 41 had been changed, were inoculated into TB medium containing 2% glucose and 40 &#x3bc;g/mL chloramphenicol and were cultured at 37&#xb0; C. and 250 rpm for 16 hours. The cultured cells were inoculated again to 6 mL of a TB medium containing 40 &#x3bc;g/mL chloramphenicol by diluting to 1:100. After culturing to OD<sub>600</sub>=0.5, followed by cooling for 20 minutes at 25&#xb0; C. and 250 rpm, the protein overexpression was induced at 25&#xb0; C. and 250 rpm for 5 hours by adding 1 mM IPTG. The same quantity of the <i>E. coli </i>was added to an e-tube through OD<sub>600 </sub>normalization and the cells were recovered through centrifugation at 14,000 rpm for 1 minute. After conducting spheroplasting in the same manner as described in Example 5, 12.5 nM of a tetrameric PD-L1-Alexa488 probe was added to the prepared spheroplasts and they were labeled with the fluorescent probe by rotating at room temperature. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cells were washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. The cells were resuspended in 1 mL of PBS and the binding affinity to PD-L1 was analyzed by measuring fluorescence using the Guava instrument (<figref idref="DRAWINGS">FIG. <b>12</b></figref>).</p><heading id="h-0024" level="1">Example 15. Construction of Secondary Error-Prone PD-1 Library for Securing PD-1 Variant Having Improved Binding Affinity</heading><p id="p-0115" num="0111">For high-throughput screening of PD-1 showing higher binding affinity to PD-L1, inserts were prepared using pMopac12-NIpA-PD-1 CKJ 41T-FLAG, which exhibited less mutations but high fluorescence intensity, as a template such that errors can be inserted in all regions. A library was constructed by amplifying genes by error-prone PCR using primers having SfiI sites on both sides (JY#3, JY#4), Taq polymerase (Takara), dNTPs (Invitrogen), MgCl<sub>2 </sub>and MnCl<sub>2 </sub>(Sigma). The amplified genome was treated with the SfiI enzyme and ligated with SfiI fragment of pMopac12-NIpA-FLAG vector, and then transformed into Jude1 cells. The transformed <i>E. coli </i>cells were spread onto a square plate and cultured at 37&#xb0; C. for 16 hours. Then, a primary library was prepared by recovering the <i>E. coli </i>cells with TB containing 2% glucose (<figref idref="DRAWINGS">FIG. <b>13</b></figref>).</p><heading id="h-0025" level="1">Example 16. Secondary Screening of PD-1 Variant by Flow Cytometry Sorting</heading><p id="p-0116" num="0112">After adding 40 &#x3bc;g/mL chloramphenicol to 25 mL of a TB medium containing 2% glucose, the constructed library was inoculated to a 250-mL flask and incubated at 37&#xb0; C. and 250 rpm for 4 hours. Then, the <i>E. coli </i>was inoculated to 100 mL of a TB medium containing 40 &#x3bc;g/mL chloramphenicol at a ratio of 1:100. After culturing to OD<sub>600</sub>=0.5, followed by cooling for 20 minutes at 25&#xb0; C. and 250 rpm, protein overexpression was induced at 25&#xb0; C. and 250 rpm for 5 hours by adding 1 mM IPTG, and the cells were recovered by centrifuging at 14,000 rpm for 1 minute. After conducting spheroplasting in the same manner as described in Example 5, 12.5 nM of a tetrameric PD-L1-Alexa488 probe was added and rotated at room temperature to label the prepared spheroplasts. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cells were washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. The cells were resuspended in 1 mL of PBS and <i>E. coli </i>cells with higher binding affinity to PD-L1 were recovered using an S3 sorter (Bio-Rad). Genes were prepared from the recovered <i>E. coli </i>by PCR using primers (JY#3, JY#4)). The genes were treated with the SfiI restriction enzyme and then ligated to SfiI fragment of pMopac12-NIpA-FLAG vector. The resulting plasmid was transformed into Jude1 and the <i>E. coli </i>was spread onto a square plate. After incubation at 37&#xb0; C. for 16 hours, the cells were recovered and stored in a deep freezer. This screening procedure was repeated 3 more times while gradually lowering the concentration of the probe.</p><heading id="h-0026" level="1">Example 17. Culturing of <i>E. coli </i>for Investigation of Enrichment of Secondary PD-1 Variants with Increased Affinity for PD-L1</heading><p id="p-0117" num="0113">After adding 40 &#x3bc;g/mL chloramphenicol to 25 mL of TB containing 2% glucose, a primary library, a 1-round library, a 2-round library, a 3-round library and a 4-round library were added to a 250-mL flask. After incubation at 37&#xb0; C. and 250 rpm for 4 hours, <i>E. coli </i>cultured in 100 mL of TB containing 40 &#x3bc;g/mL chloramphenicol was inoculated at a ratio of 1:100. After culturing to OD<sub>600</sub>=0.5, followed by cooling for 20 minutes at 25&#xb0; C. and 250 rpm, protein overexpression was induced at 25&#xb0; C. and 250 rpm for 5 hours by adding 1 mM IPTG. In addition, for use as a control group, 40 &#x3bc;g/mL chloramphenicol was added to 4 mL of a TB medium containing 2% glucose and, after inoculating wild-type PD-1 and HAC-V-PD-1 cells, respectively, the cells were cultured at 37&#xb0; C. and 250 rpm for 16 hours. The cultured cells were inoculated to 6 mL of a TB medium containing 40 &#x3bc;g/mL chloramphenicol at 1:100. After culturing to OD<sub>600</sub>=0.5, followed by cooling for 20 minutes at 25&#xb0; C. and 250 rpm, protein overexpression was induced at 25&#xb0; C. and 250 rpm for 5 hours by adding 1 mM IPTG. The same number of the <i>E. coli </i>was added to an e-tube through OD<sub>600 </sub>normalization and the cells were recovered through centrifugation at 14,000 rpm for 1 minute.</p><heading id="h-0027" level="1">Example 18. Determination of Enrichment of PD-1 Variants with Increased PD-L1 Affinity by Flow Cytometry</heading><p id="p-0118" num="0114">After conducting spheroplasting in the same manner as described in Example 5, 4 nM of a tetrameric PD-L1-Alexa488 probe was added to the prepared spheroplasts and rotated at room temperature for labeling. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cells were washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. The cells were resuspended in 1 mL of PBS and the binding affinity to PD-L1 was analyzed by measuring mean fluorescence intensity (MFI) using a flow cytometer (Guava, Millipore). It was confirmed that variants with higher binding affinity to PD-L1 were amplified from the libraries as the screening proceeded (<figref idref="DRAWINGS">FIG. <b>14</b></figref>).</p><heading id="h-0028" level="1">Example 19. Securing of Additional PD-1 Variants Having Improved Binding Affinity to PD-L1 by Flow Cytometry</heading><p id="p-0119" num="0115">Each of the single colonies from the final round (APD1-CKJ 41T: aglycosylated form of CKJ 41T, APD1-JY 101: aglycosylated form JY 101), wild-type PD-1 and HAC-V was inoculated to a TB medium containing 2% glucose and 40 &#x3bc;g/mL chloramphenicol and then cultured at 37&#xb0; C. and 250 rpm for 16 hours. The cultured cells were inoculated again to 6 mL of a TB medium containing 40 &#x3bc;g/mL chloramphenicol by diluting to a ratio of 1:100. After culturing to OD<sub>600</sub>=0.5, followed by cooling for 20 minutes at 25&#xb0; C. and 250 rpm, the protein overexpression was induced at 25&#xb0; C. and 250 rpm for 5 hours by adding 1 mM IPTG. The same quantity of the <i>E. coli </i>was added to an e-tube through OD<sub>600 </sub>normalization and the cells were recovered through centrifugation at 14,000 rpm for 1 minute. After conducting spheroplasting in the same manner as described in Example 5, 4 nM of a tetrameric PD-L1-Alexa488 probe was added to the prepared spheroplasts and they were labeled with the fluorescent probe by rotating at room temperature. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cells were washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. The cells were resuspended in 1 mL of PBS and the binding affinity to PD-L1 was analyzed by measuring fluorescence signals using the Guava instrument (<figref idref="DRAWINGS">FIG. <b>15</b></figref>).</p><heading id="h-0029" level="1">Example 20. Cloning of Variants for Comparing Mutation Sites of Screened PD-1 Variants</heading><p id="p-0120" num="0116">It was investigated whether the introduction of novel mutation of CKJ 49 and 50 to LDSS affects binding affinity by cloning a PD-1_LDSS variant having overlapping mutations of CKJ 49 and CKJ 50. In order to prepare PD-1_LDSS, Quikchange PCR was conducted using a CKJ 49 vector as a template. For this, the gene was amplified using primers (JY#21, JY#22) and Pfu Turbo polymerase (Agilent). The amplified gene was transformed into Jude1 and then sequenced.</p><heading id="h-0030" level="1">Example 21. Comparison of Binding Affinity to PD-L1 Among PD-1 Variants by Flow Cytometry</heading><p id="p-0121" num="0117">After inoculating each of wild-type PD-1, the HAC-V variant (control group) CKJ 49, CKJ 50 and LDSS to a TB medium containing 2% glucose and 40 &#x3bc;g/mL chloramphenicol, the cells were cultured at 37&#xb0; C. and 250 rpm for 16 hours. The cultured cells were inoculated to 6 mL of a TB medium containing 40 &#x3bc;g/mL chloramphenicol by diluting to 1:100. After culturing to OD<sub>600</sub>=0.5, followed by cooling for 20 minutes at 25&#xb0; C. and 250 rpm, the protein overexpression was induced at 25&#xb0; C. and 250 rpm for 5 hours by adding 1 mM IPTG. The same number of the <i>E. coli </i>was added to an e-tube through OD<sub>600 </sub>normalization and the cells were recovered through centrifugation at 14,000 rpm for 1 minute. After conducting spheroplasting in the same manner as described in Example 5, 12.5 nM of a tetrameric PD-L1-Alexa488 probe was added to the prepared spheroplasts and rotated at room temperature for labeling. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cells were washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. The cells were resuspended in 1 mL of PBS and the binding affinity to PD-L1 was analyzed by measuring fluorescence signals using the Guava instrument (<figref idref="DRAWINGS">FIG. <b>16</b></figref>). In addition, because the expression level of the PD-1 protein displayed by <i>E. coli </i>can affect fluorescence intensity, the expression level of PD-1 was determined. For this, 300 &#x3bc;L of the <i>E. coli </i>remaining after resuspending in PBS was taken and 700 &#x3bc;L of PBS and 1 &#x3bc;L of anti-FLAG-FITC were added together and spheroplasts were labeled with the fluorescent probe by rotating at room temperature. After conducting the labeling process for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. After discarding the supernatant, the cells were washed once with 1 mL of PBS and then centrifuged again at 13,500 rpm for 1 minute. The cells were resuspended in 1 mL of PBS and the binding affinity to anti-FLAG-FITC was analyzed by measuring fluorescence signals by flow cytometry (<figref idref="DRAWINGS">FIG. <b>16</b></figref>).</p><p id="p-0122" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="119pt" align="left"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 4</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry> SEQ ID</entry><entry> PD-1 variant</entry><entry>Location of PD-1 variant and  substituted amino acids</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>SEQ ID NO 90</entry><entry>CKJ 41T</entry><entry>S36P/C69T/L114P</entry></row><row><entry>SEQ ID NO 91</entry><entry>CKJ 41Y</entry><entry>S36P/C69Y/L114P</entry></row><row><entry>SEQ ID NO 92</entry><entry>CKJ 41G</entry><entry>S36P/C69G/L114P</entry></row><row><entry>SEQ ID NO 93</entry><entry>CKJ 41A</entry><entry>S36P/C69A/L114P</entry></row><row><entry>SEQ ID NO 94</entry><entry>JY101</entry><entry>N1S, F13I, L17M, S36P, M46I, </entry></row><row><entry/><entry/><entry>C69T, G79R, G100V, L114P, A139L</entry></row><row><entry>SEQ ID NO 95</entry><entry>LDSS</entry><entry>F13L, N25D, C69S, N92S</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0123" num="0118">Additionally screened PD-1 variants with improved binding affinity to PD-L1</p><heading id="h-0031" level="1">Example 22. Expression of PD-1 Variants in Animal Cells, Purification and Verification of Binding Affinity</heading><p id="p-0124" num="0119">In order to verify the binding affinity of PD-1 variants expressed in animal cells, the PD-1 variants were cloned into mammalian expression vector. The genes of HAC-V (control group) and the screened variants, CKJ 49 and CKJ50 were amplified by PCR using primers (CKJ#1, CKJ#2) and Vent polymerase. The amplified genes were treated with BssHII and XbaI enzymes were ligated into BssHII and XbaI fragment of pMaz vector. The sequence of the ligated plasmid was investigated by individual colony analysis by transforming into Jude1 <i>E. coli</i>. The prepared vector for expressing PD-1 glycovariants (pMaz-PD1 HAC-V-His tag, pMaz-PD1 CKJ 49-His tag, pMaz-PD1 CKJ 50-His tag) were transfected into animal cells (HEK293F). After culturing the cells for 6 days, the cell culture was centrifuged at 6,000 rpm for 20 minutes and the supernatant was taken and filtered through a 0.22-&#x3bc;m filter. The filtered supernatant was applied to 1 mL of Ni-NTA resin (Qiagen) at 4&#xb0; C. for 16 hours. The protein-bound resin was washed with 10 CV (column volume) of a PBS solution containing 10 mM imidazole (Sigma), and then washed again with 10 CV of a PBS solution containing 20 mM imidazole. Finally, an eluate was recovered with a PBS solution containing 250 mM imidazole (<figref idref="DRAWINGS">FIG. <b>17</b></figref>). The binding affinity of the wild-type PD-1, the control group and the two variants (GPD1-CKJ 49: glycosylated form of CKJ 49, GPD1-CKJ 50: glycosylated form of CKJ 50) to PD-L1 was investigated by ELISA. Each protein was diluted with 0.05 M Na<sub>2</sub>CO<sub>3 </sub>(pH 9.6, Junsei) to 200 ng/well and then bound to a high-binding 96-well plate (Costar) at 4&#xb0; C. for 16 hours. After removing the protein, each 96-well plate was added by blocking solution (PBST (PBS containing 0.5% Tween 20) solution containing 5% skim milk) for 1 hour at room temperature. After discarding the upper solution and washing 4 times with 200 &#x3bc;L of a PBS solution containing 0.5% Tween 20, the PD-L1 tetramer was diluted with a PBS solution and then added to each 96-well plate for 1 hour at room temperature. After washing 4 times with 200 &#x3bc;L of a 0.5% PBST solution, anti-streptavidin-HRP (Genetex) diluted with PBS to 1:2,000 was added to each 96-well plate for 1 hour at room temperature. After discarding the upper solution and washing 4 times with 200 &#x3bc;L of a 0.5% PBST solution, reaction was initiated by adding 50 &#x3bc;L of TMB (Thermo Scientific) and was terminated 20 minutes after with 4 N H<sub>2</sub>SO<sub>4</sub>. As a result, it was confirmed that, although the glycosylation resulted in the change in binding affinity to PD-L1, CKJ 49 showed the best binding affinity (<figref idref="DRAWINGS">FIG. <b>18</b></figref>).</p><p id="p-0125" num="0120">Although the specific embodiments of the present disclosure have been described in detail above, it is obvious to those of ordinary skill in the art that they are provided only as preferred exemplary embodiments and do not limit the scope of the present disclosure. Accordingly, the substantial scope of the present disclosure should be defined by the appended claims and their equivalents.</p><p id="p-0126" num="0121">[National Research and Development Project Supporting the Present Disclosure]<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0122">[Project ID] 1711053534.</li>        <li id="ul0002-0002" num="0123">[Ministry in charge] Ministry of Science and ICT.</li>        <li id="ul0002-0003" num="0124">[R&#x26;D management agency] National Research Foundation of Korea.</li>        <li id="ul0002-0004" num="0125">[Research project name] Rising research supporting project.</li>        <li id="ul0002-0005" num="0126">[Research title] Development of protein therapeutic agent and bispecific antibody using antigen-binding aglycosylated Fc variant.</li>        <li id="ul0002-0006" num="0127">[Contribution factor] 1/2.</li>        <li id="ul0002-0007" num="0128">[Research agency] Kookmin University Industry-Academic Cooperation.</li>        <li id="ul0002-0008" num="0129">[Research period] 2017.06.01 to 2018.03.31.</li>    </ul>    </li></ul></p><p id="p-0127" num="0130">[National Research and Development Project Supporting the Present Disclosure]<ul id="ul0003" list-style="none">    <li id="ul0003-0001" num="0000">    <ul id="ul0004" list-style="none">        <li id="ul0004-0001" num="0131">[Project ID] 1711058394.</li>        <li id="ul0004-0002" num="0132">[Ministry in charge] Ministry of Science and ICT.</li>        <li id="ul0004-0003" num="0133">[R&#x26;D management agency] National Research Foundation of Korea.</li>        <li id="ul0004-0004" num="0134">[Research project name] Management of new drug development pipeline.</li>        <li id="ul0004-0005" num="0135">[Research title] Identification of serum persistent Fc-based next-generation anticancer antibody targeting endothelin GPCR.</li>        <li id="ul0004-0006" num="0136">[Contribution factor] 1/2.</li>        <li id="ul0004-0007" num="0137">[Research agency] Kookmin University Industry-Academic Cooperation.</li>        <li id="ul0004-0008" num="0138">[Research period] 2017.06.30 to 2018.03.29.</li>    </ul>    </li></ul></p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002472A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A PD-1 (programmed cell death protein 1) variant having improved binding affinity to PD-L1 (programmed death-ligand 1), wherein the PD-1 variant comprises a part of the amino sequence of wild-type PD-1, and comprises substitution of the 69th amino acid of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with C69S, C69T, C69Y, C69G or C69A.</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The PD-1 variant according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the PD-1 variant further comprises substitution of the 36th amino acid of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with S36P.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The PD-1 variant according to <claim-ref idref="CLM-00002">claim 2</claim-ref>, wherein the PD-1 variant further comprises substitution of the 114th amino acid of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with L114P.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The PD-1 variant according to <claim-ref idref="CLM-00003">claim 3</claim-ref>, wherein the PD-1 variant further comprises substitution of one or more amino acid selected from a group consisting of the 12th, 34th, 92nd, 107th, 131st, 132nd and 142nd amino acids of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with a sequence different from the wild-type amino acid.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The PD-1 variant according to <claim-ref idref="CLM-00004">claim 4</claim-ref>, wherein the PD-1 variant comprises one or more amino acid substitution selected from a group consisting of T12S, N34T, N92K or N92S, K107N, H131R, P132L and F142L.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The PD-1 variant according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the PD-1 variant further comprises substitution of the 13th amino acid of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with F13I or F13L, and the 46th amino acid with M46I.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The PD-1 variant according to <claim-ref idref="CLM-00006">claim 6</claim-ref>, wherein the PD-1 variant further comprises substitution of one or more amino acid selected from a group consisting of the 1st, 17th, 36th, 50th, 79th, 100th, 114th, 127th and 139th amino acids of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with a sequence different from the wild-type amino acid.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The PD-1 variant according to <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein the PD-1 variant comprises one or more amino acid substitution selected from a group consisting of N1S, L17M, S36P, N505, G79R, G100V, L114P, V127A and A139L.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The PD-1 variant according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the PD-1 variant further comprises substitution of the 25th amino acid of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with N25D, and the 92nd amino acid with N92S or N92K.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The PD-1 variant according to <claim-ref idref="CLM-00009">claim 9</claim-ref>, wherein the PD-1 variant further comprises substitution of the 13th amino acid of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with F13I or F13L.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The PD-1 variant according to <claim-ref idref="CLM-00009">claim 9</claim-ref> or <claim-ref idref="CLM-00010">10</claim-ref>, wherein the PD-1 variant further comprises substitution of one or more amino acid selected from a group consisting of the 9th, 88th, 101st, 125th and 137th amino acids of the amino sequence of wild-type PD-1 of SEQ ID NO 61 with a sequence different from the wild-type amino acid.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The PD-1 variant according to <claim-ref idref="CLM-00011">claim 11</claim-ref>, wherein the PD-1 variant comprises one or more amino acid substitution selected from a group consisting of N9D, R88K, A101V, A125S and R137K.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The PD-1 variant according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the PD-1 variant is an aglycosylated PD-1 variant.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. A nucleic acid molecule encoding the PD-1 variant according to <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. A vector comprising the nucleic acid molecule according to <claim-ref idref="CLM-00014">claim 14</claim-ref>.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. A host cell comprising the vector according to <claim-ref idref="CLM-00015">claim 15</claim-ref>.</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The host cell according to <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein the host cell is a bacterial cell.</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. An inhibitor of the binding between wild-type PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1), comprising the PD-1 variant according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, a nucleic acid molecule encoding the PD-1 variant or a vector comprising the nucleic acid molecule as an active ingredient.</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. A composition comprising the PD-1 variant according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, the nucleic acid molecule according to <claim-ref idref="CLM-00014">claim 14</claim-ref> or a vector comprising the nucleic acid molecule as an active ingredient.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. The composition according to <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the composition is a pharmaceutical composition for preventing or treating a cancer disease or an infectious disease.</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. A method for inhibiting binding between wild-type PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1), comprising a step of administering an effective amount of the PD-1 variant according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, a nucleic acid molecule encoding the PD-1 variant or a vector comprising the nucleic acid molecule to a subject.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. A method for increasing immune response, comprising a step of administering an effective amount of the PD-1 variant according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, a nucleic acid molecule encoding the PD-1 variant or a vector comprising the nucleic acid molecule to a subject.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. A method for treating a cancer disease or an infectious disease, comprising a step of administering a therapeutically effective amount of the PD-1 variant according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, a nucleic acid molecule encoding the PD-1 variant or a vector comprising the nucleic acid molecule to a subject.</claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. A method for preparing a PD-1 variant, comprising:<claim-text>a) a step of culturing a host cell comprising a vector comprising a nucleic acid molecule encoding the PD-1 variant according to <claim-ref idref="CLM-00001">claim 1</claim-ref>; and</claim-text><claim-text>b) a step of recovering the PD-1 variant expressed by the host cell.</claim-text></claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. A method for screening a PD-1 variant, comprising:<claim-text>a) a step of establishing a library of the PD-1 variant according to <claim-ref idref="CLM-00001">claim 1</claim-ref> to which random point mutations have been introduced or a nucleic acid molecule encoding the same; and</claim-text><claim-text>b) a step of screening the PD-1 variant which inhibits the binding between wild-type PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1) from the library.</claim-text></claim-text></claim></claims></us-patent-application>